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Thesis Summary  
Introduction 
 
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease 
(ESRD), present in approximately 25%–40% of patients with long-standing diabetes 
and conferring additional risk of cardiovascular disease and mortality.  Variations in 
the clinical presentations of DKD, heritability estimates from family-based studies 
and, more recently, the results from Genome-wide Association Studies (GWAS) 
demonstrate a heritable component of DKD.  However, as is the case with the most 
of complex disorders, identifying causal genetic variants contributing to DKD has 
proven difficult.  An important step in identifying variants associated with DKD in 
diabetes will involve integration of patient populations across multiple DKD cohorts, 
investigating rarer variants and by addressing the heterogeneity in DKD disease 
phenotypes in diabetes.   
Methods 
In this thesis, I reviewed the existing literature in genetic epidemiology in diabetic 
kidney disease.  I then estimate chip-based heritability of DKD sub-phenotypes and 
replicated the association of known SNPS associated with renal function and 
upstream risk factors for diabetic kidney disease (BP, HbA1c) in patients with Type 
2 Diabetes.  I performed first GWAS for soluble receptor for advanced glycation 
products (sRAGE) a biomarker implicated in the pathogenesis of DKD.  Finally, I 
performed GWAS for various DKD phenotypes on Type 1 Diabetes cohort 
(EURODIAB) and Type 2 Diabetes cohort (Go-DARTS) and helped with joint meta-
analysis with DKD cohorts in SUMMIT consortium investigating genetic 
determinants of DKD. 
15 
 
Results 
First, I showed that some DKD sub-phenotypes (like macro-albuminuria and ESRD) 
might be more heritable than others are and demonstrate that usefulness of 
estimation of chip-based heritability for complex trait by GCTA can be limited in the 
absence of large sample sizes.  Second, I investigated the known genes for renal 
function (eGFR) and upstream risk factors for diabetic kidney disease (BP, HbA1c) 
in patients with Type 2 diabetes and showed that cumulative genetic risk for BP and 
HbA1c is associated with DKD.  Third, I replicated the association of known loci 
associated with eGFR (UMOD GCKR and SHROOM3) in patients with Type 2 
diabetes and showed that albuminuria affects the association of these variants with 
renal function.  Fourth, I conducted a GWAS for sRAGE, an important biomarker 
associated with DKD, and identified novel variants in ITGA1 and HLA-DQA1 
associated with circulating sRAGE levels.  Finally, I performed GWAS for various 
DKD sub-phenotypes, and assisted in GWAS meta-analysis with SUMMIT 
consortium and identified potential novel genetic determinants for diabetic kidney 
diseases. 
Conclusion 
In conclusion this thesis has shown that a) estimation of chip based heritability of 
various DKD sub-phenotypes using GCTA has limited utility and requires GWAS 
studies with extremely large sample sizes b) the genetic determinants of renal 
function (eGFR) can interact with albuminuria in patients with T2D c) there are yet 
unidentified genetic markers associated with DKD  and have identified  potentially 
novel genetic markers associated with sRAGE (an important biomarker for DKD) 
and  DKD itself which can be investigated in future studies for their reproducibility 
and functional consequences. 
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 Background and Literature Review  
I. Introduction  
There is an ongoing trend of a rapid increase in the incidence of diabetes mellitus, 
especially the non-insulin dependent form.  By the end of the second millennium, 
150 million cases were recorded worldwide, while the estimations predicted 
doubling the number by the year 2030
1
.  Numerous chronic complications 
accompany the disease; among them micro- as well as macro-vascular prevail, 
affecting small and large blood vessels such as diabetic kidney disease (DKD), 
retinopathy, cardiovascular disease, and lower-extremity arterial disease.  Here we 
review the existing literature on pathophysiology, heritability, and genetic 
epidemiology of DKD. 
 
II. Definition of Diabetic Nephropathy 
Diabetic nephropathy (DN) is a clinical diagnosis, which is historically based on the 
findings of persistent urinary protein excretion in the absence of any known cause of 
renal disease.  This definition was initially confined to those who are now considered 
to have macro-albuminuria (Table 1).  The development of more sensitive assays 
specific for albumin has since led to the detection of smaller increases, termed 
micro-albuminuria or “incipient nephropathy”.  The lower limit to confer micro-
albuminuria diagnosis is an albumin excretion rate (AER) of 20 µg/min, which is 
equivalent to 30 mg/24 h or an ACR of 30 mg/g
2
 (Table1).  These definitions are 
clinically relevant as individuals with macro-albuminuria show a progressive 
decrease in renal function (GFR) associated with an increase in systemic blood 
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pressure, whereas those with micro-albuminuria are considered to have stable kidney 
function but, are at high risk of subsequent development of macro-albuminuria and 
kidney failure
3
 .  Table 1 shows the cut-off values according to the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI). 
Table 1 Definitions of the abnormalities of albumin excretion 
Category Spot 
collection 
mg/g 
creatinine 
24 hour 
collection(mg/24 hour 
Timed 
collection 
ug/min 
Normoalbumiuria <30 <30 <20 
Microalbuminuria 30-300 30-300 20-200 
Macroalbuminuria >300 >300 >200 
 
Because of the variability in the UAE, two or three specimens collected within 3-6 
months period should be abnormal before considering the patient to have crossed one 
of the diagnostic thresholds.  It is not uncommon to get false positive results because 
of infections, fever, congestive heart failure, hypertension, hyperglycaemia, etc. and 
both true progression and regression can occur.  Notably, regression of micro-
albuminuria in Type 1 Diabetes is quite frequent.  Krolewski AS et.al showed that 
six-year cumulative incidence of regression of micro-albuminuria can be upto 58 
percent in patients with Type 2 Diabetes
4
.  This study showed that lower 
glycosylated haemoglobin , lower systolic blood pressure , and lower levels of both 
cholesterol and triglycerides were independently associated with the regression of 
micro-albuminuria. 
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III. Concept of Chronic Kidney Disease (CKD) in Diabetes 
Glomerular filtration rate (GFR) can be a useful indicator of renal function in 
diabetes, and is known to decline in the natural history of diabetic nephropathy 
following onset of macro-albuminuria
5
.  Based on the eGFR levels CKD has been 
divided into following stages
6
. 
 
 
Stage 1: Slightly diminished function; kidney damage with normal or 
relatively high GFR (≥90 mL/min/1.73 m2)  
Stage 2:  Mild reduction in GFR (60–89 mL/min/1.73 m2) with kidney 
damage  
Stage 3: Moderate reduction in GFR (30–59 mL/min/1.73 m2).  British 
guidelines distinguish between stage 3A (GFR 45–59) and stage 3B (GFR 30–
44) for purposes of screening and referral 
Stage 4: Severe reduction in GFR (15–29 mL/min/1.73 m2) 
Stage 5: Established kidney failure (GFR <15 mL/min/1.73 m2, permanent 
renal replacement therapy (RRT), or end stage renal disease (ESRD) 
 
Given the difference in the risk factors for GFR decline and albuminuria, it is not 
surprising to see that eGFR decline can precede the onset of albuminuria in patients 
with diabetes
7
.  Hence, eGFR alone cannot predict or diagnose diabetic kidney 
disease per se.  Indirect estimation of GFR using various formulae is described in the 
methods section, below.  
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IV.  Concept of Diabetic Kidney Disease 
Diabetic kidney disease (DKD) is a term used to annotate kidney disease in diabetes 
using both eGFR and albuminuria as eGFR and albuminuria alone cannot reflect 
renal damage of attributed to diabetes.  The likelihood of diabetic kidney disease 
(DKD) according to Staging by eGFR and albuminuria levels is summarised in 
Table 2 (NKF KDOQI guidelines)
6
.  Those with eGFR <60 mls/min/1.73m2  or 
below with normo-albuminuria and those with CKD Stage 4 or above with micro-
albuminuria are unlikely to have DKD highlighting the point that eGFR alone cannot 
be used in the diagnosis of DN.  Although these combinations of eGFR and 
albuminuria status, and other unusual clinical presentations, warrant a biopsy to 
make a definitive diagnosis of DKD
8
 mostly  DKD is a clinical diagnosis and biopsy 
is not routinely carried out. This of course has implications for genetic studies 
because the phenotype is not a clean one.  Especially in type 2 diabetes up to 50% of 
those with  declining  eGFR have non diabetic causes for their chronic kidney 
disease (CKD)
9
  and albuminuria is not specific for having true diabetic 
glomeruloscerlosis on biopsy it just increases the probability of this
10
.  
V. Role of Retinopathy in Diagnosis of DKD 
The concomitant presence of retinopathy is partly helpful in discriminating kidney 
pathology in patients with Type 2 diabetes
11
.  The presence of retinopathy in patients 
with Type 2 diabetes and macro-albuminuria is strongly suggestive of DKD, and its 
absence in micro-albuminuria suggests non-DKDs though it is not specific for DKD.  
The sensitivity (ability of test to detect true positive), specificity (ability of test to 
detect true negative), positive predictive value (proportions of positive results in 
statistics and diagnostic tests that are true positive), and negative predictive value 
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(proportions of negative results in statistics and diagnostic tests that are true 
negative) of retinopathy in the diagnosis of DKD is well documented.  In those with 
macro-albuminuria, the positive predictive value (PPV) of retinopathy for typical 
diabetic glomerulopathy ranges from 67% to 100%.  However, the negative 
predictive value (NPV) had a broader range of 20% to 84% (sensitivities between 
26% and 85% and specificities of 13% to 100%)
12
.  For micro-albuminuria, PPVs of 
retinopathy were lower at around 45% but NPVs were close to 100%, giving 
sensitivities of 100% and specificities of 46% to 62%.   
Table 2: Likelihood of DKD according to Staging by eGFR and albuminuria level
6
 
GFR CKD Stage Normbuminuria Microalbumniuria Macroalbuminuria 
>60 1+2 At Risk Possible DKD DKD 
30-60 3 Unlikely DKD Possible DKD DKD 
<30 4+5 Unlikely DKD Unlikely DKD DKD 
 
VI. Natural History of Diabetic Nephropathy and Nephropathy 
Phenotypes 
In Type 1 Diabetes, the earliest sign of DKD is often micro-albuminuria, which 
appears within 5-15 years of duration of diabetes, and the incidence of micro-
albuminuria over the lifetime is about 50%
13
.  Recent studies have suggested that 
about 40% patients with micro-albuminuria will progress to macro-albuminuria
14
.  If 
untreated, with a progressive decline in GFR, almost all the patients with macro-
albuminuria will develop end-stage renal disease ESRD and those with Stage 3 CKD 
die prematurely of cardiovascular events
15
. 
The development of DKD in T2D follows a similar course as in T1D patients but the 
lifetime prevalence of proteinuria is lower and varies according to ethnicity
16
.  
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Studies have shown that DKD is more prevalent and develops more rapidly in 
African-Americans, Asians, and Native-Americans than in Caucasians.  The reported 
prevalence of DKD in Pima Indians is about 50% within 15-year follow-up of 
diabetes
17
, while it is about 30% in African Americans
18
.  In the Caucasians 
populations on the other hand, the prevalence is about 20% in European Americans 
(WESDR)
19
 and 5% in a UK population (UKPDS)
5
  over a 10-year follow-up period. 
The natural progression of diabetic nephropathy consists of successive, coinciding 
pathologic and hemodynamic changes, which correspond to different stages of 
albumin excretion (Table 3).  The initial phase is characterised by renal hypertrophy, 
an increase in GFR, and blood pressure and normo-albuminuria.  Those who are 
resistant to subsequent changes (either because of protective genetic effects or 
environmental effects) tend to stay in this stage for a longer period (15 years or 
more) than others and are usually used as controls in genetic studies for DN.  The 
next phase is characterised by glomerular basement thickening, increase in GFR, and 
blood pressure, clinically manifesting as micro albuminuria.  Subsequently, there is 
meningeal expansion and onset of fibrosis with decline in renal function, clinically 
manifesting as macro-albuminuria.  Finally progressive renal fibrosis replaces the 
normal renal tissue resulting in minimal renal function (GFR<15) leading to elevated 
serum urea and creatinine resulting in end-stage renal disease (ESRD).  The genetic 
determinants of the pathological and hemodynamic changes in each of these phases 
are not definitively characterised.  A classification of DKD based on various stages 
of Albuminuria and eGFR can help in identifying genetic determinants specific to 
the spectrum of underlying pathologies in DKD.  For example, a genetic association 
study involving patients with micro-albuminuria and normo-albuminuria might 
identify the genetic variants associated with basement membrane thickening, 
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whereas a study involving patients with macro-albuminuria and normo-albuminuria 
can identify the genetic variants associated with mesangial expansion, fibrosis and a 
study involving patients with ESRD can uncover the genetic determinants of renal 
fibrosis.   
Table 3 Nephropathy phenotypes and corresponding hemodynamic and pathologic 
changes 
Phenotypes Diabetes and Normo-
albuminuria 
Micro-
albuminuria 
Macro-
albuminuria 
ESRD 
Hemodynamic Changes ↑ GFR and ↑BP ↑ GFR and 
↑BP 
↓ GFR and 
↑BP 
↓ ↓GFR, 
↑BP 
Predominant Pathologic 
Changes 
Renal Hypertrophy Basement 
membrane 
thickening 
Basement 
membrane 
thickening , 
Mesangial 
expansion and 
onset of global 
fibrosis 
Progressi
ve global 
fibrosis 
 
VII. Current Understanding of Key Aspects of Histology and 
Pathogenesis of DKD including some Key Pathways  
 
 Histopathology of Diabetic Kidney Disease 
The morphologic lesions in diabetic nephropathy are predominantly seen in the 
glomeruli, with an observed thickening of the glomerular basement membrane 
(GBM) and mesangial expansion early in the disease.  In Type 1 diabetes, these 
changes occur as early as 1.5 to 2.5 years after the onset of T1DM
20
.  Later in the 
course of the disease the podocytes, renal tubules, interstitium, and arterioles 
undergo substantial changes.  The hallmark of DKD histology is the ‘Kimmelstiel-
Wilson nodules’ where there is diffuse mesangial expansion, (also termed diffuse 
diabetic glomerulosclerosis); the nodular lesions consist of areas of marked 
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mesangial expansion forming large round fibrillar mesangial zones with palisading 
of mesangial nuclei around the periphery of the nodule and compression of the 
associated glomerular capillaries.  Mesangial expansion, predominantly due to an 
increase in mesangial matrix, can be detected as early as 5–7 years after the onset of 
diabetes
21
.  When the mesangium expands, it restricts and distorts glomerular 
capillaries and diminishes the available capillary filtration surface resulting in 
decline in renal function and a highly significant inverse correlation between 
mesangial expansion and GFR, AER and blood pressure
22
.  GBM thickening on the 
other hand is closely related to AER and less so to GFR or hypertension, suggesting 
that this lesion is a closer surrogate to the pathogenesis of albuminuria
22
.   
The interest in role of podocytes in DKD is increasing in recent years, although there 
are no specific evidences.  Podocyte detachment from GBM, from apoptosis, 
necrosis, or loss of adhesive interaction, may play a role in the pathogenesis of 
proteinuria.  It has been shown that proteinuria in glomerular disorders is associated 
with foot process effacement, flattening and retraction
23
. 
Physiological Changes in DKD  
DKD has several distinctive phases of development.  Before the onset of clinical 
changes and appearance of albuminuria, functional changes occur in the 
kidneys.  The process starts with hyper-filtration and hyper-perfusion of the 
glomeruli.  Hyper-filtration is typically defined as GFR between 125 mL/min to 140 
mL/min per 1.73 m
2
, or greater than two standard deviations above the mean GFR in 
normal healthy individuals
24
.  Hyper-filtration is observed in 25%-75% of patients 
with T1D and about 5-40% patients with T2D.  The degree of hyper-filtration 
appears to be related to impairment of fasting glucose and duration of diabetes in the 
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general population
25
.  For example, in a study of a Pima Indian population
26
, those 
with a normal glucose tolerance test had mean eGFR of 123 mL/min, and those with 
impaired glucose tolerance test had mean eGFR of 135 mL/min.  In the same study, 
individuals with newly diagnosed diabetes mean eGFR was 143 mL/min and, those 
with overt diabetes for more than five years and either normal albumin excretion or 
micro-albuminuria, the mean GFR was 153 mL/min.   
Although the pathogenesis of diabetic hyper-filtration is not completely understood, 
several hypothesis implicating glomerular hemodynamic and tubular factors have 
been proposed to explain the mechanisms that are responsible for hyper-
filtration
27,28
.  
There is a good experimental evidence
29
 to suggest that hyperglycaemia increases 
the production and availability of vasoactive mediators that regulate glomerular 
arteriolar tone, such as, nitric oxide (NO) system, cyclooxygenase 2 (COX2)-derived 
prostanoids, the renin angiotensin system (RAS), protein kinase C (PKC) and 
endothelin (ET).  These vasoactive substances change pre-glomerular (afferent) and 
post-glomerular (efferent) arteriolar tone, such that there is a decreased resistance at 
the afferent arteriole as compared to the efferent arteriole
29
.  This causes an increase 
in the blood flow through the glomerulus, which eventually leads to leakage of 
albumin from the glomerular capillaries, a thickening of the glomerular basement 
membrane and injury to the podocytes.  The mechanical strain resulting from these 
hemodynamic changes can induce localised release of cytokines (TGF-β1) and 
growth factors, which cause increased synthesis of collagen and fibrosis
30
 . 
The tubular hypothesis suggests that hyper-filtration is initiated by increased sodium 
reabsorption in the proximal tubule, which is mediated by the sodium-glucose 
cotransporter-2 (SGLT2)
31
.  This increase in proximal reabsorption reduces sodium 
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signalling to the macula densa, which sense a decline in effective circulating volume 
and renal perfusion.  The reduction in renal perfusion reduces adenosine in the 
juxtaglomerular apparatus of the kidneys leading to the dilatation of the afferent 
arteriole, hyper-perfusion, and hyper-filtration
32
.  Animal studies have supported the 
tubular hypothesis by showing that SGLT2 inhibition decreases hyper-filtration and 
diminishes the histological evidence of diabetic nephropathy
33
.  There are no human 
studies looking at the effects of these agents on eGFR however, they have been 
shown to be associated with lower blood sugar, blood pressure and lower weight
34
. 
 Role of Cytokines and Vascular Growth Factors in DKD 
Activation of cytokines (TGFβ-1) and vascular growth factors such as VEGF might 
play a role in the matrix accumulation that arises in diabetic nephropathy
35,36
.  
There is a strong evidence showing that TGFβ-1contributes to the cellular 
hypertrophy and increased synthesis of collagen, both of which occur in diabetic 
nephropathy
37,38.  TGFβ-1 levels are increased in the glomeruli of rats with 
streptozotocin-induced diabetes, and antibody to TGFβ-1 prevents renal changes of 
diabetic nephropathy in these animals
39
.  In addition, connective tissue growth factor 
and heat shock proteins, which are encoded by TGF-1-inducible genes, have 
fibrogenic effects on the kidneys of patients with diabetes
40
.   
There is some evidence to that VEGF increases permeability of the glomerular 
filtration barrier to proteins; however, surprisingly the levels of this growth factor 
can be low in rats with diabetes
41
.  Further evidence to support a pathogenic role for 
VEGF in diabetic nephropathy comes from the fact that VEGF blockade improves 
albuminuria in an experimental model of the disorder
35,36
.  However, some studies 
refute a causative role for high VEGF levels in diabetic nephropathy and suggest that 
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VEGF plays important role in mesangial cell development.  Eremina et al
42
 
demonstrated in a mouse model that VEGF is produced by podocytes and is crucial 
for glomerular endothelial cell survival and differentiation as well as for mesangial 
cell development and differentiation.  Gene expression of VEGF is decreased in 
humans with diabetic nephropathy, however it is not known if this is due to the 
podocyte loss in DKD.  In summary, the role of VEGF in the pathophysiology of 
nephropathy is largely unclear. 
Inflammatory cytokines also contribute to the development and progression of 
diabetic nephropathy, specifically interleukin 1 (IL-1), IL-6 and IL-18, and tumour 
necrosis factor and levels of these cytokines in serum and urine correlate with 
progression of nephropathy, as indicated by increased urinary albumin excretion
43
. 
Role of AGE-RAGE Axis in DKD 
 
There is growing body of evidence suggesting that AGE-RAGE axis is involved in 
the pathogenesis of DKD
44
.  Among various types of AGE receptors, RAGE is a 
signal transducing receptor for AGEs that could mediate the inflammatory reactions 
evoked by AGEs
45
.  In humans, RAGE expression is enhanced in podocytes and 
mesangial cells in diabetic patients with nephropathy
46
.  Animal studies show that 
RAGE-overexpressing diabetic mice have progressive glomerulosclerosis with renal 
dysfunction, compared with diabetic littermates lacking the RAGE transgene
47
.  
Studies have reported that diabetic homozygous RAGE null mice fail to develop 
mesangial matrix expansion or thickening of the glomerular basement membrane
44
.  
It has also been shown that streptozotocin-induced diabetic mice develop renal 
changes seen in human diabetic nephropathy such as glomerular hypertrophy, 
glomerular basement membrane thickening, mesangial matrix expansion, connective 
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tissue growth factor (CTGF) overexpression, and NFκB activation - all of which are 
blocked by the administration of neutralizing antibody raised against RAGE
48
.  The 
AGE-RAGE interaction can also induce sustained activation of NFκB because of 
increased levels of de novo synthesized NFκBp65 overriding endogenous negative 
feedback mechanisms and thus might contribute to the persistent damage to diabetic 
kidney
49
. 
 
Role of Oxidative Stress DKD 
Hyperglycaemia induces oxidative stress, even before diabetes becomes clinically 
apparent.  Concentrations of markers of DNA damage induced by reactive oxygen 
species are higher in patients with more-severe nephropathy (i.e. proteinuria versus 
micro-albuminuria).  Furthermore, histological analysis of human kidney biopsy 
specimens has detected products of glycooxidation (combined products of glycation 
and protein oxidation) and lipooxidation in the mesangial matrix and glomeruli, 
whereas these lesions are much less common in specimens from individuals without 
diabetes
50,51
.  However, the mechanisms by which the free oxygen radicals are 
involved in the pathogenesis of DKD are not well understood.   
Role of Lipids in Pathogenesis of DKD 
Progressive renal failure associated with proteinuria, is accompanied by 
abnormalities of lipoprotein transport
52
.  Typically, in DKD there are increased 
serum levels of triglycerides ,cholesterols, VLDL, apoB and pre-β HDL, and low 
levels of HDL and of apoA
53
. The mechanisms by which elevated lipids can progress 
the onset of DKD are unclear.  However, there is evidence that circulating lipids bind 
to and become trapped by extracellular matrix molecules , where they undergo 
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oxidation   which increases the formation of reactive oxygen species and reduces the 
actions of endothelium-derived vasodilators/growth inhibitors
54
.  This increase in 
reactive oxygen species and decrease in vasodilators can have significant vascular 
and renal pathophysiologic effects.  Small lipids derived from arachidonic acid have 
also been implicated in the pathogenesis of DKD.  Cyclo-oxygenase 2 breaks down 
arachidonic acid into several different prostanoids
55
  and in a rat model of 
streptozotocin-induced diabetes, levels of inflammatory prostanoids, such as 
prostaglandins E2 and I2, were raised.  However, a more detailed characterisation is 
needed of how the production of prostanoids affects the pathogenesis of DKD in 
humans. 
 
VIII. Heritability of diabetic nephropathy 
Heritability of DKD has been established by demonstration of familial clustering of 
the disease and estimations of heritability of albuminuria and eGFR using family 
based studies. 
Familial Clustering of Diabetic Nephropathy 
Seaquist et.al first demonstrated familial clustering of DKD
56
.  The study showed 
that out of the 29 diabetic siblings of probands with diabetic nephropathy, 24 (83%) 
had evidence of nephropathy including 12 with end-stage renal disease while 
evidence of nephropathy was found in 2 of the 12 diabetic siblings of the probands 
without nephropathy (17%).  A few years later in 1992  a study in Denmark
57
  
looked at of 619 patients with IDDM; the study identified 20 patients with and 29 
without nephropathy as having diabetic siblings.  Diabetic nephropathy was found in 
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7 out of 21 siblings to patients with nephropathy and 3 out of 30 siblings to normo-
albuminuria patients.  There were no significant differences between the two groups 
of siblings with respect to age, diabetes duration, sex distribution, blood pressure, or 
glycosylated haemoglobin A1c- levels.  A study in Pima Indians, a homogeneous 
population with a high occurrence of NIDDM showed that the families in which two 
successive generations had Type 2 diabetes the likelihood of the offspring 
developing overt nephropathy was 14% if no parent had proteinuria, 23% if one 
parent had proteinuria and 46% if both parents had proteinuria
58
.  Subsequently, the 
familial aggregation of DKD was also observed in India
59
, South America,
60
 and 
Asia
61
.  In spite of the repeated confirmation, there was always concern that all these 
single centre reports of familial aggregation could be biased and the observed 
clustering could have been a result of shared environment, for example, lack of 
access to health care or an unrecognised environmental risk factor.  Finally a large 
multi-centre analysis in 2005
62
 involving 26,000 incident dialysis patients in 450 
dialysis clinics across the United States were screened for family history of ESRD.  
After removal of individuals with known genetic or urologic disorder, the study 
found that 32% of women and 27% of men with African ancestry and a 15% and 
12% of European American women and men respectively reported having a close 
relative with ESRD.  In a small subset of the same dataset
63
, 66 unrelated index 
African American cases with overt Type 2 DN/ESRD, 132 of their diabetic sibs, and 
13 of their non-diabetic sibs, more than 60% of index cases had at least one diabetic 
sibling with overt proteinuria.  The findings of this large multi-centre study 
confirmed the earlier single centre reports across the globe and firmly established 
familial aggregation of DKD. 
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Heritability Estimates for Diabetic Nephropathy  
Heritability estimates for diabetic nephropathy have been reported for both 
albuminuria (urine albumin-creatinine ratio (ACR)) and renal function (GFR), 
confirming genetic contributions to the pathogenesis of DKD.   
Heritability measures the fraction of phenotype variability that is because of the 
genetic variation.  Most of  common complex diseases have both environmental and 
inherited effects and the purpose heritability is measure of genetic component of the 
disease 
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“H2” is the broad-sense heritability, which is the sum of all the sources of genetic 
variations that can be attributed to the disease.  “h2” on the other hand is a capture of 
whole genome additive genetic variations as measured by a microarray, which can 
be attributed to disease and is also known as “chip based” or narrow sense 
heritability. 
Heritability has been estimated for both albuminuria and eGFR in patients with T1D 
and T2D.  A heritability (H
2
=1) suggests a Mendelian disorder while and heritability 
(H
2 
<1) suggests some contribution from environment.  Estimates of heritability for 
albuminuria varied  from 0.30 to 0.44 in Finnish
65
, New England
66
, and south-
eastern US
67
 families enriched for members with Type 2 diabetes, and the estimate 
was slightly larger in (0.49) in Hypertension Genetic Epidemiology Network 
(HyperGEN) families enriched for multiple siblings with hypertension
68
.  The 
heritability estimates for GFR on the other hand varied from 0.36 to 0.75
67,69,70
 in the 
populations with European ancestry.  
 Differences in the heritability of albuminuria and eGFR suggest presence of distinct 
genetic loci, and pathogenic mechanisms affecting renal vascular permeability and 
renal function in general.  It is known that kidney diseases characterized by 
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albuminuria, such as diabetic nephropathy can have ultrafiltration and high eGFR in 
the early stage of disease while those characterised by reduced renal function like 
hypertensive kidney disease may manifest with normo-albuminuria because of the 
reduced renal efficiency
71,72
.  Differences in the heritability estimates for 
albuminuria and eGFR, and the fact that both albuminuria and eGFR influence each 
other during the course of diabetes indicate the need to adjust for albuminuria while 
estimating the loci for eGFR and vice-versa. 
 
IX. Animal Models for Diabetic Kidney Disease 
At present, there are no reliable animal models that completely mimic human DKD.  
Chemical agents such as streptozotocin (STZ) can selectively damage the insulin-
producing beta cells in the pancreas resulting in hyperglycaemia and is considered an 
important tool for developing animal models of diabetic complications
73
.  While this 
model induces kidney hypertrophy and mesangial expansion, it does not progress to 
more advanced renal disease as seen in humans (loss of glomerular filtration, overt 
proteinuria, advanced structural lesions and tubulointerstitial fibrosis)
73
.  Mouse 
models of endothelial dysfunction, with a targeted mutation in the NOS3 gene 
encoding endothelial nitric oxide synthase are one of the more robust models of 
advanced renal disease in diabetes; these animals exhibit both decline in glomerular 
filtration and tubulointerstitial fibrosis
74
.  A recently developed mouse model with a 
leptin receptor mutation develop Type 2 diabetes, hypertension, obesity and 
proteinuria, reduced glomerular filtration, mesangial matrix expansion and podocyte 
loss
75
, thereby mimicking diabetic kidney disease.  Although no single-animal model 
exists, that shows exact pathophysiological features of established DKD Type 1 and 
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Type 2 diabetes, these have provided valuable information regarding many aspects 
of DN including pathophysiology and putative roles of implicated genes.  Having 
better animal models for DKD are important to test the hypothesis generated by 
GWAS studies for DKD and to test treatment strategies based on those hypothesis.  
 
X. Candidate Gene Studies, Sib pair Studies and GWAS Studies for 
Kidney Disease 
Literature Review Candidate Gene Studies for Diabetic Nephropathy and CKD 
in Diabetes 
The candidate gene approach to conducting genetic association studies focuses on 
associations between genetic variation within pre-specified genes of interest and 
phenotypes or disease states.  Most often, selection of candidate genes for study is 
based on a priori knowledge of the gene’s biological functional impact on the trait or 
disease in question.  For DKD, the choice of the genes for study depends on 
knowledge concerning its actions in DKD pathophysiology such as those involving 
blood pressure control, severity of proteinuria, insulin resistance, lipid metabolism 
and other mechanisms implicated in the pathogenesis of diabetic nephropathy.  There 
are about 209 genes, which have been investigated for their association with DKD 
using a candidate gene approach.  Table 4 summarizes some of the commonly 
investigated genes associated with Diabetic Nephropathy and the review briefly 
discusses the top four biologically relevant and candidate genes for DKD.  
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Table 4: Top Candidate Genes for Diabetic Nephropathy 
Gene 
Number of 
Association Studies 
Number of 
Meta-analysis Involved KEGG pathways 
    ACE     56 4 Renin-angiotensin system 
    NOS3     24 5 Calcium signalling pathway, VEGF signalling pathway, 
    TGFB1     15 1 
TGF-beta signalling pathway, Colorectal cancer, Cell 
Cycle 
    MTHFR     22 3 One carbon pool by folate, Methane metabolism 
    AGT     22 2 Renin-angiotensin system 
    APOE     21 2 Alzheimer's disease, Neurodegenerative diseases 
    AGTR1     19 2 
Retroactive ligand-receptor interaction, Calcium 
signalling pathway 
    CNDP1     12 1 Histidine metabolism, beta-Alanine metabolism 
    PPARG     11 1 PPAR signalling pathway, Endometrial cancer 
    AKR1B1     11 2 
Glycolipid metabolism, Pyruvate Metabolism Galactose 
metabolism  
    RAGE     10 0 - 
    ADIPOQ     9 1 
Adipocytokine signalling pathway, PPAR signalling 
pathway, Type II diabetes mellitus 
    CCR5     9 1 Cytokine-cytokine receptor interaction 
    ELMO1     7 1 - 
 
Angiotensin Converting Enzyme gene (ACE) 
The angiotensin-converting enzyme (ACE), a potent vasoconstrictor, catalyses the 
conversion of angiotensin I to angiotensin II and inactivates bradykinin, a 
vasodilator; by proteolysis
76
.  The angiotensin-converting enzyme gene (ACE) on 
chromosome 17q23 has repeatedly been evaluated for a role in DKD.  In 1994, the 
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first evidence of involvement of ACE genotypes with DKD was reported by a 
French group
77
.  The study compared 62 IDDM subjects with diabetic nephropathy 
with 62 diabetic controls with normal kidney function - with respect to the 
insertion/deletion polymorphism of the ACE gene (which predicts circulating ACE 
levels).  This low powered study observed an imbalance of ACE genotype 
distribution, with a low proportion of subjects homozygotes for insertion at ACE 
polymorphism, was observed in IDDM subjects with diabetic nephropathy compared 
with their control subjects with diabetes without nephropathy.  Subsequent to these 
observations, several reports contested these findings and reported no association of 
ACE gene with DKD
78-82
.  Following these a first large-scale, prospective multi-
centre study (17 centres in France and Belgium) on insulin-dependent diabetic 
subjects, GENEDIAB
83
, looked at the association of  insertion/deletion (I/D) 
polymorphism with severity of nephropathy and reported a positive association, chi2 
for trend 5.135, P = 0.023; adjusted odds ratio attributable to the D allele 1.889 (95% 
CI 1.209-2.952, P = 0.0052).  Given its biological functions and its relevance to the 
renal physiology, ACE seems to be a compelling candidate for DKD susceptibility; 
however, several non-replications and lack of evidence from GWAS studies suggest 
that it might contribute to small proportion of variability of DKD in Patients with 
Type 2 diabetes.  
Nitric Oxide Synthase 3 (NOS3) Gene 
Nitric Oxide has been reported to be an important regulator of renal hemodynamic in 
the vascular endothelium
84-86
 and Nitric Oxide production can be influenced by 
polymorphisms of the NOS gene.  Polymorphisms, which can decrease Nitric Oxide 
production, can increase in arterial pressure and thus can be associated in the 
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pathways of renal disease in DM.  The first report of association of the Glu298Asp 
mutation of the NOS3 gene was shown in a study
85
 in Japanese population consisting 
of 159 patients with all cause-ESRD undergoing maintenance haemodialysis and 270 
genetically healthy control subjects.  This showed increased frequency of 
Glu298Asp(rs1799983) or eNOS-894(G894T)  mutation in patients with ESRD 
(22.0%), non-diabetic renal diseases (22.5%) and diabetic renal disease (20.8%) as 
compared to compared with controls.  Since then, three polymorphisms in the NOS3 
genes, eNOS-4b/a, eNOS-894(rs1799983) and eNOS-764(rs2070744) have been 
studied extensively for their association with DN.  A recent study by Yanming He et 
al
87
 conducted a meta-analysis of 18, 10 and 3 eligible studies eNOS-4b/a, eNOS-
894(G894T) and eNOS-764(T786C) respectively.  3,793 patients (DKD) and 3,161 
controls (diabetes without DKD) for 4b/a, 2,654 patients and 1,993 controls for 
eNOS-894 and 1,348 patients and 1,175 controls for eNOS-764 were included in the 
analysis.  This study showed that the eNOS-4b/a was significantly associated in the 
overall meta-analysis with a stronger association in Asian population (OR 1.10 
overall vs. OR=1.7 in Asian) and showed no association in the Caucasian subgroup.  
Similarly, the eNOS-894 polymorphism showed association only in the Asian 
population suggesting an ethnicity specific association of NOS3 gene with DKD.  
The eNOS-764 showed a weak association in overall study population and did not 
have enough power to detect ethnicity specific association.  A second meta-analysis 
with additional data for eNOS-894(G894T), (3,585 cases and 3,140 controls) showed 
that that the 894T was negatively associated with DKD in Caucasian populations of 
European origin but was positively associated with DKD in East Asian
88
. Taken 
together, results so far suggest that polymorphisms in NOS3 gene can alter 
susceptibility to DKD in DM; however, this association could be ethnicity specific. 
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Apolipoprotein E (APOe) 
APOE is the coding gene for apolipoprotein E.  The genetic association studies for 
diabetic nephropathy have looked at three APOE alleles, ε2 ε3 and ε4 encoding three 
isoproteins E2 E3 and E4.  A recent meta-analysis
89
 of 17 studies in the Asian 
populations show that those with an APOε2 had almost double the risk of DKD as 
compared to those without it (OR=1.85, CL=1.49, 2.29). Studies which looked at ε4 
alleles did not find an association of ε4 with DKD overall, however, a subset 
analysis in Chinese population showed an increased risk of DKD (OR=1.51, CL 
1.11-2.06) and no association in the Korean and Japanese populations.  A meta-
analysis in European population
90
, showed no association of the APO- ε2 variants 
with DN while no European study has looked at the effect of APO- ε4 on DKD.  The 
differential effect of the APOe alleles on DN by ethnicity suggests either a possible 
genetic heterogeneity in the mechanisms through which the APOE affects DKD or 
presence of additional environmental factors (lifestyle, BMI) which interact with 
APOE to produce the DKD phenotypes. 
TGFβ1 (Transforming growth factor beta 1) 
TGFβ1, a ﬁbrogenic cytokine with strong regulatory effects on renal cell 
hypertrophy and extracellular matrix accumulation is known to play a pivotal role in 
the initiation and progression of  DKD in animal models
91
.  Animal research has 
shown that mice over-expressing TGF-b1 were affected by progressive renal 
failure
92
, and administration of anti-TGF-b1 antibody could inhibit glomerular 
hypertrophy and excessive extracellular matrix gene expression, and thus prevent the 
development of DKD
93
.  Therefore, TGFβ1 is considered as a functional candidate 
for DKD.  Answer: In diabetic nephropathy matrix accumulation in both glomeruli 
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and the interstitium correlates with both degree of renal insufficiency and 
proteinuria
94
 .  TGF-beta  is potent fibrotic cytokine and therefor of considerable 
interest in DKD.  Involvement of TGF-beta   in T2D-DKD suggests that   T2D-DKD 
is a pro-fibrotic chronic inflammatory condition.  It also suggests that a better 
understanding of the activation of TGF-β signaling and its downstream regulators 
may provide new insights for the prevention of progressive diabetic nephropathy.  A 
recent meta-analysis
95
 of nine studies looked at association of TGFβ1 and DN in 
Type 1 and Type 2 diabetic nephropathy.  This study showed signiﬁcant association 
of TGF-b1 T869C polymorphism in both Asian and European population with DKD 
only in Type 2 diabetic subjects, but not in Type 1 diabetic patients.  None of the 
candidate studies till date have shown an association of TGFβ1 with T1D –DKD96; 
however, a recent GWAS in patients with Type 1 diabetes suggests that that AFF3 
gene can influences renal tubule fibrosis via the transforming growth factor-beta 
(TGF-β1) pathway97.  TGFβ1, given its functional significance is a promising 
candidate for DN and further studies looking at the association of TGFβ1 with DN 
and its interaction with other candidate genes are warranted. 
Candidate Gene Studies Summary 
The limitations of genetic sequencing technology restricted the search for genetic 
variants, which influence DKD to association studies of ‘likely genes’ that are 
selected based on their pathways and knowledge of the pathophysiology of DN.  
This approaches although very appealing, has some inherent limitations: 1) Our 
understanding of the pathophysiology of DKD is limited and all the pathways, which 
can explain the predisposition, onset, and progression of DKD, are not precisely 
defined.  Thus, this restricts the selection of ‘likely genes’ for candidate gene studies.  
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2) The candidate gene studies typically a have small sample size and very limited 
power to detect the variants, which cause modest increase in risk of DKD.  It is 
possible to increase the power by meta-analysis (combing the published data on 
genetic variants across a number of studies and ethnic groups); however, these 
studies suffer from heterogeneity introduced by different study designs different 
phenotypes, genetic models and population stratification.  A recent study by 
Mooyaart et al
90
 combined data from 671 candidate gene association studies 
investigating genetics of DKD.  In this study only three genetic variants met 
stringent criteria for significance, the ACE I/D APOE and AKRB1 in a random 
effects model, highlighting the limited power of these candidate gene meta-analyses.  
3) Finally the non-replication of most of the genes identified by candidate gene 
studies (in the recent GWAS analysis) suggest possibility of publication bias, 
wherein marginally significant, falsely positive findings appear more in the literature 
whereas falsely negative studies are not published.  With the advent of newer and 
cheaper sequencing technologies, candidate gene studies for DKD are performed to 
examine ‘extremely compelling candidates’ in novel pathways or for replication of 
genes already identified through GWAS. 
 Literature Review of Genome-wide Sib-pair studies for DKD 
If a marker is significantly more common in the family members with DKD, it 
indicates presence of a susceptibility region on the chromosome associated with the 
phenotype of interest.  For T1D usually both parents with affected offspring (trios) 
are included in the study, while in T2D the analysis involves sibling pairs since 
parents are usually unavailable at the time of recruitment.  Over the last decade, 
several genome wide linkage scans looking to identify susceptibility to T1-DKD and 
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T2-DKD have been reported (Table 5).  These studies have identified several 
chromosomal regions that appear to be associated with the development and 
progression of diabetic nephropathy.  Follow-up studies of the linkage peaks thus 
identified have demonstrated associations of several plausible candidate genes with 
DN.  For example, four independent genome-wide linkage studies have identified 
chromosome 3q as a major locus for diabetic nephropathy susceptibility gene and a 
follow-up study
98
 of the 3q peak demonstrated a significant association of diabetic 
nephropathy to IL20RB-NPMIP17 gene region on that chromosomal.  Other 
chromosomal regions have also been associated with diabetic nephropathy in 
different populations.  For example, the Family Investigation of Nephropathy and 
Diabetes (FIND)
99
, looking at the predisposition for nephropathy in diabetic sibling 
pairs concordant and discordant for diabetic nephropathy, found the strongest 
evidence of linkage to the diabetic nephropathy trait on chromosomes 7q, 10p, 14q 
and 18q.  Subsequently, these have been replicated by genome-wide linkage studies 
in other populations.  For example, the locus on chromosome 18q demonstrated in 
the FIND study has also been linked to diabetic nephropathy in African–
Americans
100
 with diabetes, Pima-Indians
101
 and African American populations
102
.  
While the linkage studies have helped in understanding the genetic architecture of 
DKD and confirmed the genetic predisposition to DKD.  However, these studies are 
non-specific and identify large regions of genome associated with the DN phenotype, 
rather than identifying the specific locus/variant.  Hence, the advent of cheaper 
genotyping technologies has seen a phasing out of linkage studies and has made 
GWAS an investigation of choice for identifying susceptibility loci for DKD. 
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Table 5: Genome wide Association studies using Sib Pair Designs for Type 1 and Type 2 Diabetic Nephropathy 
 
Authors Year Ethnicity Study Type and Sample Size Phenotypes Linkage Peaks 
Type 2 
Diabetes 
Imperator et.al103 1998 Pima Indians Sibling Pairs Proteinuria and ESRD 7q, 3q 
Vardarlu et.al101 2002 Turkish 18 Turkish families(368 subjects) Proteinuria 18q 
Bowden et.al100 2003 African Americans 
206 affected sib pairs from 166 African American families (355 
affected individuals) 
ESRD 3q,7p,18q 
Freedman et.al44 2005 Caucasians 
 
ESRD 13q, 9q,4p,1q 
Krowleski et.al104 2006 Caucasians 
63 extended families with an average of 6.8 diabetic members (range 
2–14) and 6.8 nondiabetic members (range 1–18) per family 
ACR 5q,7q,22p 
Placha et.al70 2006 Caucasians 63 extended families 406 type 2 diabetes eGFR 2q,10q,18p,3q,7p 
Iyengar et.al105 2007 
Caucasians, African American 
and Mexican Americans 
1,227 participants from 378 pedigrees Proteinuria and ESRD and ACR 10p,14q,18q,2q,7q,15q 
Chen G et al106 2007 West Africans 321 sib pairs and 36 half-sib pairs, 691 patients 
Serum creatinine, Creatinine 
clearance and eGFR 
16q24,7q 
Freedman et.al107 2008 
Caucasians and African 
Americans 
eGFR, ACR 
creatinine ratio (ACR), serum 
creatinine 
2p,7q,13q,3p,10p 
Igo Rp et.al99 2011 
African-American, American-
Indian, European-American 
and Mexican-American 
1,235 nuclear and extended pedigrees (3,972 diabetic participants) 
urine albumin: creatinine ratio 
(ACR) 
6p,7p,3p,7q,16q, 22q 
Type 1 
Diabetes 
Moczulski et.al108 1998 Caucasians 66 discordant sib pairs for DN Proteinuria, ESRD 3q 
Osterholm et.al109 2007 Finnish 83 discordant sib pairs for DN Proteinuria 3q 
Rogus et.al110 2008 Caucasians 100 discordant sibpairs for DN Proteinuria and ESRD 19q, 6p, 6q, 3q 
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 Genome-wide Association Studies for Diabetic Nephropathy 
The development of advanced DNA sequencing technologies and improvements in 
computational power to analyse large-scale data has changed the genetic 
investigation of common complex disorders.  GWAS operate on the assumption of 
“common variant common disease” hypothesis111, which predicts that common 
disease-causing alleles - or variants - will be found in all human populations which 
manifest a given common disease.  Since the prevalence of DKD is common (up to 
40%, USRDS, 2003) in both T1D and T2D patients, GWAS are considered as an 
appropriate tool to investigate the common variants associated with DKD.  Over the 
last decade, several GWAS have attempted to identify the key loci associated with 
T1D nephropathy and T2D nephropathy.  We will now review some of these some 
of these GWAS studies with adequate sample sizes and a positive replication. 
GWAS for T1D Nephropathy in Genetics of Kidneys in Diabetes Collection 
(GoKinD)  
This study
112
 genotyped  approximately 360,000 SNPs in 820 case subjects (284 
with proteinuria and 536 with end-stage renal disease) and 885 control subjects with 
Type 1 diabetes Affymetrix 5.0 500K SNP array and sought replication in 1,304 
participants of the Diabetes Control and Complications Trial (DCCT)/Epidemiology 
of Diabetes Interventions and Complications (EDIC) study
113
 - a long-term, 
prospective investigation of the development of diabetes-associated complications.  
Case subjects with diabetic nephropathy had either persistent proteinuria, defined by 
a urinary ACR ≥300 μg/mg in two of the last three measurements taken at least one 
month apart, or ESRD (dialysis or renal transplant).  Controls for DKD had Type 1 
diabetes for at least 15 years and normo-albuminuria, (defined by an ACR <20 
μg/mg in two of the last three measurements taken at least one month apart without 
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any antihypertensive treatment).  The strongest with nephropathy association was at 
the FRMD3 (odds ratio [OR] = 1.45, P = 5.0 x 10(-7)) and CARS) locus (OR = 1.36, 
P = 3.1 x 10(-6)).  Associations between both loci and time to onset of diabetic 
nephropathy were supported in the DCCT/EDIC study (hazard ratio [HR] = 1.33, P = 
0.02, and HR = 1.32, P = 0.01 respectively).  This study, however, had several 
limitations.  None of the markers tested for association with DKD reached genome-
wide significance in the discovery cohort.  The discovery cohort was a cross-
sectional case-control sample while replication was sought in a prospective survival 
analysis model looking at the time to onset of severe nephropathy in the 
DCCT/EDIC study cohort.  Due to differences in study design in the discovery and 
replication cohorts, the authors were unable to report on the joint effect of the two 
studies.  Another limitation of the study is the high proportion of patients with ESRD 
(60%) in the discovery cohort.  This limited the ability of the study to detect variants 
associated with proteinuria.  In addition, since the patients with ESRD had survived 
on dialysis or transplant for several years, a variant, which can increase mortality or 
cause a severe ESRD, can go undetected.  
GWAS for Type 1 Diabetic Nephropathy in American European Population 
(Genie Study) 
In the Genetics of Nephropathy: an International Effort (GENIE) consortium
97
, a 
meta-analysis of genome-wide association studies (GWAS) of T1D DN comprising 
~2.4 million single nucleotide polymorphisms (SNPs) imputed in 6,691 individuals 
from the UK-ROI, GOKIND US and FinnDiane cohort.  The study genotyped 41 top 
ranked SNPs representing 24 independent loci in and additional sample of 5,873 
individuals.  Combined meta-analysis revealed association of two SNPs with ESRD: 
rs7583877 in the AFF3 gene (P = 1.2×10−8) and an intergenic SNP on chromosome 
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15q26 between the genes RGMA and MCTP2, rs12437854 (P = 2.0×10−9).  
Functional data reported in the study suggested that AFF3 influences renal tubule 
fibrosis via the transforming growth factor-beta (TGF-β1) pathway.  This AFF3 
locus, however, was driven by two cohorts and technically did not replicate (p=0.25 
in stage 2 replication), although the direction of effect was consistent across studies.  
The strongest association with DKD (any albuminuria vs. no albuminuria) as a 
primary phenotype was seen for an intronic SNP in the ERBB4 gene (rs7588550, P = 
2.1×10−7).  Although both AFF3 and ERBB4 represent new signals in the 
pathogenesis of DN lack of significant association in replication analysis calls for 
independent confirmation of this locus in other studies before their implication for 
DN pathogenesis can be examined. 
GWAS for Type 2 Diabetic Nephropathy in African American Population 
(McDnough 2010) 
This study
114
 genotyped 832,357 autosomal SNPs in 965 Type 2 diabetic African 
American patients with end-stage renal disease (ESRD) and in 1029 African 
Americans without Type 2 diabetes or kidney disease as controls on an Affymetrix 
6.0 platform.  Patients with T2DM-ESRD were recruited from dialysis facilities at 
the Wake Forest University.  T2DM was diagnosed in African-Americans who 
reported developing diabetes after the age of 25 years and who did not receive only 
insulin therapy since diagnosis.  Cases had T2DM diagnosed at least 5 years before 
initiating renal replacement therapy, background or greater diabetic retinopathy, 
and/or ≥100 mg/dl proteinuria on urinalysis in the absence of other causes of 
nephropathy (T2DM-ESRD subjects).  Unrelated African American controls without 
a current diagnosis of diabetes or renal disease were recruited from the community 
and internal medicine clinics (Control subjects).  For replication of the top markers 
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African American T2DM-ESRD cases and non-diabetic, non-nephropathy controls 
were recruited using the same criteria as the case and control subjects that were used 
in the GWAS.  The strongest association on a combined analysis of discovery and 
replication cohort was seen with rs6930576 (P = 7.04×10−7) in the SASH1 gene, 
rs7769051 (P = 6.45×10−6) in the RAS12 gene, rs773506 (P = 6.45×10−6) in the 
AUH gene, rs2358944 (P = 3.54×10−6) within the RASAP2 gene.  The other SNPs 
located in the LIMK2 gene reached near GWAS significance rs2106294, rs4820043 
and rs5749286 (P = 4.11×10−6 and 5.07×10−6, 9.79×10−6).  The MYH9 SNP seen 
in the initial GWAS, rs5750250 did not replicate and had a combined P value = 
1.66×10−7.  One of the major limitations of the study design was the fact that it 
looked at the association of diabetic ESRD versus non-diabetic non-ESRD controls.  
So the associated SNPs could either be associated with T2D nephropathy or all-cause 
ESRD or T2D itself.  The authors tried to address this issue by genotyping additional 
1,246 AA T2DM, non-nephropathy cases and 1,216 non-T2DM ESRD cases to 
differentiate between T2DM-ESRD, T2DM, and all-cause ESRD loci.  The authors 
hypothesized that T2DM-ESRD SNPs should have allele frequency differences 
when compared with cases with T2DM alone (lacking nephropathy) and observed 
that there were difference in the allele frequencies  between T2DM-ESRD SNPs and 
T2DM-non-ESRD SNPs for the top 25 SNPs in the combined analysis, suggesting 
that there were therefore indeed ESRD associated SNPs.  However, since the 
discovery cohort and the replication cohort had compared diabetic ESRD vs. non-
diabetic non-ESRD controls it is possible that the study failed to identify DM 
specific ESRD loci with modest effect sizes.  The study also evaluated preciously 
reported genetic associations (PVT1, FRMD3, CARS, ACACB, NEDD4L, 
SERPINB7, CNDP1, CNDP2, ELMO1, SHROOM3, UMOD, GATM-SPATA5L1, 
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GCK2, ALMS1, DAB2, SLC34A1, VEGFA, SLC22A2, PRKAG2, STC1, ATXN2, 
DACH1, SLC7A9) with DN/ESRD in Caucasians and Asian populations.  None of 
these genes were associated with DKD in African-American population after 
correction for multiple comparisons indicating either a genetic heterogeneity in the 
pathogenesis of  DKD-ESRD in those with African ancestry or a limited power of 
the study to detect these genetic effects in an admixed population.  Finally, none of 
the markers in the study reached threshold for GWAS significance suggesting a need 
for further replication and analysis of these markers in larger cohorts of  DKD-
ESRD. 
GWAS for DKD stratified by MYH9 and APOL1 Risk Variants  
This study
115
 performed genome-wide association analyses using the Affymetrix 
SNP Array 6.0 in 966 African Americans with T2DN and 1,032 non-diabetic, non-
nephropathy (NDNN) controls, with and without adjustment for MHY9 and APOL1 
nephropathy risk variants on chromosome 22.  The study hypothesized that 
since
115,116
 MHY9 and APOL1 are strongly associated with nephropathy in African 
Americans
116
; these variants could mask the effects of other variants with smaller 
effect size.  MYH9/APOL1 locus was first identified by admixture mapping study 
for ESRD in African-American population.  The admixture mapping studies are 
based on the hypothesis that the since the African ancestry is a risk factor of ESRD, 
the regions of genome with significantly high proportion of African Ancestry (as 
compared to the controls) are more likely to harbour the disease causing gene.  This 
study
116
 looked at 1372 cases with ESRD and 806 controls with ESRD and found 
significantly excess African ancestry for ESRD phenotype on 22q12 region 
harbouring the MYH9/APOL1 gene.  
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 Stratified analyses based on the chromosome 22-nephropathy risk haplotypes 
demonstrated that FRMD3 variants were associated with diabetic nephropathy risk in 
cases without two MYH9 (or APOL1) risk haplotypes.  This effect was replicated in 
an independent sample of 640 African Americans cases of DN and 683 African 
American Controls without DKD.  An important lesson from the study is that if there 
is a common haplotype with big effect size on a given phenotype, it may mask the 
effects at other loci with modest effect sizes.  This is important information to 
consider while designing GWAS studies, where most of the variants tend to have 
smaller effect sizes and their effects can be masked by a single variant with big 
effect size.  Hence, it is important to do genome-wide conditional analysis to see 
after the DKD GWAS to identify if a single SNP with a big effect size is masking 
the effects of other SNPS with smaller effects. 
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Table 6:  Genome-wide Association Study for Diabetic Nephropathy 
 
Study Phenotype  Initial Sample Size Replication Size Gene  Region  OR/Beta Top P-value Platform 
Maeda,2007117 ESRD 
94 cases,  
No replication ELMO1  7p14.2 2.67 8x10-6 NR [~80,000] 
94 controls  
Hanson,2007118  ESRD 
105 cases,  
No replication PVT1 8q24.21 2.97 2x10-6 
Affymetrix 
[115,352] 102 controls 
Craig,2009119  ESRD 
547 Caucasian cases,  
No replication 
ZMIZ1   1.47 8.1 x 10-5 
Illumina [474,050] 
(pooled) 
549 Caucasian controls  LOC100132891   1.56 1.6 x 10-5 
Pezzolesi,2009112  ESRD  
820 cases,  
1,304 individuals 
FRMD3 9q 1.45 6.3 × 10-7 
Affymetrix 
[359,193] 885 controls  
  
CARS 11p 1.36 6.4 × 10-7 
CPVL/CHN2 7p 1.39 5.0 × 10-6 
McDonough, 2010114 ESRD  
965 African American cases,  
709 African 
American cases, 690 
African American 
controls 
RPS12 6q23.2 1.28  2x10-6 
Affymetrix 
[832,357] 
SASH1  6q24.3 1.31  7x10-7 
1,029  
African American controls 
LIMK2  22q12.2 1.75  4x10-6 
MSRB3-HMGA2  12q14.3 1.33  4x10-6 
Freedman BI, 2011115  ESRD  
952 African American cases,  640 African 
American cases, 683 
African American 
controls 
FRMD3  9q21.32 1.28 4.82x10−4 
Affymetrix 
[832,357] 
988  
African American controls 
N Sandholm 201297 DN and ESRD 
1399 cases,  387 cases/3465 
controls 
AFF3  2q11.2-q12  1.23 2.04x10-9 
Omni1-Quad array 
/Affymetrix 500  
5253 controls 
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 Summary of Genetic Epidemiology studies for Diabetic Nephropathy 
Advances in sequencing technologies have led to a series of candidate gene studies 
linkage studies and GWAS in the last two decades.  With these efforts, there is 
indeed a better understanding of genetic susceptibility to DKD; however, the lack 
reproducibility of genetic DN studies has been a disappointing factor.  For example, 
some of the obvious candidates for DN such as the ACE, APOe and TGFβ2 have not 
replicated in the GWAS studies so also are the established loci from the sib-pair 
analysis; while most of the GWAS loci do not fall in the known linkage peaks.  
There can be several reasons for this non-replication.  
The variable definition of DKD in genetic epidemiology studies can explain the 
overall disappointing reproducibility of genetic DKD studies.  There are two 
important aspects to diabetic kidney disease- diabetic albuminuria and renal function 
decline.  DKD is characterised by intersecting stages of declining GFR and 
progressive proteinuria, both influencing each other
120
 finally leading to ESRD.  
However, most of the studies looking at the DKD focus only on one aspect of the 
disease – mostly albuminuria.  Some studies have used the most severe forms of 
DKD (ESRD) to define cases reduces some potential misclassification of phenotype 
but still this does not overcome the critical inaccuracy of case definition not based on 
histology.  In addition, cases with ESRD are by definition survivors (although 
nephropathy is also the leading risk factor for premature mortality at population 
level); and by modelling ESRD these studies might be identifying genes protective 
for DKD mortality.  One way of addressing this issue in GWAS would be modelling 
all the intermediate phenotypes in DKD such a micro-albuminuria, macroalbumiuria 
and ESRD and adjusting for eGFR while modelling albuminuria in GWAS studies of 
DKD.   
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Chip-based heritability can now be estimated using GWAS data set quantifying the 
additive genetic variance explained by all SNPs in GWAS datasets
121
 and this 
information can be used to make a priori selection of  DKD phenotypes.  Estimation 
of chip-based heritability with GCTA needs large sample sizes-and can be 
computationally challenging, however, this approach can be used to fine-tune the 
phenotypic definitions for DKD. 
Another problem with trying to identify genetic loci for diabetic nephropathy in 
Type 2 diabetes is that in most studies it is difficult to obtain information regarding 
the major risk factors – duration of diabetes and duration of hyperglycaemia.  Most 
people with Type 2 diabetes are diagnosed years after the disease begins: therefore, 
there is great inaccuracy in diabetes duration prior to the development of diabetic 
nephropathy.  This has detrimental effects on the measurement of long-term 
glycaemia – if we do not know when the diabetes and glycaemia began, we cannot 
adequately adjust of the most important determinant of DN in genetic models.  These 
can reduce the power to estimate true genetic effects. 
Finally, most of the candidate genes and GWAS until date have been underpowered 
due to the limited sample sizes.  The reductions in the costs for genotyping 
technologies and international collaborations can overcome this problem and 
adequately power GWAS meta-analysis can provide adequate power to identify the 
DKD susceptibility variants. 
In spite of the shortcomings and challenges of the GWAS studies in DKD, it is clear 
that GWAS studies with adequate sample size, precise phenotype definitions, and 
well-defined analysis plan can identify novel loci associated with DKD and pursuit 
of these loci can provide new insights into the pathogenesis of DKD.  These insights 
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in turn will help in designing methods for screening prevention and treatment of 
DKD. 
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Aims 
The broad aim of this thesis is to increase our understanding of the genetic 
determination of diabetic kidney disease.  This will be achieved by the following 
sub-aims: 
I. Estimating the chip-based heritability of various DKD sub-phenotypes 
Diabetic kidney disease can be classified into various stages based on the levels of 
albuminuria excretion and estimated Glomerular filtration rate (eGFR).  These sub-
groups can represent various stages in pathogenesis of DKD, which in turn can have 
different genetic and environmental determinants.  There are no heritability estimates 
for genetic determinants of these albuminuria and eGFR based subgroups.  The aims 
of this analysis are  
1) to quantify and compare chip based heritability of various DKD subgroups 
using a GWAS dataset in patients with Type 2 diabetes 
2) to conduct a bivariate analysis to estimate shared heritability between blood 
pressure and DKD,  and HbA1c and DKD using a GWAS dataset in patients 
with Type 2 diabetes 
 
II. Replication of known SNPs for upstream risk factors for DKD (HbA1c 
and BP) and look at the cumulative effect of these on DKD 
HbA1c and BP are known upstream risk factors for DKD.  Several GWAS studies 
have identified loci associated with HbA1c and BP.  To what extent diabetes status 
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attenuates or exaggerates these associations with HbA1c and BP is unknown.  The 
aims of this analysis are  
1) to establish the association of known GWAS identified SNPs for HbA1c and 
BP in patients with Type 2 diabetes 
2) to study the cumulative effect of HbA1c and BP associated SNPS on DKD 
using genetic risk score analysis in patients with Type 2 Diabetes  
 
III. Replication of the known loci for eGFR in general population in patients 
with T2D and identifying loci for CKD by contributing to the 
international consortia studying genetics of CKD (CKDGen) 
GWAS studies have identified SNPs associated with eGFR in general population.  
However, there are no independent replications exclusively in patients with Type 2 
diabetes.  The aim of this study is  
1) to replicate the association of  eGFR associated loci in general population in 
patients with T2D 
2)  to estimate the effect of albuminuria on association of  eGFR with known 
SNPs for eGFR 
3) to contribute data to the CKDGen consortium for replication of their top 
SNPs 
 
IV. Performing a GWAS for known biomarker (sRAGE) for DKD 
There is a growing body of evidence suggesting that AGE-RAGE axis is involved in 
the pathogenesis of diabetic nephropathy.  However, very little is known about the 
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genetic determinants of the circulating form of RAGE (sRAGE).  Given its role in 
DKD, it is important to identify if sRAGE is a genetically fixed trait or if it can be 
modified by environment and drugs.  The aims of this study are  
1) to estimate the heritability of sRAGE 
2) to do a GWAS to identify Genetic determinants of sRAGE 
 
V. Performing genome-wide meta-analysis to identify novel SNPs associated 
with DKD 
High heritability of DKD and limited GWAS data for DKD suggests that GWAS 
studies with adequate sample size, precise phenotype definitions, and well-defined 
analysis plan can identify novel loci associated with DKD.  The aims of this study re 
1) to do GWAS analysis for various DKD phenotypes for Type1 and Type 2 
Diabetes 
2) to combine data in  meta-analysis of GWAS datasets to identify novel 
determinants of DKD 
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Methods  
I. Datasets used in the thesis  
Three datasets, namely Genetics of Diabetes Audit and Research Tayside `
122,123
, 
EURODIAB
124
, and Collaborative AtoRvastatin Diabetes Study (CARDS)
125
 were 
used for statistical analysis in this thesis.  This chapter briefly describes the data 
sources, quality controls procedures, and generic and specific analysis methods for 
each of the three datasets. 
II. DARTS and Go-DARTS  
CHI-Master Index and SMRO1 and GRO data  
The Health Informatics Centre (HIC) in partnership with the University of Dundee, 
National Health Service Tayside, and the information services division of national 
services provides researchers and others with information derived from person-
specific datasets.  These datasets originate from data held by the University of 
Dundee and the National Health Service and are anonymised in accordance with the 
Standard Operating Procedures approved by the Caldicott Guardians.  In Scotland, 
every person registered with a medical practitioner is assigned a Community Health 
Number (CHI).  CHI is a unique 10-digit identification number, which is linked to 
personal information (e.g. address, postcode, and date of birth) and clinical data 
recorded during health care activities from primary to tertiary care including a record 
of medical practitioner registration status, date of birth and date of death.  In Tayside 
this information pertaining to the entire population is held by the Tayside Health 
Board.  Tayside also uses this number thus allowing for the record-linkage of 
datasets. 
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The Diabetes Audit and Research in Tayside Scotland (DARTS) research database 
includes information for all patients diagnosed with diabetes in Tayside (Figure 1).  
Individuals with diabetes were identified from hospital records
126
.  This database was 
validated against general practice records and confirmed to be robust.  Furthermore, 
the methodology used was shown to be more sensitive for the identification of 
individuals with diabetes when compared with the use of general practice records 
alone
126
.  
Participants with T2D were identified for enrolment through DARTS - a 
comprehensive and well-validated region-wide clinical information system for 
diabetes that incorporates multiple clinical data sources
127
.  Age- and sex-matched 
diabetes-free participants were identified in populations within the region of Tayside 
from general practice records.  Taken together these two populations form the Go-
DARTS cohort which includes 17,602 participants enrolled between December 1998 
and May 2009 and in which there are approximately equal numbers of participants 
with T2D (N=9,829) and without T2D (N=7,773). 
Relevant clinical data available for the Tayside region for all Go-DARTS 
participants were drawn from electronic records of hospital admissions (Scottish 
Morbidity Register, SMR01), deaths (General Registry Office, GRO), biochemical 
tests, and dispensed drug prescriptions.  Data were available from 1980 until present 
for the SMR hospital admissions data; from 1998 for deaths from the GRO; from 
1993 until present for prescriptions; and from 1980 until present for biochemical 
tests.  
The Tayside Committee for Medical Research Ethics approved the Go-DARTS 
study and written informed consent was obtained from each participant.  A single 
sample of blood was collected for DNA extraction and genotyping and the 
56 
 
participant was assigned a unique anonymised system identifier.  Baseline 
characteristics were recorded at the time of recruitment for all participants
127
. 
 
 
Figure 1: DARTS and Go-DARTS study 
Laboratory Data for eGFR and Albuminuria (ACR and MA) and Renal 
Phenotypes  
Data for eGFR (serum creatinine) and ACR (albumin creatinine ratio) were extracted 
from the Laboratory Biochemistry file and the SCI-DC Biochemistry file available in 
the Go-DARTS dataset. 
eGFR was estimated using the MDRD equation-Modification of Diet in Renal 
Disease Study Group
128
.  This equation estimates eGFR using four variables: serum 
creatinine mg/mmol, age in years, ethnicity, and gender.  
 MDRD Equation is given as 
 ((GFR = 175 x SerumCr
1.154
 * age
0.203 
* 1.212 (black) * 0.742 (if female))   
These MDRD equations are to be used only if the laboratory has not calibrated its 
serum creatinine measurements to isotope dilution mass spectrometry (IDMS).  
When IDMS-calibrated serum creatinine is used (which is about 6% lower), the 
above equations should be multiplied by 175/186, or by 0.94086.  There can be 
variations in the creatinine measures  over the period of time due to differences in 
the assays used by lab (IDMS-traceable Jaffe and enzymatic creatinine assays), 
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however, the SUMMIT and other studies looking at creatinine measures in this 
thesis, involved analysis of most recent cross-sectional creatinine levels.  Hence, the 
variations in the assays is unlikely to affect the analysis. 
Other equation to estimate eGFR from serum creatinine includes the CKD-EPI
129
 
(Chronic Kidney Disease Epidemiology Collaboration).  This was developed in an 
effort to create a formula more accurate than the MDRD formula, especially when 
actual GFR is greater than 60 mL/min per 1.73 m2.   
CKD-EPI Equation is given as 
GFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 
1.159 [if black] 
Where Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is –
0.329 for females and –0.411 for males, min indicates the minimum of Scr/κ or 1, 
and max indicates the maximum of Scr/κ or 1. 
The CKD-EPI equation performs better than the MDRD equation, especially at 
higher GFR, with less bias and greater accuracy
130
.  However, we chose to use the 
MDRD equation to maintain uniformity in eGFR estimation across various cohorts 
in the multi-centre GWAS meta-analysis as some of the centres only had MDRD 
eGFR  Also the CKD-EPI performs better only in those with higher eGFR
131
.  Since 
most of our study participants were older patients with Type 2 diabetes diagnosis 
over a long duration, they are expected to have a lower eGFR at baseline and MDRD 
is expected to perform well at these lower eGFRs.   
Two measures of albuminuria were available for classification of patients in those 
who had albuminuria and those who did not:  1) Macro-albumin (MA) test - is a test 
conducted routinely in the diabetes clinic at Ninewells hospital, which measures 
albumin on spot urine.  2) Albumin creatinine ratio (ACR) - a test conducted only in 
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a subset of patients attending the diabetes clinic.  These ratios correct for variations 
in urinary concentration due to hydration and provide a more convenient method of 
assessing protein and albumin excretion than that involved with timed urine 
collections (measurement of protein excretion in a 24-hour collection).  Based on the 
review of evidence accumulated over three decades, the KDOQI Work Group
6
 
recommends the use of “spot” urine measurements that compares the concentration 
of protein to the concentration of creatinine.  
Since ACR data was not available on all patients in 2010 we wanted to evaluate the 
Macro-albumin (MA) test results to see if these can be used to define phenotypes for 
the GWAS analysis.  One way to do this was to compare the albuminuria status of 
patients at their first available Macro-albumin (MA) test result with their last 
available Macro-albumin (MA) test result.  This was to see if the results remained 
consistent over time.  Table 7 below compares the albuminuria status at baseline 
versus the albuminuria status at the last follow up using Macro-albumin (MA) test 
result. 
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Table 7: Comparison of albuminuria status at baseline versus the albuminuria status at the last follow up using Macro-albumin 
(MA) test result 
 
Albuminuria status at last MA reading 
Albuminuria status at First MA reading Controls High-micro Macro Micro Total 
Controls(<20 mg/L) 7013(90%) 
 
50 (29%) 
 
39 (28%) 
 
878 (55%) 
 
7980 
 
Highmicro (≥100 < 200mg/L) 53(0.06%) 
 
48 (27%) 
 
20 (14%) 
 
63 (3%) 
 
184 
 
Macro (≥200mg/L) 18(0.02%) 
 
12 (6%) 
 
56 (40%) 
 
28 (1%) 
 
114 
 
Micro (≥20 < 100mg/L) 677 (8%) 
 
62 (36%) 
 
23 (16%) 
 
625 (39%) 
 
1387 
 
Total 
7761 172 138 1594 9665 
 
 
 
 
 
 
60 
 
 
 
 
Table 8: Comparison of Albuminuria status at last follow-up using Albumin Creatinine ratio and Macro-albumin test 
 
ACR-status 
MA status 
Controls Highmicro Macro Micro Total 
Controls(< 2.5) 4080 (84.5%) 5 (5%) 4 (6%) 300 (32%) 4389 
Micro (≥20 < 100mg/L) 558 (11.5%) 30 (32%) 5 (8%) 409 (44%) 1002 
Highmicro (≥20 < 100mg/L) 84 (1.5%) 29 (31%) 13 (20%) 108 (11%) 234 
Macro (≥200mg/L) 87 (1.5%) 27(29%) 40 (64%) 102 (11%) 256 
Total 4809 91 62 919 5881 
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The above Table 7 shows that about 9% of patients who had albuminuria at baseline 
were classified as controls at their last follow-status with Macro-albumin (MA) test 
result.  There is also a misclassification in terms of albuminuria subgroups.  For 
example, 24% of those who have macro-albuminuria at baseline were classified as 
having micro-albuminuria at the last follow-up.  In Table 8, we compare the 
albuminuria status in those who had both ACR and MA test results.  Of the total 
4,809 patients with diabetes classified as having normo-albuminuria by MA test, 
11% had micro-albuminuria, 1% had high micro-albuminuria and 1% had macro-
albuminuria based on their status on ACR test.  Given the fluctuations in the Macro-
albumin (MA) test result and poor agreement with ACR data, a decision was taken to 
request ACR for all the patients in Ninewells Diabetes clinic starting year 2011.  The 
final phenotype for GWAS analysis was defined exclusively by the ACR test results 
in patients with Type 2 Diabetes.  
Genotype Data  
The quality of the genomic DNA was validated using the Sequenom iPLEX assay 
designed to genotype four gender SNPs and 26 SNPs present on the Illumina 
Beadchips.  DNA concentrations were quantified using a PicoGreen assay 
(Invitrogen) and an aliquot assayed by agarose gel electrophoresis.  A DNA sample 
was considered to pass quality control if the DNA concentration was ≥ 50 ng/μl, the 
DNA was not degraded, the gender assignment from the iPLEX assay matched that 
provided in the patient data manifest, and genotypes were obtained for at least two 
thirds of the SNPs on the iPLEX. 
62 
 
Genotype data quality control of the discovery samples was similar to other 
Wellcome Trust Case Control Consortium 2 (WTCCC2) studies published 
elsewhere
132
.  
For all individuals, we explicitly modelled the data as a mixture of 'normal' and 
'outlier' individuals for each of ancestry, missing data, heterozygosity, and sex 
assignment.  We fitted each model in a Bayesian framework and excluded 
individuals whose posterior probability of belonging to the outlier class was above 
0.5145.  This approach replaces the traditional concept of fixed exclusion thresholds 
for parameters such as call rate, heterozygosity and ancestry. 
To assess relatedness among study individuals, we compared each individual with 
the 100 individuals they were most closely related to (on the basis of genome-wide 
levels of allele sharing) and used a Hidden Markov Model (HMM) to decide, at each 
position in their genome, whether the two individuals shared 0, 1 or 2 chromosomes 
Identical By Descent (IBD).  This allowed a more refined assessment of the 
relatedness between individuals than genome-wide sharing statistics (for example, 
parent-child relationships can be distinguished from those of siblings).  Individuals 
were removed from the study iteratively to ensure there was no pair of individuals 
with IBD≥ 5%.  Within each pair of putatively related individuals, the individual 
with more missing genotypes was removed. 
Four thousand diabetic cases were genotyped on the Affymetrix 6.0 SNP genotyping 
array that includes 1,000,000 SNPs.  These individuals were specifically chosen for 
genotyping as they had all gone on to receive statins after recruitment to Go-
DARTS. 
Four thousand diabetic cases were genotyped on the Illumina Omni-express array, 
which consists of ~ 700K SNPs, selected from Hap Map 1-3 for SNPs with a MAF 
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greater than 5%.  The array was designed by selecting tag SNPs to serve as a proxy 
for a number of others SNPs across the genome.  This approach allows for the 
broadest selection of maximally informative markers, resulting in genome-wide 
coverage of both common and rare variants. 
III. CARDS Clinical Trial  
The Collaborative Atorvastatin Diabetes Study (CARDS) is a multicentre; placebo-
controlled, double-blind study that enrolled 2,838 white men and women aged 
between 40 and 75 years of age and randomised them to receive 10 mg/day of 
atorvastatin or placebo
125
.  Patient selection was dependent on a positive diagnosis of 
Type 2 diabetes in addition to at least one other risk factor for coronary heart disease.  
The aim of the Collaborative Atorvastatin Diabetes Study (CARDS) was to assess 
the effectiveness of 10mg of atorvastatin daily versus placebo in the primary 
prevention of cardiovascular disease in patients with Type 2 diabetes. 
Investigators in 132 clinical centres around the UK and Ireland identified potentially 
eligible individuals by reviewing computerised registers of patients and by 
opportunistic assessment of people attending diabetes clinics.  Men and women aged 
40–75 years with Type 2 diabetes mellitus (defined with 1985 WHO criteria) 
diagnosed at least 6 months before study entry were considered for inclusion, 
provided they had at least one or more of the following: a history of hypertension, 
(defined as receiving antihypertensive treatment or having systolic blood pressure of 
140 mm Hg or greater or, diastolic blood pressure of 90 mm Hg or greater on at least 
two successive occasions); retinopathy(any retinopathy; maculopathy or previous 
photocoagulation); micro-albuminuria or macro-albuminuria (defined as a positive 
Micral or other strip test; an albumin creatinine ratio of 2•5 mg/mmol or greater; or 
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an albumin excretion rate on timed collection of 20 μg/min or more, all on at least 
two successive occasions); or currently smoking (no minimum number of cigarettes 
per day was required).  All patients reporting current smoking were counselled to 
quit.  Patients were ineligible if they had any history of myocardial infarction, 
angina, coronary vascular surgery, cerebrovascular accident, or severe peripheral 
vascular disease (defined as warranting surgery).  The clinical trial checked 
eligibility against the patient's clinical notes and their own recall and assessed lipid 
eligibility criteria by blood testing at one screening and four pre-treatment visits over 
a 10-week period.  Patients were asked to attend these visits after a 12h fast.  Mean 
serum LDL-cholesterol concentration during baseline visits had to be 4•14 mmol/L 
or lower and serum triglycerides 6•78 mmol/L or less.  Patients were excluded if 
they had a plasma creatinine concentration >150 μmol/L, glycated haemoglobin 
(HbA1c) of >12% or, if during the baseline phase they had <80% compliance with 
placebo.  Patients were randomised between November 1997, and June 2001. 
CARDS Phenotype Data  
For the GWAS analyses, patients who were randomised to atorvastatin were 
included.  Covariate information was also extracted e.g. age, sex, BMI sRAGE and 
esRAGE levels at baseline. 
CARDS Genotype Data  
This work was not done during the thesis and is a supplementary information 
relevant to genotyping of CARDS dataset.  No genotyping was done in this thesis 
project( It was performed by Perlegen).  For CARDS, DNA was extracted from 
whole blood EDTA samples.  DNA was isolated from 10ml of frozen blood using 
the Gentra Puregene DNA Isolation Kit from Qiagen (Cat no. 158389), USA.  
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Briefly, RBC was lysed with an anionic detergent in the presence of a DNA 
stabilizer which limits the activity of intracellular DNases.  WBC was collected by 
centrifugation at 2000g for 2 min.  RNA was removed by treatment with RNase A.  
Protein was removed by salt precipitation (centrifugation at 2000g for 5 min).  
Genomic DNA was recovered by precipitation with isopropanol and centrifugation at 
2000g for 5 min, the DNA pellet was washed in 70% ethanol, air dried, and 
dissolved in hydration solution (1 mM EDTA, 10 mM Tris•CI pH 7.5).  Purified 
DNA was stored at -20°C.  DNA aliquots were genotyped at Perlegen Sciences using 
a proprietary SNP set comprising 599,164 SNPs.  243 SNPs that had discrepant map 
positions between HapMap and Perlegen were dropped; 517,746 SNPs at which the 
call rate was >80% and at which the p-value for a test of deviation from Hardy-
Weinberg equilibrium (HWE) was at least 10-5 were retained in the analysis.  SNP 
annotation was based on build 36 of the Human Genome Sequence.  All SNPs were 
used in the analysis regardless of allele frequency but the allele frequency was 
considered when evaluating putative associations.  Allele frequency was below 1% 
at 6% of SNPs.  Samples were selected from those people who had been allocated 
atorvastatin 10mg daily, had given consent for genotyping and had a sample SNP 
call rate >80%.  After applying the exclusions of HWE, we estimated relatedness 
with PLINK and those individuals with Pi_HAT > 0.25 (excluding first and second-
degree relatives) were removed (n=0).  Only LDL-c values from time points at 
which the person was compliant with atorvastatin (based on pill count >80/%) were 
used. 
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IV. EURODIAB Study 
A cross sectional survey of 3,250 people with IDDM in 29 centres in Europe was 
funded by the EC in 1989-91 and a follow-up study of this cohort was funded by 
biomed program in 1996 (The EURODIAB Prospective Complications Study or 
EURODIAB PCS)
133
.  The baseline examination included 3,250 patients (1,668 men 
and 1,582 women; mean [±SD] age, 32.7±10.2 years; mean duration of diabetes, 
14.7±9.3 years).  These patients were  randomly selected in a stratified manner from 
31 diabetes clinics across Europe
134
.   
  
EURODIAB Phenotype data  
The EURODIAB phenotype data for SUMMIT studies was evaluated based on 
presence or absence of dialysis, serum creatinine, and timed 24-hour urine collection.  
Cases for the study comprise patients with Type 1 diabetes on dialysis or with 
macro-albuminuria (any micro-albuminuria ≥ 300 mg / 24 hours on a timed urine 
collection) or elevated serum creatinine (>200 µmol/lit) consistent with ESRD.  For 
SUMMIT studies, we added cases of persistent micro-albuminuria (i.e. any micro-
albuminuria at both baseline and follow up in EURODIAB PCS) and high micro-
albuminuria (any micro-albuminuria ≥ 100 mg / 24 hours on a timed urine 
collection).  As described above we captured cases from several sources 
(EURODIAB at baseline, EURODIAB at follow up, additional cases from these 
centres not in the original cohort study and renal failure cases from several new non-
EURODIAB centres).  Controls were only recruited from the original EURODAIB 
IDDM Complications Study cohort.  These Type 1 DM patients had at least 15 years 
of Type 1 Diabetes remained normo-albuminuric for that period.  In addition to local 
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MICRAL strip testing, they have normo-albuminuria confirmed by the central 
EURODIAB on two overnight collections at follow up and on one collection at 
baseline.   
EURODIAB Genotype data  
1,231 T1D diabetic cases were genotyped on the Illumina Omni-express array, 
which consists of ~700K SNPs, selected from Hap Map 1-3 for SNPs with a MAF 
greater than 5%.  The array was designed by selecting tag SNPs to serve as a proxy 
for a number of others SNPs across the genome.  This approach allows for the 
broadest selection of maximally informative markers, resulting in genome-wide 
coverage of both common and rare variants. 
EURODIAB Genotype data quality control  
Since EURODIAB is an old study with DNA preserved for more than 10 years, we 
performed sensitivity analysis on the genotyped data by a) comparing the GWAS 
data with previously genotyped EURODIAB data for candidate genes and b) testing 
the GWAS data in well-characterised variants and trait. 
The concordance rate between randomly selected GWAS SNPs and the in-house 
generated GWAS data was about 96%.  Furthermore, association of APOe2 variant 
was examined with baseline lipids and FTO variant with BMI.  The direction of 
effect for this very well characterised genotype-phenotype correlation was consistent 
with previously reported effects in the literature. 
Twenty individuals showed gender mismatch gender reported from the Sequenome 
run as compared to reported gender.  These individuals were removed from 
subsequent analysis. 
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Table 9:  Concordance rate between the GWAS sNPS common to the prior 
candidate SNP EURODIAB data 
Sr number SNP Total genotype count 
Genotype 
matched in 
GWAS and 
old 
EURODIAB 
data 
Genotype 
miss-match 
in GWAS 
and old 
EURODIAB 
 data 
% 
agreement 
1 rs10318GWASA 679 648 31 95.43 
2 rs17168032GWASC 678 658 20 97.05 
3 rs1869261GWASG 665 639 26 96.09 
4 rs1881538GWASA 679 651 28 95.88 
5 rs1982436GWASG 706 682 24 96.6 
6 rs2270812GWASA 693 670 23 96.68 
7 rs3194515GWASA 697 667 30 95.7 
8 rs3807337GWASG 692 659 33 95.23 
9 rs3812934GWASG 694 666 28 95.97 
10 rs6467557GWASA 702 677 25 96.44 
11 rs6555055GWASC 701 683 18 97.43 
Overall agreement between EURODIAB GWAS data and old EURODIAB data 96% 
 
Table 10: Testing the GWAS data in well characterised variants and traits 
Association of APOe2 variant with baseline LDLc levels 
CHR SNP modelled allele TEST NMISS BETA P 
19 rs7412(APOe2) A ADD 174 -0.5199 0.005995 
       Association of FTO variant with BMI 
CHR SNP Modelled Allele NMISS BETA SE P 
16 RS8050136 (FTO) A 872 0.4178 0.1744 0.01681 
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V. Statistical Analysis  
The software programs for statistical analysis and genotype imputation were SAS 
9.2, R IMPUTE2
135
, SHAPE-IT
136
, GTOOL
137
 (J. Marchini) and SNPTEST
138
.  The 
analyses were performed on the Linux platform.  SHAPE-IT was used to phase the 
data before imputations, Impute 2 was used for imputations, GTOOL was used for 
manipulation of imputed data, and SNPTEST was used to perform association 
analysis on the imputed datasets. 
VI. Genotype Imputation  
Imputation takes place in two stages: the first is the estimation of haplotypes from 
the study population and the second is the imputation of genotypes by comparing 
study haplotypes to reference panel haplotypes. 
 
VII. Haplotype Inference  
There are many methods for haplotype inference in unrelated populations
139
 that 
estimate haplotypes with varying accuracy.  The segmented haplotype estimation 
and imputation tool (SHAPE-IT, http://www.shapeit.fr/) is the recommended method 
to estimate haplotypes for downstream imputation with IMPUTEv2.  The method is 
highly accurate and computational light when compared with other available 
methods
136
  and is particularly suited to populations that contain high linkage 
disequilibrium in their genomes such as Caucasians
140
.  The inference of haplotypes 
is computed in a similar way to Phase v2 where all possible haplotypes are estimated 
from the available genotype set with an associated probability.  
70 
 
 
VIII. Imputation with IMPUTEv2 
“IMPUTEv2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) uses the 
estimated haplotypes from SHAPE-IT to impute genotypes from the haplotype set.  
Imputev2 compares the study population haplotypes with up to two reference panels 
for the imputation of missing genotypes in the study population.  Alleles are imputed 
into the study population by running a forward-backward algorithm to impute 
missing alleles with a certain probability.  The two sets of haplotypes are compared 
to each other and missing alleles are imputed into the study panel from the reference 
panel with certain probability.  Certain SNPs will be found in haplotypes together 
therefore, if one SNP was not present in the study panel, but the haplotypes matched, 
an allele for that SNP was imputed with a certain probability given the alleles that 
are present in the reference panel and the alleles that are given in the study panel.  So 
if there is good coverage of a haplotype on a particular chip and the haplotype is 
present in the reference panel the alleles will be imputed accurately.  If haplotypes 
are sparsely covered or SNPs are not in linkage disequilibrium with any other SNPs 
to form haplotypes then the alleles may be imputed with low confidence in their 
accuracy or may be missing all together.  Given that, we assume both sets of 
haplotypes are sampled from populations in Hardy-Weinberg equilibrium the allelic 
probabilities can be converted to genotypic probabilities”.  
IX. Cluster Computing  
The manipulation of these large genotype files and the imputation procedures are 
computationally intensive.  Parallel computing on a high performance cluster (HPC) 
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of computers was used to analyse and impute the genetic data.  The HPC is managed 
by a Sun Grid Engine, which is responsible for accepting jobs from users, scheduling 
and distributing jobs to cores within the HPC.  SHAPE-IT supports threading of 
multiple cores so that they can be used as one processor to perform the pre-phasing 
steps chromosome by chromosome.  Specific Perl programs were written to run the 
pre-phasing steps on the HPC using the multi-threading capabilities of SHAPE-IT.  
Each chromosome was imputed by dividing the imputation intervals across 5Mb 
chunks of each chromosome.  Each chunk was distributed to a separate core and 
specific bash (Shell script) program were written to run each of the imputation steps.  
The resulting files were combined into single chromosomes using bash scripting.  
Imputed files were also analysed chromosome by chromosome on the HPC.  The 
analyses programs used for directly and imputed genotypes are described below. 
X. Genetic Associations with SNPTEST  
Genotypes of directly typed SNPs are assigned using a threshold method at a 
probability of 0.9.  SNPs can be modelled in logistic and linear regressions on a log-
additive scale.  Similar to non-genetic covariates the effect of the SNP is modelled 
by steps from one genotype to another.  SNPs are coded 0 for homozygotes of the 
non-effect allele, 1 for one copy of the effect allele in a heterozygote and 2 for a 
homozygote of the effect allele so the effect of each step translates to the effect of an 
additional copy of the effect allele on the outcome.  Imputed SNPs are more complex 
to model as the three genotypes are estimated with some probability and the imputed 
data are assumed to be ‘missing’ in that they are not observed.  Models of 
association for imputed genotypes need to take into account genotype uncertainty.  
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SNPTESTv2 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/old/snptest.html) considers 
genotype uncertainty by using a missing data likelihood score test.  Since SNPs may 
be imputed with varying certainty, a threshold method may lead to a high proportion 
of missing data.  It is possible to sum the probabilities of each genotype across 
individuals for a SNP and use all the available data in the association analysis.  For a 
particular SNP data may be missing in some individuals and not in others so the data 
can be partitioned into observed and missing data.  A score test can be used to 
estimate the likelihood of the observed data given the full set of data and taking into 
account the missing data.  
XI. Principal Component Analysis using EIGENSOFT    
The EIGENSOFT package combines functionality from population genetics 
methods
141
  and EIGENSTRAT is a method
142
 for correction of population 
stratification.  We used eigenvectors (principal components) obtained from the 
Principal Component analysis implemented in EIGENSOFT to adjust for population 
stratification in our datasets. 
“Population stratification is the presence of a systematic difference in allele 
frequencies between subpopulations in a population possibly due to different 
ancestry, especially in the context of association studies”.  Population stratification 
can be a problem for association studies, such as case-control studies, where the 
association found could be due to the underlying structure of the population and not 
a disease-associated locus.  The two most widely used approaches to this problem 
include genomic control, a  nonparametric method for controlling the inflation of test 
statistics
143
 and structured association methods
144
  which use cumulative genetic 
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information to estimate and control for population structure.  Currently, the most 
widely used structured association method is Eigenstrat, (PCA analysis) developed 
by Alkes Price. 
“PCA is a statistical method for exploring and of datasets with a large number of 
measurements (which can be thought of as dimensions) by reducing the dimensions 
to the few principal components (PCs) that explain the main patterns.  Thus, the first 
PC is the mathematical combination of measurements that accounts for the largest 
amount of variability in the data”.   
“PCA has a population genetics interpretation and can be used to identify differences 
in ancestry among populations and samples.  In particular, by assessing whether the 
proportion of the variance explained by the first PC is sufficiently large, it is possible 
to obtain a formal P value for the presence of population substructure and to identify 
the number of PCs that are statistically significant.  These can then be used to adjust 
for population stratification in the datasets.  However, in practise since the top three 
PC explain generally explain most of the variation in data, these are using in 
adjusting for population stratification in regression models”. 
XII. Example of Principal Component Analysis using the EURODIAB 
Dataset  
Analysis was done by EIGENSOFT SMARTPCA program using, 2,90,517 
uncorrelated markers.  For this process, we used ten Outlier removal iterations.  First 
three Principal components explained most of the variation in the datasets and were 
used as covariates to adjust for population structure in the genome-wide association 
tests.  Figure 2 shows the plot of 1
st
 and 2
nd
 principal components on x and y-axis 
respectively, the colour coding indicates self-reported ethnicity. 
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Figure 2: Principal Component Analysis in EURODIAB Dataset 
It is evident that people from same ethnicity cluster together in the graph, showing 
the power of the PCA to cluster individuals using their genotype information. 
 
XIII. Meta-analysis 
In a meta-analysis, summary statistics such as effect estimates and the variance of 
the effect estimates from individual studies are combined.  This process allows us to 
estimate the effects of SNPs across any number of studies without the need to access 
individual level data.  Summary statistics can be combined using a fixed effects 
model or random effects models
145
.  Random effect models were used if there was 
significant heterogeneity across the estimates. 
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XIV. Fixed Effects Meta-analysis  
The fixed effects model assumes that the effect sizes are the same or fixed across 
studies.  Effects are commonly combined using inverse-variance weighted effect size 
estimate and the weighted sum of z scores.  
      
∑     
∑  
 
Where Wi =1/(SE)
2 
and the SEmeta =√∑  
  
 
ZFE = 
     
      
 
 
A p value can be calculated from the z score assuming a two-sided test: 
PFE= 2Ф(-|ZFE|) 
Where Ф is the cumulative density function of the standard normal 
distribution. 
 
XV. Random Effects Meta-analysis  
The random effects model assumes that the effect sizes are sampled from a 
probability distribution that has a variance  2 that can be estimated using various 
approaches such as the method of maximum likelihood and restricted maximum 
likelihood (Cooper HM The handbook of research synthesis and meta-analysis.  New 
York: Russell Sage Foundation; 2009).  The estimated between study variance  2 hat 
is included in the calculation of the effect size estimate where 
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In addition, the z score can be calculated as follows: 
     
 
     
 
 
The p value can then be calculated as PRE= 2Ф(-|ZRE|) 
 
The current RE model assumes that there is heterogeneity under the null hypothesis 
however there should be no heterogeneity under the null hypothesis as all effect sizes 
are equal to zero.  This assumption leads to overly conservative p values. 
XVI. Specific Methods for Heritability Estimation using GCTA 
 
GCTA version 1.11 was used to calculate the pair-wise genetic relationship between 
individuals and create the genetic relationship matrix
146
.  Principal components 
analysis was then applied to all the SNPs to calculate the first 10 eigenvectors, which 
were included as covariates in all the heritability estimation analyses to control for 
potential population structure.  Univar ate heritability estimation of each definition of 
diabetic kidney disease phenotype was then performed by restricted maximum 
likelihood method in GCTA with gender and age at starting at baseline included as 
covariates. 
Statistical significance was determined using the likelihood-ratio test of specific 
hypothesis.  We report the asymptotic 95% confidence interval by 1.96 times the 
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standard error.  As the standard errors of the parameter estimates were derived from 
first-order Taylor series expansions about the likelihood in GCTA, they may be 
prejudiced for small study sample size
147
, which at borderline levels of significance 
explains the inconsistency between p-value and 95% CI reported. 
In addition, a bivariate analysis was utilised to jointly estimate the heritability of 
baseline HbA1c, BP and the heritability of DKD.  The most informative parameter 
estimated from such bivariate analysis was the genetic correlation rg.  It represents 
the proportion of variance shared between baseline HbA1c BP and diabetic kidney 
disease that was contributed by common genetic determinants. 
 
XVIII. Specific Methods for sRAGE GWAS 
CARDS Dataset 
The design of the CARDS trial has been reported previously.  The trial was 
conducted in 132 clinical centers in the United Kingdom and the Republic of Ireland. 
In it, 2,838 patients with Type 2 diabetes without previous CVD were randomised to 
receive either atorvastatin 10mg daily or placebo.  Patients were ineligible if they 
had any history of myocardial infarction, angina, coronary vascular surgery, 
cerebrovascular accident, or severe peripheral vascular disease.  We checked 
eligibility against the patient's clinical notes.  The median follow up duration in the 
trial was 3.9 years.  The primary endpoint was major cardiovascular disease events 
comprising myocardial infarction including silent infarction, unstable angina, 
acute coronary heart disease death, resuscitated cardiac arrest, coronary 
revascularisation procedures, or stroke.   
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Using pre-randomisation samples serum sRAGE was measured using the R&D 
Systems Quantikine Immunoassay that is specific for the extracellular domain of 
human RAGE (Quantikine; R&D systems, Minneapolis, MN USA).  The assay 
coefficient of variation was 4.4%.  esRAGE was measured using the B-Bridge 
ELISA (B-Bridge International Cupertino, Ca USA).  This assay specifically 
measures the esRAGE/RAGEv1 protein only due to the use of an antibody directed 
against the unique C-terminus sequence of RAGEv1, and does not cross-react with 
other potential forms of sRAGE.  The coefficient of variation was 6%.  Sufficient 
sample was available for total sRAGE and esRAGE measurement 715 participants.  
The study utilised data generated by genotyping 2,362 individuals in the CARDS 
trial.  sRAGE level was measured in 587  patients with Type 2 Diabetes and 
eSRAGE was measured in 645 patients with diabetes .  
The CARDS genotype data were combined with phased haplotypes from HapMap 
phase II CEU r22to compute posterior probability distribution of genotype at all 
HapMap loci using the  IMPUTE program.  The genotypes thus generated were used 
for association testing with sRAGE levels using linear regression implemented in 
SNPTEST. The association tests were adjusted for age, gender, BMI, population 
stratification (eigenvectors generated from Principle Component Analysis). In order 
to normalize the distribution of esRAGE and sRAGE levels the sRAGE and 
eSRAGE levels were log-transformed. 
 
Go-DARTS Dataset 
The Go-DARTS cohort was ascertained from the Diabetes Audit and Research 
Tayside Study (DARTS).  Validated prescribing data, biochemistry data, as well as 
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clinical phenotypes back to 1992 can be retrieved from central databases for all the 
DARTS patients.  Prospective longitudinal data were also collected on these patients. 
Since October 1997, all patients with diabetes were invited to give written informed 
consent to DNA as part of the Wellcome Trust United Kingdom Type 2 Diabetes 
case control collection. As of June 2009, 8,000 cases and 7,000 controls of European 
ancestry have participated in this Genetics of DARTS (Go-DARTS) study.  sRAGE 
was measured using the human Quantikine ELISAs (R&D Systems).  50ul of serum 
was required the measuring range was 0-5000 pg/mL and the Intra-assay and inter-
assay CV were 3.89% and 8.5% for sRAGE.  In the Go-DARTS dataset sRAGE was 
measured in 1,193 individuals of whom 455 were genotyped on Affymetrix platform 
and 463 on the Illumina platform.  Three hundred and forty-eight individuals 
genotyped on the Affy platform passed quality control while 440 individuals 
genotyped on the illumine platform passed quality control.  The Go-DARTS 
genotype data were combined with phased haplotypes from HapMap phase II CEU 
to compute posterior probability distribution of genotype at all HapMap loci using 
the  IMPUTE programme.  The genotypes thus generated were used for association 
testing with sRAGE levels using linear regression implemented in SNPTEST.  The 
association tests were adjusted for age, gender, BMI, and population stratification 
(eigenvectors generated from Principle Component Analysis). 
 
Conditional Analysis of RAGE Gene in CARDS Dataset 
We used all the markers in the AGER gene region which passed the threshold for 
significance on the CARDS-GoDARTS GWAS meta-analysis (P-value <10-E-
8(n=22)).  These were then pruned for LD and only those with LD <20% were 
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carried into next stage.  LD based pruning was done with --indep command.  The 
parameters for --indep are: window size in SNPs equal to 50, the number of SNPs to 
shift the window at each step equal to 5 and  the VIF threshold of 2.  The VIF is 
1/(1-R^2) where R^2 is the multiple correlation coefficient for a SNP being 
regressed on all other SNPs simultaneously.  That is, this considers the correlations 
between SNPs but also between linear combinations of SNPs.  “A VIF of 10 is often 
taken to represent near collinearity problems in standard multiple regression analyses 
(i.e. implies R^2 of 0.9).  A VIF of 1 would imply that the SNP is completely 
independent of all other SNPs.  The LD pruned markers were then used in a linear 
regression analysis with sRAGE levels as dependent variables and age, sex, BMI, 
and population eigenvectors as covariates” (source Plink Manual).  
  
Chip-based Heritability Estimation and Genome-wide Joint Conditional 
Analysis using Genome-Complex Trait Analysis (GCTA) 
Heritability of sRAGE was estimated with GCTA using combined panel of 
Affymetrix and Illumina datasets in the Go-DARTS study.  Summary level statistics 
from CARDS- Go-DARTS meta-analysis were used to perform a Genome-wide 
conditional analysis.  There may be multiple causal variants in a Gene and the total 
variation that could be explained at a locus may be undervalued if only the most 
significant SNP in the region is selected.  To identify independent SNPs we ideally 
can perform a conditional analysis, starting with the top associated SNP, across the 
whole genome followed by a stepwise procedure of selecting additional SNPs, one 
by one, according to their conditional P values.  Such a strategy would allow the 
discovery of more than two associated SNPs at a locus.  To identify independent 
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SNPs across the genome-wide data we used an approximate conditional and joint 
analysis approach implemented in GCTA software
148
.  We used summary level 
statistics from CARDS-Go-DARTS meta-analysis and LD corrections between 
SNPs estimated from CARDS GWAS data.  SNPs on different chromosomes or 
more than 10Mb distant are assumed to be in linkage equilibrium.  The model 
selection process in GCTA starts with the most significant SNP in the single-SNP 
meta-analysis across the whole genome with P value below a cutoff P value, such as 
5 × 10
−8
.  In the next step, it calculates the P values of all the remaining SNPs 
conditional on the top SNP that have already been selected in the model.  To avoid 
problems due to co-linearity, if the squared multiple correlations between a SNP to 
be tested and the selected SNP(s) is larger than a cut-off value, such as 0.9, the 
conditional P value for that SNP will be set to 1.  Select the SNPs with minimum 
conditional P value that is lower than the cut-off P value.  Fit all the selected SNPs 
jointly in a model and drop the SNPs with the P value that is greater than the cut-
off P value.  This process is repeated until no SNPs can be added or removed from 
the model.  
Power Calculation 
Power calculations for the study was performed using the software GWAPower
149
 
GWAPower calculates statistical power using the following input parameters: (1) 
The heritability (a number in the range 0~1); (2) Total sample size; (3) The number 
of SNPs in the GWA study; (4) The type 1 error rate: The default value is calculated 
using a Bonferroni correction.  With an approximate discovery sample size of 1,100, 
our study had 60% power to detect a SNP which explains 3% variation in the levels 
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of sRAGE and more than 95% power to detect a SNP which explains 5% variation in 
the levels of sRAGE. 
Meta-analysis 
Meta-analysis of the GWAS data was performed using Metal
150
.  This program 
selects a reference allele for each marker and calculates a z-statistic characterizing 
the evidence for association.  The z-statistic summarizes the magnitude and the 
direction of effect relative to the reference allele and all studies are aligned to the 
same reference allele.  An overall z-statistic and p-value are then calculated from a 
weighted sum of the individual statistics.  Weights are proportional to the square root 
of the number of individuals examined in each sample and selected such that the 
squared weights sum to 1.0. 
 
XIX.  Specific Methods for CKDGen Replication  
 
The study population comprised of 3,028 patients with T2D identified from an on-
going study of the Genetics of Diabetes Audit and Research Tayside (Go-DARTS) 
and recruited in Tayside, Scotland, between 1
st
 October 1997 and 1
st
 March 2010.  
The study cohort was described in detail in earlier.  A subset of Go-DARTS 
genotyped on Affymetrix platform was used in the current study.  The baseline 
clinical characteristics of the Go-DARTS subset included in these analyses are very 
similar to the baseline clinical characteristics of the remaining Go-DARTS collective 
(data not shown).  Hence, the subset of patients used for this analysis is very 
representative of the entire Go-DARTS cohorts.   
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Calculations for eGFR were made using the Modification of Diet in Renal Disease 
(MDRD) formula
128
, which requires age, sex, race, and creatinine.  Association 
testing for the 16 SNPs with eGFR for baseline was performed using linear 
regression analysis implemented in GPLINK
151
 adjusting for age, sex, BMI, 
population structure, HbA1c, duration of diabetes, and systolic blood pressure. To 
investigate if the association of these loci with eGFR differed by albuminuria status, 
we conducted a stratified analysis with a test for interaction in patients with 
sustained normoalbuminuria (ACR<2.5mg/mmol in males and <3.5mg/mmol in 
females and duration of diabetes; >15 years at the end of follow-up) and in those 
with any albuminuria (ACR≥2.5mg/mmol in males and ≥3.5mg/mmol in females; 
either  baseline or end of follow-up).  Interaction of individual SNPs with 
albuminuria was tested using PLINK option ‘interaction’ with age, sex, BMI, 
albuminuria, and genotypes as covariates in the linear regression model. 
To investigate if any of these polymorphisms were associated with rapid decline in 
renal function over the follow-up period, we performed a time to stage 3B of CKD 
(eGFR<45 mls/min/1.73m2) analysis.  By using this cut-off, we lost 4% of our 
patients from the analysis (4% were prevalent cases (baseline eGFR<45 or Stage 3B 
CKD) therefore excluded from the analysis).  If we had chosen to study progression 
to Stage 3A CKD (eGFR<60) we would have lost 20% patients from the analysis.  
Individuals with stage 3B CKD at baseline were excluded.  Stage 3B of CKD was 
defined as three consecutive measurements of eGFR <45 mls/min/1.73m2 at least 
one month apart.  Those who did not progress to stage 3B CKD were censored at the 
end of the follow-up period or date of death where applicable.  We used a cox-
proportional hazards model (proc phreg in SAS) with date of birth as ‘time in’; ‘last 
date’ was defined as the first date of eGFR <45 mls/min/1.73m2 or the end of 
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follow-up period or date of death.  Additional covariates included genotype, age, sex, 
BMI, and baseline eGFR.  
We examined the association of these SNPS with albuminuria in the study 
population.  ‘Albuminuria case’ was defined as ACR≥ 2.5 in males and ≥ 3.5 in 
females on their last ACR measurement and ‘Albuminuria control’ was defined as 
ACR<2.5 in males and < 3.5 in females and used in logistic regression analysis 
adjusting for age, sex and BMI. 
We adopted a conservative threshold for significance (0.05/number of loci tested) 
and p-values below 0.003 were considered significant.  All analyses were performed 
in PLINK version 1.07
151
 and SAS 9.2. The study complies with the Declaration of 
Helsinki. 
 Power calculation 
Power calculation for quantitative trait was completed with R 
(http://genome.sph.umich.edu/wiki/Power_Calculations:_Quantitative_Traits).  For 
the quantitative trait, eGFR, the study had 99% power (at 5% level of significance) 
to detect an association with a SNP explaining 1% variability in the eGFR and 97% 
power to detect an association with a SNP explaining 0.5% variability in eGFR. 
Genetic Risk Score 
A weighted genetic risk score analysis (wGRS) was performed to test the joint effect 
of these 16 loci on baseline eGFR and time to CKD Stage 3B.  We calculated wGRS 
(number of risk alleles*Beta), for each individual, using all 16 SNPs included in this 
study and tested the association of this GRS with baseline eGFR and time to CKD 
Stage 3B, adjusting for age, sex, BMI, hba1c, duration of diabetes, and systolic 
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blood pressure.  The genetic risk score was also calculated for ~80 SNPS for BP and 
~25 SNPs for HbA1C identified from the NGHRI database. 
Model selection 
Several epidemiological studies have shown that age, gender, duration of diabetes, 
BMI, (all at baseline), are important predictors of DN.  For example, in the DCCT 
Type 1 diabetes study
152
, time to diabetic nephropathy was related to age, AER, 
duration of diabetes, BMI, HbA1c (all at baseline), and gender.  By adjusting for 
these same covariates in our ‘maximum adjusted model’, we aimed to identify the 
genetic variants which contribute to the variance in eGFR beyond the effect of these 
covariates.  We also looked at the ‘minimum adjusted model’, with only age and 
gender as covariates in order to identify variants which can affect the eGFR by their 
effect on BMI and HbA1c.  Since we did not see any difference in the two models, 
we present the results of maximum adjusted model only. 
XX Specific methods for SUMMIT GWAS analysis for DKD 
Phenotype Definitions 
For the main phenotypes were patients with Type 1 diabetes and Type 2 diabetes 
with European ancestry.  Albuminuria is classified based on timed overnight urinary 
albumin excretion rate (AER, µg/ min or mg/24 h) or an albumin-creatinine ratio 
(ACR, mg/mmol) as follows or patients with CKD and ESRD. 
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Table 11: Cut-off used for Phenotype definitions in SUMMIT GWAS analysis of 
DKD 
 
 
AER/min 
AER 24 hours 
(UP) 
ACR mg/mmol 
Normoalbuminuria <20μg <30 mg 
<2.5mg/mmol(M) 
<3.5mg/mmol(F) 
High 
Microalbuminuria 
100-200μg 150-300mg 
12.5-25 mg/mmol(M) 
17.5-35 mg/mmol(F) 
Macroalbuminuria >200 μg >300 mg 
>25 mg/mmol(M) 
 
>35 mg/mmol(F) 
ESRD eGFR<15ml/min or dialysis  or kidney transplant 
Chronic Kidney 
Disease 
eGFR is <60 ml/min 
 
Binary phenotypes 
Diabetic albuminuria (DA):  
 Cases: patients with any type of albuminuria or ESRD 
 Controls: normo-albuminuria patients (duration of diabetes 15 years for T1D 
and 10 years for T2D) 
Macroalbuminuria 
 Cases: patients with macro-albuminuria or ESRD 
 Controls: patients with Normo-albuminuria (duration of diabetes 15 years for 
T1D and 10 years for T2D) 
Microalbuminuria  
 Cases: patients with micro-albuminuria and high micro-albuminuria   
 Controls: patients with Normo-albuminuria (duration of diabetes 15 years for 
T1D and 10 years for T2D) 
Chronic kidney disease (CKD) 
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 Cases: patients with eGFR<60 
 Controls: patients with eGFR>60 (duration of diabetes 15 years for T1D and 
10 years for T2D) 
Continuous phenotype 
 eGFR: Log Transformed eGFR.  Average of last two eGFR reading was 
taken. 
Minimal adjustment model (min): Adjust model for age, duration of T2D, sex and 
Principle components from eigenstrat 
 
Imputation 
Imputation was performed based on HapMap2 NCBI build 36 reference haplotypes 
for first stage analysis and 1000 genomes reference haplotypes for the second stage 
analysis using SHAPTEit for phasing  and IMPUTE 2 for imputation. 
 
Analysis details 
The primary analysis was a case control study that groups all individuals with 
microalbuminuria, high microalbuminuria, macroalbumiuria or ESRD as cases.  
Normoalbuminuric individuals with duration >15 years will be used as controls in 
Type 1 diabetes and Normoalbuminuric individuals with duration >15 years will be 
used as controls in Type 2 diabetes.  Two regression models were used: one 
including only sex, duration, age at onset of diabetes and study specific covariates 
(min model), and one including HbA1c (max model).  Duration of diabetes was 
defined as date of onset of diabetes to the date at which eGFR or ACR was measured 
in the lab.  Thus, the duration of diabetes varied across different DKD phenotypes.  
The date of onset of diabetes had been generated in the Go-darts dataset and it was 
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based on an algorithm, which mainly used information about factors such as usage of 
diabetes drugs, HbA1c and the reported date of diagnosis on medical records. 
 
SNPTEST Runs 
 
SNPtest is installed on the linux server and called in a bash script.  It is run 
sequentially on each of the 22 chromosomes.  SNPtest takes in a genotype file of 
probabilities generated by IMPUTE 2 and takes a phenotype file.  The order of id’s 
in the phenotype and genotype files should match each other. SNPtest runs classical 
regression models and allows us to include covariates in the model.  The -method 
option controls the way genotype uncertainty is taken into account when carrying out 
association tests.  R script for doing quality control following SNPTEST run is in 
appendix 1. 
 
Meta-analysis 
Meta-analyses were implemented in GWAMA.  Combined effect estimates were 
obtained using a fixed effect model.  The Meta-analysis was performed using 
Chr:Position to identify SNPs not rs-ids to account for the different dbSNP . 
Power Calculation for SUMMIT DKD studies 
 
Power calculation for SUMMIT T1D and T2D were performed using CaTS
153
.  
Detailed results of power calculation are shown in Table 12 and Table 13.  For the 
main DKD phenotype the SUMMIT studies have more than 75% power to detect a 
SNP with MAF of 10% and effect size (OR) of 1.4. 
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Table 12: Power calculations for T2D-DKD in SUMMIT studies 
Phenotype Case Control 
Power with 
MAF=10% 
Power with 
MAF=20% 
Diabetic 
Nephropathy 3,345 2,372 75 100 
CKD 3,094 2,906 81 100 
Micro-albuminuria 1,989 2,238 57 83 
Macro-albuminuria 1339 2372 59 98 
ESRD 371 2,076 5 14 
Macroalbuminuria
+CKD 897 1,610 8 47% 
To detect a OR of 1.40 at alpha=0.00000001 
 
 
 
 
 
 
Table 13: Power calculations for T1D-DKD in SUMMIT studies 
Phenotype Case Control Power_10%MAF Power_20%MAF 
Diabetic Nephropathy 2,563 2,593 79 100 
CKD 2353 1811 57 97 
Micro-albuminuria 806 2,593 12 63 
Macro-albuminuria 1,757 2,595 55 97 
ESRD 813 2398 9 52 
Macroalbuminuria+CKD 1,750 1,385 30 82 
To detect a OR of 1.40 at alpha=0.00000001 
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Results  
I. Estimating Heritability of Various DN Phenotypes  
The chip-based heritability of the several DKD phenotypes (based on albuminuria 
status) was estimated using GCTA.  For this analysis, 4.5 million SNPs imputed with 
1,000 genomes data for both the affymetrix and illumina cohort were merged using 
GTOOL.  These SNPs had an information content of >0.75% and minor allele 
frequency of >1%. 
Table 11 shows baseline characteristics of Go-DARTS cohort genotyped separately 
on the affymetrix and the illumina platform.  The demographic characteristics were 
comparable in both the datasets expect age; those genotyped in the illumina cohort 
were older at baseline.  The affymetrix dataset had 46% females, with a BMI of 
30.6(5.3), eGFR of 73.9(18.7), HbA1c of 7.54(1.3) and an 8.71(7.4) year duration of 
diabetes at baseline.  The illumina group had 42% females, with a BMI of 31.5(6.1), 
eGFR of 70.9(15.8), HbA1c of 7.3(1.4) and a 7.75(6.61) year duration of diabetes at 
baseline. 
Table 12 shows the estimated chip-based heritability for various diabetic kidney 
disease phenotypes.  The heritability estimates were highest for Macro-albuminuria 
&ESRD (macro-albuminuria and ESRD vs controls) phenotype followed by 
CKD+DN phenotype (highmicro&macro&eGFR<45 vs No Albuminuria 
&eGfR>60).  The heritability estimates were lowest for micro-albuminuria about 
1%.  Continuous phenotypes eGFR and ACR had heritability of about 10-12%.  
Statistical significance was determined using the likelihood-ratio test of specific 
hypothesis.  eGFR as a quantitative trait showed highest statistical significance (P 
value = 1.03E-05) followed by CKD phenotypes (P-value = 0.006).  All the 
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remaining DKD phenotypes, except DN and micro-albuminuria showed statistically 
significant heritability at P-value threshold of 0.05. 
 
Table 13 shows bivariate analysis of age and sex standardized residuals of average 
eGFR and average blood pressure during the study period.  The study shows 
moderate genetic correlation between the two states 0.14(±0.36).  These point 
estimates for rg suggest that a small amount of the shared genetic determinants for 
eGFR and BP.  The heritability estimates for blood pressure was 0.04(±0.03). 
 
Table 14 shows bivariate analysis of age and sex standardized residuals of average 
eGFR and average HbA1c during the study period.  The study shows high genetic 
correlation between the two states 0.71(±0.96) however, with a large SE.  The 
heritability estimates for HbA1c was 0.02(±0.03) and lower than expected 
suggesting inadequate power of the study to estimate heritability and to do the 
bivariate analysis. 
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Table 14: Demographic Characteristics of the Go-DARTS Population 
Characteristic, mean (sd) Go-DARTS Affymetrix Go-DARTS Illumina 
Age at baseline, years 59.1 (11.0) 66.2 (11.6) 
Sex,% female 46.4 42.3 
Baseline BMI 30.6 (5.3) 31.5 (6.1) 
Baseline eGFR, ml/min/1.73m
2
 73.9 (18.7) 70.9 (15.8) 
Baseline systolic blood pressure, 
mmHg 
142.8 (18.4) 141.7 (18.8) 
Baseline HbA1C, mmol/mol 7.54 (1.3) 7.3 (1.4)  
Baseline cholesterol, mmol/L 4.40 (0.97) 4.34 (0.91) 
Duration of diabetes at baseline, 
years 
8.71 (7.44) 7.75 (6.61) 
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 Table 15: Narrow –Sense Heritability of DN Phenotypes using GCTA 
Phenotype narrow sense Heritability SE P-value 
DN(any albuminuria Vs No Albumiuria) 0.08 0.07 0.1 
Micro(micro-albuminuria Vs No Albumiuria) 0.01 0.07 0.49 
Macro+ESRD(macroalbuminuria+ESRD Vs No Albumiuria) 0.21 0.11 0.03 
ESRD(ESRD Vs No Albumiuria) 0.23 0.13 0.03 
ESRD Vs ALL ( ESRD Vs ALL) 0.08 0.06 0.06 
CKD(eGFR<60 vs eGFR>60+10 year duration of diabetes) 0.12 0.05 0.006 
eGFR(quantitative trait) 0.12 0.03 1.03E-05 
CKD-DN(highmicro+macro+eGFR<45 vs No Albumiuria +eGfR>60 0.21 0.14 0.04 
ACR 0.09 0.05 0.04 
sRAGE 0.37 0.19 0.01 
Systolic blood Pressure 0.04 0.03 0.1 
eGFR 0.12 0.03 0.04 
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Table 16: Bivariate analysis of age and sex standardized residuals of average eGFR and average systolic blood pressure during 
the study period 
 
Point Estimate SE 
eGFR 0.12 0.03 
Systolic Blood Pressure 0.04 0.03 
rg 0.14 0.36 
 
Table 17: Bivariate analysis of age and sex standardized residuals of average eGFR and average HbA1c during the study period 
 
 
Point Estimate SE 
eGFR 0.12 0.03 
HbA1c 0.02 0.03 
rg 0.71 0.96 
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I. Association of known SNPs for upstream risk factors for DN and 
their association with Diabetic Kidney Disease  
 
Table 12 shows baseline characteristics of Go-DARTS cohort genotyped separately 
on the affymetrix and the illumina platform.  The demographic characteristics were 
comparable in both the datasets expect age; those genotyped in the illumina cohort 
were older at baseline.  The affymetrix dataset had 46% females, with a BMI of 
30.6(5.3), eGFR of 73.9(18.7), HbA1c of 7.54(1.3) and an 8.71(7.4) year duration of 
diabetes at baseline.  The illumina group had 42% females, with a BMI of 31.5(6.1), 
eGFR of 70.9(15.8), HbA1c of 7.3(1.4) and a 7.75(6.61) year duration of diabetes at 
baseline.  Genotype data for the candidate SNPs for BP and HBA1C in the 
affymetrix and illumine platforms were merged using GTOOL.   
 We utilized the NHGRI Catalogue of Published Genome-Wide Association Studies 
(updated July 2013) to identify gene/loci associated with BP (n=60) and HbA1c 
(n=25) with P-value <10-15 and at least one independent replication.  For the 
quantitative traits, BP and HbA1C, the study had more than 90% power (at 5% level 
of significance) to detect an association with a SNP explaining 1% variability in the 
BP and HbA1C.  Genotype distribution for these markers was in Hardy-Weinberg 
equilibrium (P >0.001) and the MAF was comparable to HAPMAP CEPH. Given 
the strong prior information about the role of the SNP tested here, we considered this 
a replication study, and therefore, p values below 0.05 could be considered 
significant.  However, we adopted a more conservative threshold for significance 
(0.05/number of loci tested) and p values below 0.003 were considered significant. 
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Table 15 shows replication results of SNPs associated with BP in Type 2 diabetes 
Go-DARTS  with P-value <0.001).  SNPs in MTHFR, CAPZA1, GPR39, CNTN4, 
ADH1C-ADH7, SLC39A8, C5orf23-LOC340113, RANBP3L-SLC1A3, TRPA1-
LOC100129527, MAL2-NOV, ZFAT, LOC100128248-LOC100131290, TBX3-
LOC100129020,TBX3-LOC100129020, GRINL1A-ALDH1A2, CSK,LOC100132798, 
CDH13, and FAT1P1-C20orf187 were significantly associated with BP after 
correction for multiple testing.  The direction of effect of these SNPs was consistent 
with the direction of effects reported in the original GWAS papers. 
Table 16 shows replication results of SNPs associated with HbA1c in Type 2 
diabetes Go-DARTS  with P-value <0.01).  SNPs in G6PC2, ABCB11, ANK1, 
ANK1, HK1, TCF7L2, FN3KRP were significantly associated with HbA1c after 
correction for multiple testing.  The direction of effect of these SNPs was consistent 
with the direction of effects reported in the original GWAS papers. 
Table 17 shows association of beta-weighted genetic risk scores for BP (N=60) and 
HbA1c (n=25).  In a logistic regression model with age and sex as covariates, the 
genetic risk scores for both BP (OR=25 CL=3.44-166, P=0.001) and HbA1c 
(OR=1.26 CL=1.16-1.38, P-value<0.0001) were significantly associated with the 
likelihood of having macro-albuminuria and ESRD.
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Table 18 : Replication of SNPs associated with BP in Type 2 diabetes Go-DARTS (n=7276) (Total SNPS~ 60) 
CHR SNP BP A1 BETA P Gene 
1 rs17367504 11862778 G -2.067 4.59E-04 MTHFR 
1 rs17030613 1.13E+08 C 1.298 2.92E-03 CAPZA1 
2 rs13420028 1.33E+08 G -1.858 4.42E-04 GPR39 
3 rs4370013 2654691 T -2.005 9.52E-04 CNTN4 
4 rs991316 1E+08 C -0.8756 7.82E-03 ADH1C-ADH7 
4 rs13107325 1.03E+08 T -1.738 6.49E-03 SLC39A8 
5 rs1173771 32815028 G -0.8925 4.11E-03 C5orf23-LOC340113 
5 rs7735940 36423931 T -0.8506 2.01E-03 RANBP3L-SLC1A3 
8 rs1963982 73106916 G -1.191 1.02E-03 TRPA1-LOC100129527 
8 rs2469997 1.2E+08 C -0.8941 9.53E-04 MAL2-NOV 
8 rs7827545 1.36E+08 T -1.663 6.87E-05 ZFAT 
12 rs7960483 45925755 T -1.046 3.55E-04 LOC100128248-LOC100131290 
12 rs2384550 1.15E+08 A -1.196 3.18E-03 TBX3-LOC100129020 
12 rs35444 1.16E+08 G -1.203 2.24E-03 TBX3-LOC100129020 
15 rs1550576 58213414 T -1.701 5.63E-03 GRINL1A-ALDH1A2 
15 rs1378942 75077367 A -0.875 2.76E-03 CSK 
15 rs2398162 96830550 G -1.473 3.77E-03 LOC100132798 
16 rs3096277 83764204 C -0.736 6.73E-03 CDH13 
20 rs1327235 10969030 G -1.028 2.78E-03 FAT1P1-C20orf187 
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Table 19: Replication of SNPs associated with HbA1c in Type 2 diabetes Go-DARTS (n=7276) (Total SNPS~ 25) 
CHR SNP BP A1 BETA P gene 
2 rs1402837 1.7E+08 T -0.07404 1.33E-02 G6PC2 
2 rs552976 1.7E+08 G -0.08739 6.87E-05 ABCB11 
8 rs6474359 41549194 C 0.3232 9.27E-03 ANK1  
8 rs4737009 41630405 A -0.081 2.85E-02 ANK1  
10 rs16926246 71093392 T -0.08038 4.01E-02 HK1  
10 rs7072268 71099913 C -0.1065 1.80E-05 HK1  
10 rs7903146 1.15E+08 T 0.06434 1.67E-02 TCF7L2 
17 rs1046896 80685533 T -0.1029 1.08E-03 FN3KRP 
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 Table 20: Genetic risk scores for BP (~60 SNPs), HbA1C (~25 SNPs) and its association with DKD 
  
OR(95%CI) 
for wGRS for 
BP* 
P-value 
for 
association 
with 
wGRS for 
BP 
OR(95%CI) 
wGRS for 
HbA1c** 
P-value 
for 
association 
with 
wGRS for 
HbA1c Phenotype 
Any Albuminuria 4 (1.28-12.5) 0.01 1.08 (1.02-1.03) 0.007 
Microalbuminuria 3.03 (0.9-13.09) 0.06 1.03 (0.9-1.08) 0.33 
Macro-albuminuria +ESRD 25 (3.44-166) 0.001 1.26 (1.16-1.38) <0.0001 
  
*adjusted for age, sex and baseline HbA1c 
**adjusted for age, sex and baseline BP 
          
100 
 
III. GWAS for biomarker for DN (sRAGE)  
 
RESULTS 
Table 18 shows demographic characteristics of the study participants.  Genotype 
data and sRAGE was available in 589 participants in CARDS, 348 in Go-DARTS-
Affymetrix and 440 in Go-DARTS-Illumina Datasets.  The demographic 
characteristics in the three datasets were similar expect duration of diabetes which 
was higher in the Go-DARTS dataset.  The median (inter quartile range) sRAGE 
levels was 1426 pg/ml (1108-1812) in CARDS dataset and 1303.8 pg/ml (1017.5-
1702.2) in Go-DARTS dataset.  Median (inter quartile range) esRAGE levels in the 
CARDS dataset were 340 pg/mL (250–460).  The sRAGE and esRAGE levels in 
CARDS dataset were highly correlated, with a Pearson’s correlation coefficient of 
0.88 (P<0.0001).  Figures 3 and 4 shows distribution of log transformed sRAGE 
levels in CARDS and Go-Darts datasets. 
 
Figure 5 shows a Q-Q plot of the –log10 p-values from a meta-analysis of genome-
wide association study for sRAGE levels in CARDS and Go-DARTS data set; the 
cumulative distribution of test-statistic follows the null distribution over most of its 
range but there is a tail of extreme results.  Most of these extreme results arise from 
chromosome 6 as seen in the Manhattan plot (Figure 6) of the genome-wide 
association between the SNPs and sRAGE levels.  A similar distribution of P-values 
on Q-Q plots was seen in the CARDS, Go-DARTS Affymetrix and Go-DARTS-
Illumina datasets (Figures 8, 9, 10).   
Table 19 shows results of SNP association tests of the top 22 SNPS (with P≤10E-8) 
with total sRAGE levels in CARDS-Go-DARTS meta-analysis.  The top markers 
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were contained in the genes PPT2, LY6GD6, AGER, NOTCH4 and HLA-DQA-2 and 
HLA-DQB1 region.  The estimates of effect (β) are for the log-transformed response 
variable.  rs2070600 (G28S) in the AGER gene was the topmost marker associated 
with sRAGE levels with the ‘T’ allele associated with lower sRAGE levels (β =-
0.14, P=8.25E-18).   
Using the summary level data from CARDS-Go-DARTS meta-analysis, we then 
performed a genome-wide conditional analysis implemented in GCTA to identify 
markers independently associated with sRAGE levels across the genome (Table 20).  
Our genome-wide conditional analysis showed presence of two independent loci in 
AGER-HLA-DQA1 gene regions, rs2070600 (G28S) (β = -0.13, P=4.32E-13) and 
rs9272346 (β = 0.04, P=2.40E-07) (Figure 8).  Three additional markers, rs6857222 
in the COX5BLI-LOC441026 gene (BETA= -0.05 P=8.76E-08), rs2807326 on the 
WNT4-LOC343384 gene region (BETA= 0.04 P=3.47E-07), and rs10940285 in the 
ITGA1-ITGA2 gene region (BETA= 0.04 P=1.85E-07) were independently 
associated with sRAGE levels.  
Table 21 shows the association of the 5 SNPs from the genome-wide conditional 
analysis (with P≤10-E6) in  666 patients with Type 2 diabetes in SDR study, 140 
patients with Type 2 diabetes in the KORA study and 3,456 patients with Type 1 
diabetes in the FinnDiane Study.  The association of two markers in the AGER-HLA 
region (rs2070600 and rs9272346) replicated in the Type 1 and Type 2 diabetes 
cohorts while rs10940285 replicated in Type 2 diabetes cohort and was borderline 
significant in Type 1 diabetes cohort.  The direction of effect for these three SNP 
was consistent in all the cohorts.  rs6857222 in COX5BLI-LOC441026 gene and 
rs2807326 in WNT4-LOC343384 gene region did not replicate in Type 1 or Type 2 
diabetes cohorts. 
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Using summary levels statistics in CARDS and Go-DARTS cohorts, we estimated 
chip based heritability of sRAGE levels.  GCTA showed a point estimate of h
2
 = 
0.37 for circulating sRAGE levels (standard deviation (sd) = 0.19, P-value=0.01) 
consistent with high heritability.  The p-values are from likelihood tests with null 
hypothesis of heritability being zero.  After adjustments for age, sex and BMI, three 
SNPs (rs10940285, rs2070600, and rs9272346) explained 10% variation (adjusted r-
squared in SAS) in circulating sRAGE levels in the SDR dataset (validation cohort).  
There was no LD between AGER SNP rs2070600 (G28S) and HLA-DQA1 SNP 
rs9272346 in the SDR cohort (r
2
=0.02) confirming that rs9272346 is not directly 
tagging rs2070600 in AGER gene. 
We looked at the association of SNPs with total esRAGE levels with P≤10×10-8 in 
the CARDS dataset.  The associations with SNPs showed similar trend as association 
with sRAGE levels with a slightly lower order of magnitude.  We did not identify 
any variants differentially affecting esRAGE and sRAGE and esRAGE/sRAGE ratio 
levels in the CARDS dataset. 
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Table 21:  Demographics and Baseline Characteristics of the Three Datasets 
 
CARDS  
(n=589) 
Go-DARTS Affymetrix 
 (n=348) 
Go-DARTS Illumina 
(n=440) 
Age 61.8(±7.9) 56(±12.6) 71.6(±10.9) 
Sex(% Female) 30% 38% 41% 
BMI 30.9(±5.02) 30.9(±5.07) 31.3(±6.07) 
Duration of Diabetes 7.89(±6.2) 9.8(±7.6) 13.1(±6.7) 
HbA1c 7.87(±1·42) 7.5(±1.26) 7.4(±1.40) 
sRAGE levels(log10 transformed) 3.13(±0.18) 3.11(±0.18) 3.12(±0.18) 
Platform Perlegen 5 Affymetrix Illumina 6 
Sample Call Rate >98% >98% >98% 
pHWE exclusion 10
-5 
10
-5
 10
-5
 
Reference Panel/imputation software HAPMAP 2 / IMPUTE2 HAPMAP 2/IMPUTE2 HAPMAP 2 / IMPUTE2 
SNPs after imputation and QC 2,298,008 2,477,804 2,351,765 
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Table 22: Distribution of raw sRAGE values in CARDS and GO-DARTS datasets 
  
Distribution of raw sRAGE values in CARDS 
and Godarts 
  Mean Median Maximum Minimum 
CARDS  1501.67 1426 4626  169.99 
GAODARTS  1451.68 1303.80 4955.9 271 
 
 
 
Figure 3: Distribution of Log10-sRAGE in CARDS   
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Figure 4: Distribution of Log10-sRAGE in Go-DARTS dataset   
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Table 23: GWAS Meta-analysis for sRAGE in CARDS and GO-DARTS cohorts 
          Cards_perlegen Godarts_illumina Godarts_Affy Meta-analysis   
CHR BP MARKER EA MAF_average BETA SE Pval beta SE Pval beta SE Pval beta SE Pval Gene 
6 32259421 rs2070600 T 0.08 -0.17 0.02 4.99E-12 -0.16 0.05 8.91E-04 -0.1 0.03 4.91E-05 -0.14 0.02 8.25E-18 PBX2 SRAGE 
6 32232402 rs10947233 T 0.08 -0.16 0.02 7.99E-13 NA NA NA -0.11 0.02 1.89E-05 -0.14 0.02 8.57E-17 PPT2 
6 32293583 rs2854050 G 0.08 -0.13 0.02 2.82E-11 0.17 0.05 3.65E-04 0.08 0.02 5.38E-04 -0.12 0.01 2.64E-16 NOTCH4 
6 31790008 rs805284 G 0.08 -0.14 0.02 8.40E-12 NA NA NA 0.09 0.02 3.05E-04 -0.12 0.02 1.33E-14 LY6G6D 
6 32930164 rs4148878 T 0.08 -0.14 0.02 1.49E-10 0.05 0.04 2.64E-01 0.08 0.03 2.81E-03 -0.1 0.02 5.17E-12 TAP1 PSMB9 
6 32288409 rs2071285 T 0.09 -0.16 0.03 1.66E-09 NA NA NA -0.09 0.03 4.05E-04 -0.12 0.02 8.77E-12 NOTCH4 
6 32822121 rs2071800 G 0.08 -0.1 0.02 2.77E-08 0.14 0.05 3.92E-03 0.07 0.03 8.07E-03 -0.09 0.01 2.19E-11 HLA-DQA2 
6 32287410 rs2854047 T 0.09 -0.16 0.03 9.06E-09 NA NA NA -0.09 0.03 3.82E-04 -0.12 0.02 5.63E-11 NOTCH4 
6 32287472 rs2555469 G 0.09 -0.16 0.03 9.06E-09 NA NA NA -0.09 0.03 3.86E-04 -0.12 0.02 5.72E-11 NOTCH4 
6 32820796 rs17500510 G 0.09 NA NA NA 0.13 0.04 1.34E-03 0.06 0.02 9.18E-03 -0.08 0.01 6.84E-11 HLA-DQA2 
6 32274362 rs8192575 G 0.09 -0.18 0.03 3.93E-08 NA NA NA -0.09 0.03 2.53E-04 -0.13 0.02 2.20E-10 NOTCH4 
6 32788554 rs7764819 T 0.14 -0.07 0.02 2.15E-06 0.07 0.02 1.07E-03 0.06 0.02 9.61E-03 -0.07 0.01 2.49E-10 HLA-DQB1 
6 32765659 rs9405119 G 0.25 -0.06 0.01 6.02E-06 -0.05 0.02 1.34E-02 -0.05 0.02 1.04E-03 -0.05 0.01 9.21E-10 HLA-DQB1 
6 32790790 rs9275602 C 0.22 -0.09 0.02 9.43E-07 0.08 0.03 4.87E-03 0.05 0.02 1.26E-02 -0.07 0.01 1.90E-09 HLA-DQB1 
6 32771666 rs5000632 T 0.24 -0.05 0.01 1.41E-05 0.05 0.02 1.41E-02 0.05 0.02 1.06E-03 -0.05 0.01 2.25E-09 HLA-DQB1 
6 32772949 rs9348891 G 0.24 -0.05 0.01 1.41E-05 -0.05 0.02 1.40E-02 -0.05 0.02 1.14E-03 -0.05 0.01 2.39E-09 HLA-DQB1 
6 32773145 rs9394113 G 0.24 -0.05 0.01 1.41E-05 -0.05 0.02 1.40E-02 -0.05 0.02 1.15E-03 -0.05 0.01 2.40E-09 HLA-DQB1 
6 32787710 rs9378125 G 0.29 -0.06 0.01 1.54E-05 -0.04 0.02 5.55E-02 -0.06 0.02 2.64E-04 -0.05 0.01 3.62E-09 HLA-DQB1 
6 32712350 rs9272346 G 0.41 0.06 0.01 8.54E-07 0.02 0.01 1.60E-01 0.05 0.01 9.17E-04 0.05 0.01 7.30E-09 HLA-DQA1 
6 32265342 rs2856437 G 0.08 -0.13 0.04 1.92E-03 0.17 0.05 3.65E-04 0.09 0.02 3.12E-04 -0.11 0.02 1.00E-08 GPSM3 
6 31777475 rs1266071 T 0.12 -0.07 0.02 1.93E-05 -0.08 0.04 3.88E-02 -0.06 0.02 7.78E-03 -0.07 0.01 5.50E-08 BAT5 
6 32734289 rs6906021 T 0.48 -0.05 0.01 1.21E-05 0.02 0.02 3.74E-01 0.05 0.01 1.33E-03 -0.04 0.01 6.60E-08 HLA-DQB1 
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Table 24 Genome-wide conditional analysis of CARDS-Go-DARTS dataset  
CARDS GODARTS meta-analysis results Joint analysis results Gene 
Chr SNP freq b se p bJ bJ_se pJ   
1 rs2807326 0.37 0.04 0.01 5.30E-07 0.04 0.01 3.47E-07 WNT4-LOC343384 
4 rs6857222 0.14 -0.05 0.01 1.86E-05 -0.05 0.01 8.76E-08 COX5BLI-LOC441026 
5 rs10940285 0.33 0.03 0.01 3.61E-06 0.04 0.01 1.85E-07 ITGA1-ITGA2 
6 rs2070600 0.07 -0.14 0.02 8.25E-18 -0.13 0.02 4.32E-13 RAGE 
6 rs9272346 0.39 0.05 0.01 7.30E-09 0.04 0.01 2.40E-07 RAGE-HLADQA1 
 
 
Table 25 Replication of the top hits from CARDS- Go-DARTS meta-analysis in Type 1 and Type 2 Diabetes cohorts 
CARDS + Go-DARTS meta-analysis  (n=1373) 
Replication in Type 2 
diabetes cohorts 
SDR(n=666) and Kora 
(n=140) 
Replication in Type 1 
diabetes cohort 
Finndiane(n=3546) 
 Meta-analysis in 
type 2 Diabetes 
cohorts 
 Meta-analysis in 
Type1 and Type 2 
Diabetes cohorts 
  
Chr SNP Beta SE P-value Beta SE P-value Beta SE P-value z-score P-value z-score P-value Gene 
1 rs2807326 0.04 0.01 3.47E-07 0.01 0.01 2.69E-01 0.01 0.01 0.59 3.42 6.34E-04 1.61 1.06E-01 WNT4-LOC343384 
4 rs6857222 -0.05 0.01 8.76E-08 -0.01 0.01 4.47E-01 -0.01 0.01 0.23 4.66 3.11E-06 2.13 3.33E-02 COX5BLI-LOC441026 
5 rs10940285 0.04 0.01 1.85E-07 0.03 0.01 1.69E-03 0.01 0.01 0.05 6.06 1.33E-09 5.43 5.67E-08 ITGA1-ITGA2 
6 rs2070600 -0.13 0.02 4.32E-13 -0.13 0.02 1.61E-11 -0.13 0.01 9.36E-54 -9.75 1.89E-22 -18.58 4.78E-77 RAGE 
6 rs9272346 0.04 0.01 2.40E-07 0.02 0.01 3.63E-02 0.03 0.01 2.54E-05 5.34 9.40E-08 6.52 7.08E-11 RAGE-HLA-DQA1 
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Figure 5: QQ plot of GWAS meta-analysis for sRAGE in CARDS and Go-DARTS dataset 
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Figure 6: Manhattan plot of GWAS meta-analysis 
 
Figure 6: Manhattan plot of GWAS meta-analysis for sRAGE in CARDS and Go-DARTS dataset 
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Figure 7: Regional Association plot RAGE-HLA gene region – association with circulating sRAGE levels 
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Figure 8: QQ plot for GWAS of sRAGE levels of CARDS Perlegen dataset 
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Figure 9: QQ plot for GWAS of sRAGE levels of Go-DARTS affymetrix  dataset 
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Figure 10: QQ plot for GWAS of sRAGE levels of Go-DARTS Illumina dataset 
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Figure 11: Result of LD based pruning of the top 22 markers associated with sRAGE levels in CARDS and Go-DARTS meta-analysis 
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IV. Replication of SNPs in CKDgen I consortium and contribution to 
CKDgen II consortium  
Results 1: Replication of CKDgen Consortium I 
 
Table 24 shows baseline characteristics of the study population.  Genotype data was 
available for 3,028 patients (46.4% females) with T2D with mean baseline BMI of 
30.6(±5.3), mean age 59.1(±11), mean HbA1c 58 mmol/mol (7.54(±1.3) and 
consisted of 57% males.  The mean follow-up period for the entire study was 
10.6(±9.1) years with a median of three eGFR readings/year/person (IQR=2-4) and a 
mean baseline eGFR of 73.9(±18.7) mls/min/1.73m
2
.  There were no significant 
difference in the LDLc levels in the individuals genotyped on  affymetrix and 
illumina chip at baseline.  In those genotyped on affymetrix platform the ldl-c levels 
were 2.03 (±0.93) mmol/l and on the illumina platform the LDLc levels were 2.11 
(±0.98) mmol/l. Table 25 shows baseline characteristics of cases that progressed to 
Stage 3B CKD and controls.  As expected, those who progressed to Stage 3B CKD 
were likely to be older, with a higher BMI, HbA1c, systolic BP and longer duration 
of diabetes 
Figure 6 is the Linkage-Disequilibrium plot of the 16 SNPs in the study and shows 
all were in linkage equilibrium with each other.  Table 26 shows the identified 
association of 16 eGFR-associated loci with baseline eGFR, with eGFR stratified by 
albuminuria status, and the association of these polymorphisms with time to Stage 
3B CKD.  The minor alleles ‘T’ of GCKR (Beta=1.30 P-value=3.23E-03), and ‘T’ of 
UMOD (Beta=2.0 P-value=8.84E-04) were associated with a higher eGFR at 
baseline; the minor allele ‘A’ of SHROOM3 (Beta= -1.28 P-value=3.18E-03) was 
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associated with a lower eGFR at the predefined threshold (P≤0.003).  None of the 
other SNPs was associated with baseline eGFR.  None of the SNPs included in the 
study were associated with albuminuria after correction for multiple testing (Table 
26).  In patients with sustained normoalbuminuria (n=613), minor allele ‘T’ of 
UMOD was associated with higher eGFR (beta=4.03, P-value=1.10E-03) while, in 
patients with albuminuria (n=2,096), minor allele ‘T’ of GCKR (Beta=1.12, P-
value=4.27E-02) and ‘A’ of SHROOM3 (Beta=-1.43, P-value=7.28E-03) were 
associated with a lower eGFR.  Of the 17 SNPs UMOD (HR= 0.83(0.70, 0.99), P-
value=0.03), PIP5K1B (HR= 0.85(0.75, 0.96), P-value=0.01) and SLC7A9 (HR= 
0.86(0.76, 0.98) P-value=0.02) was associated with time to Stage 3B CKD 
(eGFR<45mls/min/1.73m2) at 0.05 threshold for significance.  Since these are 
genetic variants are associated with age-related decline in eGFR in the general 
population (and not any disease specific decline), we used time to event analysis 
with date of birth as starting point.  However, we performed a sensitivity analysis in 
which we used starting point as the baseline of Go-DARTS study.  Although this 
analysis decreases power due to reduction in the person-year follow-up, we see 
similar effect size of association with progression to CKD Stage 3B.  For example, 
the hazard ratio of UMOD with time to CKD Stage 3B with starting point of Go-
DARTS study (HR= 0.87(0.74, 1.03) P-value=0.1) is very similar to the hazard ratio 
with date of birth as a starting point.  The wGRS for the 16 SNPs explained 1% 
variation in baseline eGFR and was significantly associated with baseline eGFR after 
adjustments for age, sex, BMI, HbA1c, duration of diabetes and systolic blood 
pressure (P=0.0026  Beta= 0.84(±0.28).  The wGRS was not associated with time to 
Stage 3B CKD (P=0.52).  None of the markers were associated with albuminuria 
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after correction for multiple testing however; SHROOM3 and UMOD were 
significant at 0.05 threshold of significance. 
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Table 26: Reported eGFR associated loci in Kottgen A et al paper  
First Author Region Chr_id Chr_pos Reported Gene(s) SNPs p-value Initial Sample Size Replication Sample Size 
Kottgen A 1q21.3 1 150951477 ANXA9,FAM63A,PRUNE,BNIPL,LASS2,SETDB1 rs267734 1.00E-12 67,093 22,982 
Kottgen A 2p23.3 2 27730940 GCKR, IFT172, FNDC4 rs1260326 3.00E-14 67,093 22,982 
Kottgen A 2p13.1 2 73868328 NAT8,NAT8B,ALMS1 rs13538 5.00E-14 67,093 22,982 
Kottgen A 3q23 3 141807137 TFDP2 rs347685 3.00E-11 67,093 22,982 
Kottgen A 4q21.1 4 77368847 SHROOM3, CCDC158 rs17319721 1.00E-19 67,093 22,982 
Kottgen A 5p13.1 5 39397132 DAB2,C9 rs11959928 1.00E-07 67,093 22,982 
Kottgen A 5q35.3 5 176817636 SLC34A1,GRK6,RGS14,LMAN2,PRR7,F12,PFN3 rs6420094 1.00E-14 67,093 22,982 
Kottgen A 6p21.1 6 43806609 VEGFA rs881858 9.00E-14 67,093 22,982 
Kottgen A 7q36.1 7 151407801 PRKAG2 rs7805747 4.00E-12 67,093 22,982 
Kottgen A 8p21.2 8 23751151 STC1 rs10109414 1.00E-08 67,093 22,982 
Kottgen A 9q21.11 9 71434707 PIP5K1B,FAM122A rs4744712 8.00E-14 67,093 22,982 
Kottgen A 12q24.12 12 112007756 ATXN2 rs653178 4.00E-11 67,093 22,982 
Kottgen A 13q21.33 13 72347696 DACH1 rs626277 3.00E-11 67,093 22,982 
Kottgen A 15q24.2 15 76158983 UBE2Q2,FBX022 rs1394125 3.00E-17 67,093 22,982 
Kottgen A 16p12.3 16 20367690 UMOD,ACSM5,GP2,PDILT rs12917707 1.00E-20 67,093 22,982 
Kottgen A 19q13.11 19 33356891 SLC7A9,CCDC123,ECAT8 rs12460876 3.00E-15 67,093 22,982 
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Table 27: Demographic characteristics of the study population (Go-DARTS data genotyped on Affymetrix platform) 
Study Characteristic Mean(±Stdev) 
Age at baseline 59.1(±11) 
Sex (Female %) 46.4% 
Baseline BMI 30.6(±5.3) 
Baseline eGFR 73.9(±18.7) 
Baseline Systolic BP 142.8(±18.4) 
Baseline HbA1C 7.54(±1.3) 
Baseline cholesterol 4.40(±0.97) 
Duration of Diabetes at the end of follow-up 13.76(±7.74) 
Duration of Follow-up(IQR) 10.6(±9.1) 
 
Table 28: Baseline characteristics of  cases with progression to CKD Stage 3B CKD and Controls 
  CKD Stage 3B Case  Control P-value 
Age 60.45(10.0) 58.7(11.28) 0.001 
Sex % Females 46.75% 47.63% 0.72 
BMI 30.8(6.6) 29.2(8.7) 0.0001 
Cholesterol 1.72(5.3) 2.76(4.5) 0.0001 
HbA1c 5.4(5.5) 4.6(6.6) 0.005 
Systoloic BP 123.7(52.02) 114.9(63.3) 0.001 
Duration of Diabetes 15.9(7.9) 13.1(7.5) 0.0001 
First eGFR 77.6(15.0) 72.8(18.8) 0.0001 
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Table 29: Association of the known SNPs with baseline eGFR, eGFR stratified by albuminuria status and time to stage 3B CKD  
  
Association with baseline 
eGFR(n=2970) 
Association with eGFR in 
patients with sustained 
normoalbuminuria**(n=6
13) 
Association with eGFR in 
patients with 
albuminuria(n=2097) 
Interaction 
term                      
Heterogene
ity P-value 
Association with time to Stage 
3B CKD(eGFR<45)¥* 
  
 
Direction of 
effect in Go-
DARTS 
consistent with 
Anna Kottgen 
et al 
CH
R 
Gene SNP 
Effec
t 
Allel
e 
Beta(SE) P-value Beta(SE) P-value Beta(SE) P-value HR (CL) P-value 
1 LASS2 rs267734 C 0.77(±0.51) 1.30E-01 2.24(±1.07) 3.63E-02 0.71(±0.62) 2.57E-01 9.60E-02 1.12(0.98,1.29) 7.00E-02 Yes 
2 GCKR rs1260326 T 1.30(±0.44) 3.23E-03 0.45(±0.89) 6.12E-01 1.12(±0.55) 4.27E-02 8.70E-02 0.98(0.86,1.11) 7.60E-01 Yes 
2 NAT8 rs13538 G 0.40(±0.51) 4.32E-01 0.55(±1.12) 6.24E-01 0.29(±0.62) 6.34E-01 8.92E-01 1.02(1.023,1.027) 2.70E-01 Yes 
3 TFDP2 rs347685 C -0.51(±0.48) 2.82E-01 0.54(±0.97) 5.77E-01 -1.07(±0.59) 6.76E-02 3.95E-01 0.96(0.83,1.10) 5.50E-01 No 
4 
SHROOM
3 
rs17319721 A -1.28(±0.43) 3.18E-03 -0.07(±0.89) 9.34E-01 -1.43(±0.53) 7.28E-03 3.00E-03 1.02(0.90,1.15) 6.90E-01 Yes 
5 DAB2 rs11959928 A -0.43(±0.45) 3.39E-01 -1.45(±0.90) 1.07E-01 -0.29(±0.55) 5.99E-01 3.41E-01 0.97(0.86,1.10) 7.00E-01 Yes 
5 SLC34A1 rs6420094 G -1.35(±0.61) 2.74E-02 -2.92(±1.24) 1.87E-02 -0.69(±0.75) 3.60E-01 2.79E-01 0.93(0.78.1.10) 4.00E-01 Yes 
6 VEGFA rs881858 G 0.54(±0.48) 2.63E-01 1.31(±1.01) 1.92E-01 1.34(±0.59) 2.21E-02 4.40E-02 0.95(0.83,1.08) 4.70E-01 Yes 
7 PRKAG2 rs7805747 A -0.31(±0.49) 5.24E-01 -0.72(±0.98) 4.62E-01 0.31(±0.60) 6.02E-01 9.30E-01 1.03(0.90.1.19) 6.00E-01 Yes 
8 ADAM28 rs10109414 T -0.51(±0.44) 2.41E-01 -1.57(±0.90) 8.17E-02 -0.17(±0.54) 7.49E-01 5.10E-01 0.99(0.87,1,12) 8.70E-01 Yes 
9 PIP5K1B rs4744712 A 0.09(±0.44) 8.47E-01 1.71(±0.91) 6.25E-02 -0.33(±0.55) 5.41E-01 9.31E-01 0.85(0.75,0.96) 1.00E-02 No 
12 ATXN2 rs653178 T 0.20(±0.42) 6.28E-01 0.71(±0.85) 4.05E-01 -0.13(±0.52) 8.09E-01 9.47E-01 0.95(0.83,1.08) 9.50E-01 Yes 
13 DACH1 rs626277 C 0.75(±0.44) 9.14E-02 0.85(±0.90) 3.46E-01 0.28(±0.54) 6.02E-01 3.93E-01 0.98(0.87,1.10) 7.50E-01 Yes 
15 UBE2Q2 rs1394125 A -0.86(±0.53) 1.03E-01 -1.14(±1.07) 2.89E-01 -0.86(±0.65) 1.85E-01 2.68E-01 1.11(0.96,1.28) 1.50E-01 Yes 
16 UMOD rs12917707 T 2.0(±0.60) 8.84E-04 4.03(±1.23) 1.10E-03 1.72(±0.76) 2.30E-02 2.00E-03 0.83(0.70.0.99) 3.00E-02 Yes 
19 SLC7A9 rs12460876 C 0.24(±0.51) 6.90E-01 0.58(±0.94) 5.30E-01 0.29(±0.57) 6.00E-01 4.50E-01 0.86(0.76,0.98) 2.00E-02 Yes 
*Adjusted for age at baseline, durdiab, baseline-eGFR, systolicbp, averagedHbA1c, averagedBMI 
**Patients with normo-albuminuria at baseline and at the end of follow-up with a duration of diabetes>15 years ¥* Stage 3B CKD defined as 3 consecutive readings of eGFR <45.  
Those already at stage 3B CKD at baseline were excluded for this analysis  
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Table 30: Association of eGFR loci with Albuminuria in the Go-DARTS Cohort 
CHR SNP BP A1 BETA SE L95 U95 P Gene 
1 rs267734 149218101 C 0.705 0.6214 -0.5128 1.923 0.2567 LASS2 
2 rs1260326 27584444 T 1.12 0.5525 0.03759 2.203 0.04269 GCKR 
2 rs13538 73721836 G 0.2939 0.6173 -0.916 1.504 0.6341 NAT8 
3 rs347685 143289827 C -1.073 0.5865 -2.222 0.0769 0.06757 TFDP2 
4 rs17319721 77587871 A -1.431 0.5328 -2.476 -0.3871 0.007277 SHROOM3 
5 rs11959928 39432889 A -0.2898 0.5515 -1.371 0.7912 0.5993 DAB2 
5 rs6420094 176750242 G -0.6862 0.7496 -2.155 0.783 0.3602 SLC34A1 
6 rs881858 43914587 G 1.344 0.5868 0.1941 2.494 0.02208 VEGFA 
7 rs7805747 151038734 A 0.3142 0.6027 -0.867 1.496 0.6022 PRKAG2 
8 rs10109414 23807096 T -0.1728 0.5398 -1.231 0.8851 0.7489 ADAM28 
9 rs4744712 70624527 A -0.3342 0.5459 -1.404 0.7357 0.5405 PIP5K1B 
12 rs653178 110492139 T -0.1263 0.5217 -1.149 0.8962 0.8087 ATXN2 
13 rs626277 71245697 C 0.2816 0.5397 -0.7762 1.339 0.6018 DACH1 
15 rs1394125 73946038 A -0.8559 0.646 -2.122 0.4102 0.1854 UBE2Q2 
16 rs12917707 20275191 T 1.723 0.7574 0.2388 3.208 0.023 UMOD 
19 rs12460876 38048731 C 0.2992 0.5759 -0.8295 1.428 0.6034 SLC7A9 
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Figure 12 : Linkage Disequilibrium plot of the 16 known SNPs included in the study looking for association with eGFR  
 Figures in the squares indicate r-squared between the SNPs.  All the r-squared<20 indicating that the SNPS are not in  short or long 
range LD with each other. 
 
 
123 
 
Results II:  Contribution to CKDgen consortium II 
The contribution  to the second round of analysis required estimation of eGFR from 
the MDRD equation and analysing eGFR as a continuous variable  and as 
dichotomous variable (CKD60=eGFR<60 vs eGFR>60 and CKD45=eGFR <45 vs 
eGFR >45).  Age and sex adjusted residuals for eGFR were used as quantitative trait 
(eGFRcrea).  Results were stratified by age, sex and hypertension status.  eGFR data 
was available for 2893 individuals while the CKD60 phenotype had 427 cases and 
2466 controls case control and the CKD45 phenotype had N= 195 cases and 2466 
controls.  Here overall results for the three phenotypes are shown.  Table 27 shows 
association of 35 SNPs with the CKD-60 phenotype, Table 28 shows the association 
of the 35 SNPs with CKD-45 phenotype and Table 29 shows the association of the 
35 SNPs with eGFR as a quantitative trait. 
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Table 31: Replication for 35 SNPS for CKD 60 phenotype (N= 427 cases and 2466 controls) in Go-DARTS cohort 
 
 
CHR SNP Pos coded_allele beta se pval allele_freq_coded _allele oevar_imp Nearby_Gene 
1 rs12124078 15742486 G -0.12 0.09 0.15 0.31 1.00 DNAJC16 
2 rs6431731 15780453 C -0.14 0.20 0.49 0.05 0.86 NA 
2 rs13014379 28966356 C 0.02 0.11 0.86 0.18 0.97 NA 
2 rs4549145 48555686 G -0.06 0.10 0.59 0.20 0.97 CCDC128 
2 rs10490130 169807357 C 0.06 0.15 0.69 0.07 0.99 LRP2 
2 rs6433115 169899211 C -0.04 0.10 0.65 0.21 1.00 LRP2 
2 rs11683577 170004477 T -0.03 0.09 0.71 0.31 0.99 NA 
3 rs9827843 76557775 G 0.03 0.08 0.74 0.39 1.00 NA 
3 rs9824190 98163910 G 0.21 0.15 0.18 0.06 1.00 EPHA6 
4 rs11935537 130709590 G 0.11 0.11 0.32 0.15 0.99 NA 
5 rs10068737 118064446 C -0.03 0.08 0.69 0.48 1.00 NA 
6 rs1264701 30174337 T -0.21 0.12 0.07 0.15 0.96 NA 
6 rs1322199 165345507 G -0.04 0.09 0.62 0.29 1.00 NA 
7 rs500456 54566276 G -0.07 0.09 0.40 0.40 0.98 NA 
8 rs1500896 96555858 A -0.13 0.08 0.11 0.42 0.99 NA 
9 rs2184241 3574112 T 0.02 0.10 0.80 0.36 0.94 NA 
9 rs4149333 106592745 G 0.03 0.11 0.76 0.13 0.99 ABCA1 
9 rs1050700 134757764 C 0.16 0.09 0.07 0.28 0.97 TSC1 
10 rs7911360 122795537 A -0.09 0.08 0.24 0.39 1.00 NA 
10 rs4751890 124151781 C 0.06 0.08 0.48 0.42 1.00 PLEKHA1 
10 rs11245299 126253483 A 0.04 0.09 0.68 0.27 1.00 LHPP 
11 rs6421967 973966 T 0.01 0.08 0.90 0.36 0.99 AP2A2 
11 rs3925584 30716911 C -0.19 0.08 0.02 0.46 1.00 NA 
11 rs489381 62408639 A -0.11 0.15 0.48 0.08 0.95 SLC3A2 S 
11 rs752805 125798495 A 0.07 0.08 0.40 0.48 1.00 KIRREL3 
12 rs3741414 56130316 T 0.04 0.09 0.63 0.23 0.99 INHBC 
15 rs2928148 39188842 G 0.07 0.08 0.35 0.46 0.99 INOC1 
15 rs9302109 39399472 T 0.01 0.08 0.92 0.33 1.00 OIP5 
15 rs7176121 98662843 T -0.09 0.08 0.26 0.47 1.00 ADAMTS17 
16 rs249942 23552849 A -0.14 0.20 0.50 0.05 0.93 PALB2 
16 rs6499166 66884418 G 0.02 0.09 0.80 0.24 0.99 SLC7A6 
17 rs2453580 19378913 C -0.12 0.13 0.33 0.31 0.92 SLC47A1 
17 rs7208487 34796975 G 0.01 0.11 0.91 0.15 0.99 FBXL20 
17 rs11078903 34885450 G -0.11 0.12 0.36 0.17 0.97 CRKRS 
18 rs17446008 23875364 A 0.25 0.32 0.43 0.02 0.70 CDH2 
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Table 32: Replication for 35 SNPS for CKD 45 phenotype (N= 195 cases and 2466 controls) in Go-DARTS cohort 
CHR SNP Pos coded_allele beta se pval allele_freq_coded _allele oevar_imp Nearby_Gene 
1 rs12124078 15742486 G 0.10 0.16 0.53 0.32 1.00 DNAJC16 
2 rs6431731 15780453 C -0.26 0.43 0.55 0.04 0.86 NA 
2 rs13014379 28966356 C 0.11 0.21 0.60 0.18 0.97 NA 
2 rs4549145 48555686 G 0.06 0.20 0.78 0.20 0.97 CCDC128 
2 rs10490130 1.7E+08 C -0.03 0.29 0.91 0.07 0.99 LRP2 
2 rs6433115 1.7E+08 C -0.40 0.20 0.05 0.21 1.00 LRP2 
2 rs11683577 1.7E+08 T 0.00 0.17 0.99 0.31 0.99 NA 
3 rs9827843 76557775 G -0.23 0.16 0.13 0.40 1.00 NA 
3 rs9824190 98163910 G 0.37 0.27 0.17 0.07 1.00 EPHA6 
4 rs11935537 1.31E+08 G 0.26 0.23 0.26 0.15 0.99 NA 
5 rs10068737 1.18E+08 C -0.10 0.16 0.54 0.46 1.00 NA 
6 rs1264701 30174337 T -0.29 0.23 0.21 0.15 0.96 NA 
6 rs1322199 1.65E+08 G 0.06 0.16 0.71 0.30 1.00 NA 
7 rs500456 54566276 G -0.28 0.18 0.12 0.40 0.98 NA 
8 rs1500896 96555858 A -0.04 0.16 0.77 0.43 0.99 NA 
9 rs2184241 3574112 T 0.02 0.21 0.94 0.36 0.94 NA 
9 rs4149333 1.07E+08 G 0.26 0.22 0.25 0.12 0.99 ABCA1 
9 rs1050700 1.35E+08 C 0.00 0.17 0.98 0.31 0.97 TSC1 
10 rs7911360 1.23E+08 A 0.15 0.16 0.34 0.40 1.00 NA 
10 rs4751890 1.24E+08 C 0.11 0.16 0.47 0.42 1.00 PLEKHA1 
10 rs11245299 1.26E+08 A -0.02 0.18 0.93 0.26 1.00 LHPP 
11 rs6421967 973966 T 0.20 0.15 0.19 0.37 0.99 AP2A2 
11 rs3925584 30716911 C -0.30 0.16 0.06 0.46 1.00 NA 
11 rs489381 62408639 A -0.10 0.29 0.72 0.08 0.95 SLC3A2 S 
11 rs752805 1.26E+08 A 0.09 0.16 0.56 0.47 1.00 KIRREL3 
12 rs3741414 56130316 T -0.21 0.19 0.27 0.23 0.99 INHBC 
15 rs2928148 39188842 G 0.18 0.15 0.23 0.45 0.99 INOC1 
15 rs9302109 39399472 T -0.13 0.17 0.45 0.32 1.00 OIP5 
15 rs7176121 98662843 T 0.32 0.15 0.03 0.48 1.00 ADAMTS17 
16 rs249942 23552849 A 0.75 0.34 0.03 0.05 0.93 PALB2 
16 rs6499166 66884418 G -0.30 0.19 0.11 0.24 0.99 SLC7A6 
17 rs2453580 19378913 C 0.00 0.26 0.99 0.30 0.92 SLC47A1 
17 rs7208487 34796975 G 0.19 0.21 0.38 0.16 0.99 FBXL20 
17 rs11078903 34885450 G 0.52 0.21 0.01 0.17 0.97 CRKRS 
18 rs17446008 23875364 A -0.31 0.80 0.70 0.02 0.70 CDH2 
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Table 33: Replication for 35 SNPS for eGFR phenotype (N=2893) in Go-DARTS cohort 
CHR SNP Pos coded_allele strand beta se pval allele_freq_coded _allele oevar_imp Nearby_Gene 
1 rs12124078 15742486 G + 0.00 0.01 8.19E-01 0.31 1.00 DNAJC16 
2 rs6431731 15780453 C + 0.01 0.02 4.87E-01 0.05 0.86 NA 
2 rs13014379 28966356 C + 0.00 0.01 9.97E-01 0.18 0.97 NA 
2 rs4549145 48555686 G + 0.01 0.01 2.71E-01 0.20 0.97 CCDC128 
2 rs10490130 169807357 C + -0.01 0.02 5.22E-01 0.07 0.99 LRP2 
2 rs6433115 169899211 C + 0.01 0.01 1.50E-01 0.21 1.00 LRP2 
2 rs11683577 170004477 T + 0.01 0.01 2.39E-01 0.31 0.99 NA 
3 rs9827843 76557775 G + 0.00 0.01 7.56E-01 0.39 1.00 NA 
3 rs9824190 98163910 G + -0.02 0.02 1.76E-01 0.06 1.00 EPHA6 
4 rs11935537 130709590 G + 0.00 0.01 8.33E-01 0.15 0.99 NA 
5 rs10068737 118064446 C + 0.00 0.01 9.56E-01 0.48 1.00 NA 
6 rs1264701 30174337 T + 0.03 0.01 1.72E-02 0.15 0.96 NA 
6 rs1322199 165345507 G + 0.00 0.01 9.12E-01 0.29 1.00 NA 
7 rs500456 54566276 G + 0.01 0.01 4.58E-01 0.40 0.98 NA 
8 rs1500896 96555858 A + 0.01 0.01 5.16E-01 0.42 0.99 NA 
9 rs2184241 3574112 T + 0.01 0.01 4.43E-01 0.36 0.94 NA 
9 rs4149333 106592745 G + 0.00 0.01 9.10E-01 0.13 0.99 ABCA1 
9 rs1050700 134757764 C + -0.01 0.01 2.89E-01 0.28 0.97 TSC1 
10 rs7911360 122795537 A + 0.01 0.01 1.99E-01 0.39 1.00 NA 
10 rs4751890 124151781 C + 0.00 0.01 6.75E-01 0.42 1.00 PLEKHA1 
10 rs11245299 126253483 A + -0.01 0.01 4.98E-01 0.27 1.00 LHPP 
11 rs6421967 973966 T + 0.00 0.01 6.54E-01 0.36 0.99 AP2A2 
11 rs3925584 30716911 C + 0.03 0.01 8.24E-04 0.46 1.00 NA 
11 rs489381 62408639 A + -0.01 0.02 4.20E-01 0.08 0.95 SLC3A2 S 
11 rs752805 125798495 A + 0.00 0.01 6.71E-01 0.48 1.00 KIRREL3 
12 rs3741414 56130316 T + 0.01 0.01 3.97E-01 0.23 0.99 INHBC 
15 rs2928148 39188842 G + -0.01 0.01 3.40E-01 0.46 0.99 INOC1 
15 rs9302109 39399472 T + 0.00 0.01 6.78E-01 0.33 1.00 OIP5 
15 rs7176121 98662843 T + 0.00 0.01 8.97E-01 0.47 1.00 ADAMTS17 
16 rs249942 23552849 A + 0.01 0.02 7.80E-01 0.05 0.93 PALB2 
16 rs6499166 66884418 G + -0.01 0.01 5.07E-01 0.24 0.99 SLC7A6 
17 rs2453580 19378913 C + 0.00 0.01 9.25E-01 0.31 0.92 SLC47A1 
17 rs7208487 34796975 G + 0.00 0.01 8.27E-01 0.15 0.99 FBXL20 
17 rs11078903 34885450 G + -0.01 0.01 5.69E-01 0.17 0.97 CRKRS 
18 rs17446008 23875364 A + -0.02 0.04 5.87E-01 0.02 0.69 CDH2 
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V. GWAS for DKD in EURODIAB and GO-DARTS dataset 
 
In the following section, we show summary of the results of the GWAS analysis for 
DKD phenotypes in EURODIAB and Go-DARTS data set.  The intention of the 
analysis was to contribute data to the SUMMIT GWAS meta-analysis.  The results 
below show q-q plot of the five DKD phenotypes and the top hit in each of the 
phenotypes.  Most of the top hits show MAF of <5% and are likely to be false 
positive, given the low power of this single study to detect rare variants.  We have 
not discussed these results in details as these analyses were primarily done to 
perform meta-analysis with other SUMMIT consortium datasets.  Table 30 shows 
sample sizes for T2D DKD Phenotypes in the GO-DARTS Affymetrix and Go-
DARTS Illumina cohorts. 
 The  sample sizes (Case/Control) for Go-DARTS DKD  GWAS were 1744/1496 for 
Any Albuminuria, 1997/2066 for CKD,  1347/1496 for Micro-albuminuria, 
397/1496  for Macro-albuminuria ,  128/1496  for ESRD  and 288/1303 for 
Macroalbuminuria&CKD phenotypes. 
The Sample sizes for (Case/Control) for Eurodiab DKD GWAS were 298/491for 
Any Albuminuria, 113/467 for CKD, 95/491 for Micro-albuminuria, 203/491 for 
Macro-albuminuria, 84/491 for ESRD and 210/357 for Macroalbuminuria&CKD 
phenotypes.  Analysis was performed in SNPTEST for all the GWAS studies 
adjusting for age, sex, and duration of diabetes.  The SNPTEST output was then 
analysed with R to perform quality control before the meta-analysis.  The R script 
for quality control is listed in Appendix A; it briefly consisted of following steps 
a) Calculate the effect allele frequency 
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b) Remove SNP with MAF<1% 
c) Remove SNP with HWE P-value<10-5 
d) Remove SNP with information content <0.40 
Once the quality control was performed Manhattan plots and  Q-Q plots were drawn 
using  R scripts listed in Appendix 1. 
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Figure 13: QQ-Plots of DN phenotype in EURODIAB dataset 
 
Figure 14: QQ-Plots of CKD phenotype in EURODIAB dataset 
 
 
Figure 15: QQ-Plots of CKD-DN phenotype in EURODIAB dataset 
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Figure 16: QQ-Plots of Macro-albuminuria phenotype in EURODIAB dataset 
 
 
 
 
 
 
Figure 17: QQ-Plots of Micro-albuminuria phenotype in EURODIAB dataset 
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Figure 18: QQ-Plots of ESRD phenotype in EURODIAB dataset 
 
 
Figure 19: QQ-Plots of DN phenotype in GO-DARTS dataset 
 
Figure 20: QQ-Plots of CKD phenotype in GO-DARTS dataset 
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Figure 21: QQ-Plots of CKD-DN phenotype in GO-DARTS dataset 
 
 
 
 
 
Figure 22: QQ-Plots of Macro-albuminuria phenotype in GO-DARTS dataset 
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Figure 23: QQ-Plots of Micro-albuminuria phenotype in GO-DARTS dataset 
 
Figure 24: QQ-Plots of ESRD phenotype in GO-DARTS dataset 
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Table 34:  Sample Size for T2D-DKD phenotypes 
Phenotype 
Diabetic 
Nephropathy CKD 
Micro-
albuminuria 
Macro-
albuminuria ESRD 
Macroalbuminuria
+CKD 
Case  Control Case  Control Case  Control Case  Control Case  Control Case  Control 
Godarts_affy 885 816 1,025 1,553 667 816 218 816 80 816 168 716 
Steno 163 131 100 174 NA NA 163 131 NA NA NA NA 
GoDARTS_illumina 859 680 972 513 680 680 179 680 48 680 120 587 
MNI 188 165 NA NA 122 162 66 165 NA NA NA NA 
SDR 1,250 580 997 666 520 580 713 580 243 580 609 307 
Total 3,345 2,372 3,094 2,906 1,989 2,238 1339 2372 371 2,076 897 1,610 
 
Table 35: Sample Size for T1D-DKD phenotypes 
Phenotype 
Diabetic Nephropathy CKD Micro-albuminuria Macro-albuminuria ESRD Macroalbuminuria+CKD 
Case  Control Case  Control Case  Control Case  Control Case  Control Case  Control 
Eurodiab 298 491 113 467 95 491 203 491 84 491 210 357 
SDR 266 290 163 365 98 290 168 292 75 294 118 239 
FinnDiane 1,802 1,613 2,077 979 463 1,613 1,339 1,613 654 1,613 1,422 789 
Cambridge 197 199 NA NA 150 199 47 199 NA NA  NA NA 
Total 2,563 2,593 2353 1811 806 2,593 1,757 2,595 813 2398 1,750 1,385 
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Table 36: Top GWAS hit for each of the DKD phenotypes in EURODIAB and Go-DARTS dataset 
Study Cohort Phenotype CHR Position SNP MAF P-value Nearby-Gene 
EURODIAB CKD 5 rs113471261 51701706 0.02 4.90E-09 
 CTD-
2288O8.1 
EURODIAB CKD-DN 8 rs74888877 58650530 0.01 5.18E-07 
RP11-
388G22.1 
EURODIAB ESRD 15 rs2708291 67197785 0.04 8.91E-07 RP11-798K3.4 
EURODIAB Macro-ESRD 10 rs192513143 71060011 0.01 2.02E-09 HK1 
EURODIAB Micro-albuminuria 3 rs140827779 55464667 0.03 3.80E-08 WNT5A 
EURODIAB Any-albuminuria 4 rs6553996 31871630 0.28 8.30E-07 
 RP11-
734I18.1 
Go-DARTS CKD 3 rs75224764 192126446 0.01 3.71E-08 FGF12 
Go-DARTS CKD-DN 2 rs181726291 102287994 0.01 6.05E-09 MAP4KA 
Go-DARTS ESRD 2 rs145414014 189576382 0.01 1.00E-04 GULP1 
Go-DARTS Macro-ESRD 10 rs41307583 127344489 0.03 1.06E-08 HNF1 
Go-DARTS Micro-albuminuria 19 chr19:2766244:D 2766244 0.01 1.03E-07 NA 
Go-DARTS Any-albuminuria 7 rs76562431 125478081 0.40 7.13E-07 AC005276.1 
 
*Since the intention was to Meta-analyse the data with cohorts in SUMMIT DKD phenotypes only the top SNP for each phenotype  with its P-value are 
shown 
** All the SNPS had information content in SNPTEST>0.40
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VI. Meta-analysis of GWAS data with other datasets 
Tables 32 and 33 show baseline demographic characteristics of the GWAS studies 
for T1D-DKD and T2D-DKD used in the meta-analysis.  Tables 34-45 and Figures 
26-37 show Q-Q  plot,  Manhattan plot and top 5 signals from the GWAS meta-
analysis of  6 DKD sub-phenotypes;  CKD, CKD-DN, Macro-albumiuria+ESRD, 
ESRD, Micro-albuminuria and  DN(any-albuminuria). 
Top Results in T1D-DKD 
The strongest association (P=5.96x10
-7
) was observed for rs12632850 on 
chromosome 3q25.33 between SCHIP1 (schwannomin interacting protein 1) and 
IL12A (interleukin 12A) genes.  For the CKD-DN phenotype strong association was 
also seen for rs17023084 (P=4.08x10
-8
), located in the AFF3 gene.  For the ESRD 
phenotype strongest association was also seen for rs76729345 in INSR (Insulin 
Receptor, P=4.40x10
-6
) gene.  For macro-albuminuria+ESRD phenotype a strong 
association (P=2.18x10
-6
) was observed for rs681586 on chromosome 2 between 
EN1 (engrailed homeobox 1) and INSIG2 (insulin induced gene 2).  For micro-
albuminuria the strongest association (P=2.15x10
-7
) was observed for rs62404695 in 
LINC00340 (long intergenic non-protein coding RNA 340).  For the main DN 
phenotype, strongest association was seen for rs11123857 on chromosome 2, 
P=4.6×10
-7
.  rs11123857 is located intronic in NPAS2 gene (neuronal PAS domain 
protein 2). 
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Top Results in T2D-DKD 
The strongest association with CKD was seen for rs2206136 in PLCB4 is associated 
with CKD at genome-wide significance (p=2.1x10
-8
).  The strongest association with 
the combined CKD + Albuminuria phenotype is seen for rs6997279 (p=2.2x10
-7
) in 
the SLC30A8 gene.  For the ESRD phenotype, two loci were associated at p<10
-6
: 
rs2475363, near EIF5AL1 and rs13224128, near CHN2.  A less significant but 
biologically relevant signal was detected near KLF10, rs4734659 (p=1.0x10
-6
).  For 
macro-albuminuria+ ESRD phenotype three SNPs are associated with p<10
-6
: 
rs116354014 (p=2.5x10
-7
), near TBC1D5; rs112765093 (p=2.9x10
-7
), near GTDC1; 
and rs147523203 (p=5.9x10
-7
), near GALNTL6.  For macro-albuminuria+ ESRD a 
biologically relevant association rs7942230 (p=2.25x10
-6
) was seen at intronic SNP 
in the GRM5 gene encoding glutamate receptor 5. The strongest association for 
micro-albuminuria was observed for rs2150814 (p=8.1x10
-8
) situated between 
GABRR1 and GABRR2.  An additional three loci were associated with micro-
albuminuria at p <10
-7
, including rs1143914 in the intron of COL4A1. Two loci were 
associated with the primary phenotype (DN) with p<10
-6
: Rs183249293 (p=2.4x10
-
7
), a rare variant (MAF=0.016) located in an intergenic region near SLITRK6, and 
rs9942471 (p=4.8x0
-7
), a common variant (MAF=0.36) located between GABRR1 
and GABRR2.  From the top 20 associations chr4: 55939605:I  (p=2.1x10
-6
) situated 
downstream of the KDR gene may be an interesting candidate locus 
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Table 37:  Baseline characteristics of Type 1 Diabetes Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EURODIAB  
(n=1016) 
FinnDiane  
(n= 3435) 
Scania Type 1 
Diabetes 
(n=513) 
Cambridge Type 1 
Diabetes Cohort 
(n=400) 
Age in years 42(±10.3) 38.5(±12.3) 40.5(±12.3) 37.5(±11.3) 
Age of onset of Type 1 diabetes 18(±6.2) 19(±4.2) 18(±8.4) 19(±8.3) 
Sex (%Males) 50.30% 48.20% 45.20% 47.20% 
BMI 24.8(±3.4) 25.1(±2.5) 26.1(±3.5) 24.1(±3.5) 
HbA1c 7.8(±1.7) 8.3(±1.4%) 8.1(±1.3%) 8.2(±13%) 
Duration of Diabetes in years 24.3(±8.3) 23.4(±6.8) 22.4(±12.9) 21.4(±12.8) 
Number of SNPs ~9 million ~9 million  ~9 million ~9 million 
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Table 38: Baseline characteristics of Type 2 diabetes cohort 
 
Go-DARTS I 
(n=1701) 
Go-DARTS 2 
(n=1539) 
Steno diabetes 
centre 
(n=294) 
Scania Type 2 
diabetes register 
(n=1830) 
Age in years 
59.1 (11.0) 66.2 (11.6) 
51.7(11.2) 53.7(11.5) 
Sex (%Males) 
46.40% 42.30% 
56% 55% 
BMI 
30.6 (5.3) 31.5 (6.1) 
30.1(5.8) 30.1(5.8) 
HbA1c 7.54(1.3) 7.3(1.4) 6.2(1.6) 7.2(1.6) 
Duration of Diabetes in years 8.71(7.44) 7.75(6.61) 7.1(5.5) 15.1(5.5) 
Number of SNPS ~ 9 million ~ 9 million ~ 9 million ~ 9 million 
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Table 39: Meta-Analysis of CKD phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
  
i  
 
RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L P Nearest Gene 
rs12632850 3 1.6E+08 5.96E-07 0.20 G 0.84 0.74 0.65 5.96E-07  IQCJ-SCHIP1  
rs72842475 2 1.34E+08 1.49E-06 0.06 G 0.75 0.61 0.49 1.49E-06  AC010890.1  
rs9342772 6 70461240 1.55E-06 0.38 C 0.86 0.78 0.70 1.55E-06  NPM1P37  
rs9509964 13 22581435 2.16E-06 0.03 C 2.89 2.11 1.54 2.16E-06  NME1P1  
rs13113236 4 424368 2.20E-06 0.17 T 0.83 0.72 0.62 2.20E-06  AC092574.1  
 
  
 Figure 25: Manhattan Plot and QQ-plot  SUMMIT CKD Phenotype T1D 
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Table 40: Meta-Analysis of CKD-DN phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
  
Fig
  
RS_NUMBER CHR BP P eaf reference_al
lele 
OR_95U OR OR_95L Within Gene  
rs75569002 13 1.13E+08 1.49E-07 0.13 T 1.89 1.59 1.33  ATP11A  
rs17023084 2 1E+08 4.08E-07 0.05 G 2.59 2.00 1.54  AFF3  
rs6027504 20 58893816 7.19E-07 0.43 C 0.83 0.74 0.66  RP5-1043L13.1  
rs12632850 3 1.6E+08 1.79E-06 0.20 G 0.82 0.72 0.62 NA 
rs77501404 6 1.16E+08 2.28E-06 0.05 T 2.40 1.85 1.43 NA 
 
  
Figure 26: Manhattan Plot and Q-Q plot SUMMIT CKD-DN Phenotype Type 1 Diabetes 
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RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L Within Gene  
rs72841506 2 1.24E+08 5.61E-07 0.06 A 2.39 1.86 1.45  NA 
rs61675991 8 96399614 6.38E-07 0.10 T 2.12 1.72 1.39  KB-1047C11.2  
rs13113236 4 424368 1.45E-06 0.18 T 0.80 0.67 0.56  ZNF721  
rs58573474 13 73938534 1.55E-06 0.42 G 1.49 1.32 1.17  NA 
rs78247479 3 1.91E+08 1.58E-06 0.06 C 2.32 1.80 1.39  RP11-197K6.1  
Table 41: Meta-Analysis of ESRD phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
 
Figure 27: Manhattan Plot and Q-Q plot SUMMIT ESRD  Phenotype Type 1 Diabetes 
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Table 42: Meta-Analysis of Macro-ESRD  phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
  
Figure 19
 
 
RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L Within Gene  
rs12632850 3 1.6E+08 1.71E-07 0.20 G 0.82 0.73 0.65  IQCJ-SCHIP1  
rs145462438 12 1.07E+08 1.73E-07 0.02 A 4.14 2.81 1.91  C12orf23  
rs2970761 8 59279292 1.91E-07 0.77 G 1.48 1.33 1.19  RP11-114M5.1  
rs880057 8 59135088 2.12E-07 0.81 A 1.51 1.34 1.19  FAM110B  
rs72831309 5 1.67E+08 6.99E-07 0.04 A 2.64 2.00 1.52  TENM2  
 
 
 
Figure 28: Manhattan Plot and Q-Q plot SUMMIT Macro-ESRD Phenotype Type 1 Diabetes 
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Table 43: Meta-Analysis of Micro phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
  
Figure 21
 
 
RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L Within Gene 
rs62404695 6 22100761 2.15E-07 0.02 C 7.04 4.15 2.45 LINC00340 
chr13:70304398:I 13 70304398 3.64E-07 0.05 AAT 2.84 2.07 1.51 KLHL1 
rs56003443 2 1.02E+08 5.22E-07 0.22 A 1.64 1.42 1.23 NPAS2 
rs75270220 22 19989739 7.97E-07 0.02 C 10.49 5.53 2.91 ARVCF 
rs60813019 5 1.32E+08 1.16E-06 0.05 A 2.95 2.15 1.57 AC010240.3 
 
  
Figure 29: Manhattan Plot and Q-Q plot SUMMIT Micro-albuminuria Phenotype Type 1 Diabetes 
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Table 44: Meta-Analysis of DN phenotype in SUMMIT consortium in patients with Type 1 Diabetes 
  
Figure 23
 
 
RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L Within Gene  
rs11123857 2 1.02E+08 4.61E-07 0.29 G 1.37 1.25 1.14  NPAS2  
rs11793270 9 1.19E+08 9.43E-07 0.07 T 0.77 0.65 0.55  LINC00474  
rs62154650 2 84001447 1.29E-06 0.10 A 0.75 0.62 0.52  NA 
rs79336030 11 22785294 3.06E-06 0.03 A 0.68 0.50 0.37  GAS2  
rs71478350 15 45263421 3.29E-06 0.03 C 2.33 1.78 1.37  C15orf43  
 
 
 
Figure 30: Manhattan Plot and Q-Q plot SUMMIT DN Phenotype Type 1 Diabetes 
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Table 45: Meta-Analysis of CKD phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  
Figure 25
 
 
 
RS_NUMBER CHR BP P eaf reference_allele OR_95U OR OR_95L Within Gene 
rs2206136 20 9351150 2.13E-08 0.42 A 1.32 1.20 1.10 PLCB4 
rs2293280 7 1.09E+08 8.73E-08 0.07 G 0.86 0.72 0.61 AC073071.1 
rs206439 18 10444655 1.07E-07 0.54 T 1.33 1.21 1.11 RP11-243E13.1 
rs61981778 14 49648584 5.20E-07 0.05 C 1.96 1.57 1.25 NA 
rs12251637 10 1.26E+08 5.44E-07 0.04 T 2.07 1.65 1.32 LHPP 
 
 
QQ-Plot  Figure 31: Manhattan Plot and Q-Q plot SUMMIT CKD Phenotype Type 2 Diabetes 
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Table 46: Meta-Analysis of CKD-DN phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  
Figure 27
  
RS_NUMBER CHR BP P eaf reference_allele other_allele OR_95U OR OR_95L eaf Within Gene  
rs6997279 8 1.18E+08 2.22E-07 0.25 T G 1.79 1.51 1.28 0.25  SLC30A8  
rs188700382 3 1.01E+08 1.09E-06 0.02 A G 12.07 5.56 2.57 0.02  CEP97  
rs183409769 4 1.08E+08 1.30E-06 0.12 A G 2.59 1.95 1.46 0.12  NA 
rs138532692 15 84637219 1.75E-06 0.18 G A 0.80 0.66 0.54 0.18  ADAMTSL3  
 
 
QQ-Plot  
Figure 32: Manhattan Plot and Q-Q plot SUMMIT CKD-DN Phenotype Type 2 Diabetes 
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Table 47: Meta-Analysis of ESRD phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  Figure 29
  
RS_NUMBER CHR BP P eaf reference_allele other_allele OR_95U OR OR_95L Within Gene  
rs2475363 10 81278814 2.94E-07 0.04 C T 10.65 4.74 2.11  NA 
rs13224128 7 29283395 8.54E-07 0.04 T C 6.27 3.68 2.17  CHN2  
rs149034284 7 51066779 1.11E-06 0.03 A G 8.49 4.23 2.11  RP4-724E13.2  
rs117392950 8 47419544 1.17E-06 0.08 A T 5.50 3.27 1.94 NA  
 
  
Figure 33: Manhattan Plot and Q-Q plot SUMMIT ESRD Phenotype Type 2 Diabetes 
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Table 48: Meta-Analysis of Macro-ESRD  phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  
Figure 31
 
Figure 32 
RS_NUMBER CHR BP P eaf reference_allele other_allele OR_95U OR OR_95L 
Within 
Gene 
rs116354014 3 17170864 2.54E-07 0.02 C A 8.06 4.52 2.53 NA 
rs112765093 2 1.45E+08 2.87E-07 0.03 C G 4.70 2.94 1.84 GTDC1 
rs147523203 4 1.73E+08 5.95E-07 0.01 A G 44.53 17.32 6.74 GALNTL6 
rs7942230 11 88469683 2.25E-06 0.43 T G 0.86 0.77 0.69 GRM5 
chr11:81277664:D 11 81277664 2.55E-06 0.47 A AC 1.48 1.33 1.19 NA 
 
  
Figure 34: Manhattan Plot and Q-Q plot SUMMIT Macro-ESRD Phenotype Type 2 Diabetes 
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Table 49: Meta-Analysis of Micro phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  
Figure 33
 
 
RS_NUMBER CHR BP P eaf reference_allele other_allele OR_95U OR OR_95L 
Within 
Gene 
rs2150814 6 89942934 8.10E-08 0.36 T G 0.88 0.79 0.72 
GABRR1-
GABRR2 
rs1143914 13 1.11E+08 3.07E-07 0.49 G A 0.88 0.80 0.72 COL4A1 
chr2:170759049:D 2 1.71E+08 6.33E-07 0.53 A AG 1.40 1.26 1.14 UBR3 
rs11651114 17 4696736 9.77E-07 0.44 A G 1.43 1.29 1.16 NA 
chr4:146704225:D 4 1.47E+08 1.06E-06 0.28 C CAT 1.47 1.31 1.17 ZNF827 
 
 
 
Figure 35: Manhattan Plot and Q-Q plot SUMMIT Micro-albuminuria Phenotype Type 2 Diabetes 
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Table 50: Meta-Analysis of DN phenotype in SUMMIT consortium in patients with Type 2 Diabetes 
  
Figure 35
 
 
RS_NUMBER CHR BP P eaf reference_allele other_allele OR_95U OR OR_95L 
Within 
Gene 
rs183249293 13 86971561 2.44E-07 0.02 G A 0.61 0.42 0.29 NA 
rs9942471 6 89948232 4.76E-07 0.36 C A 0.91 0.83 0.76 NA 
rs2347470 6 63997318 1.04E-06 0.51 A G 0.90 0.83 0.76 LGSN 
rs139484064 20 35620979 1.25E-06 0.03 C T 0.70 0.54 0.41 NA 
rs182638570 2 97805602 1.28E-06 0.02 T C 0.44 0.27 0.17 ANKRD36 
 
 
Figure 36: Manhattan Plot and Q-Q plot SUMMIT-DN Phenotype Type 2 Diabetes 
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Table 51: Replication of reported loci associated with diabetic kidney disease in SUMMIT meta-analysis 
    DN CKD MACRO+ESRD ESRD MICRO Directionvs. original 
finding 
Gene SNP EA NEA OR P OR P OR P OR P OR P 
- rs1411766 G A 1.00 0.999 0.99 0.886 1.00 0.911 0.97 0.612 1.00 0.951  
ACACB rs2268388 G A 0.98 0.613 0.94 0.258 1.01 0.816 0.98 0.740 1.09 0.156  
ACE rs1800764 T C 1.01 0.794 1.07 0.080 1.00 0.945 1.03 0.627 1.08 0.102  
ADIPOQ rs17300539 G A 0.88 0.077 0.88 0.122 0.84 0.062 0.73 0.030 0.89 0.238 same 
AFF3 rs7583877 T C 1.01 0.771 0.89 0.002 0.92 0.041 0.78 0.00002 1.06 0.198 same 
AGT rs699 G A 1.04 0.192 0.98 0.587 1.02 0.549 1.04 0.372 1.10 0.020 same 
AGTR1 rs5186 C A 1.05 0.295 1.01 0.905 1.08 0.161 1.03 0.817 1.01 0.879  
AKRB1 rs3896278 T C 1.03 0.432 1.00 0.877 1.04 0.372 1.02 0.692 1.08 0.075  
APOC1 rs4420638 G A 1.05 0.333 1.08 0.143 1.00 0.959 1.01 0.878 1.04 0.567  
CARS rs739401 T C 1.04 0.204 0.98 0.579 1.04 0.313 1.02 0.659 1.03 0.474  
CARS rs451041 G A 1.04 0.197 0.98 0.582 1.06 0.308 1.02 0.702 1.03 0.502  
CPVL/CHN2 rs39075 G A 1.00 0.988 0.93 0.053 1.00 0.950 0.98 0.692 1.00 0.913  
CPVL/CHN2 rs39059 G A 1.01 0.874 1.05 0.175 0.99 0.746 1.02 0.683 1.03 0.478  
ELMO1  rs1558688 T C 1.04 0.213 1.06 0.140 1.04 0.290 1.18 0.004 1.01 0.851 Opposite to JPT. same 
with European (12) 
EPO rs1617640 C A 1.08 0.012 1.02 0.700 1.03 0.509 0.99 0.803 1.08 0.085 same 
ERBB4 rs7588550 G A 0.86 0.042 0.91 0.281 0.80 0.015 0.78 0.062 0.87 0.191 same 
FRMD3 rs942280 T C 1.00 0.883 1.04 0.282 1.05 0.266 1.01 0.847 0.99 0.750  
FRMD3 rs10868025 G A 1.00 0.932 0.98 0.570 0.98 0.692 0.93 0.211 1.08 0.068  
FRMD3 rs1888747 G C 0.99 0.720 0.98 0.687 1.00 1.000 1.08 0.173 0.92 0.057  
GLUT1 rs841853 C A 1.03 0.435 0.99 0.751 1.02 0.615 0.99 0.892 1.01 0.846  
GREM1 rs1129456 T A 1.05 0.348 1.01 0.903 1.01 0.072 1.06 0.519 0.99 0.886  
HSPG2 rs3767139 T C 1.04 0.303 0.99 0.743 1.02 0.622 1.02 0.745 1.03 0.587  
LIMK2  rs2106294 T C 1.03 0.464 1.01 0.832 1.08 0.074 1.03 0.656 0.99 0.751  
LOC100132891 rs9298190 T C 0.94 0.041 0.97 0.384 0.93 0.062 0.95 0.332 0.93 0.111 same 
MSRB3-HMGA2  rs2358944 G A 1.02 0.656 1.00 0.929 0.98 0.716 0.98 0.731 1.02 0.692  
 
 
153 
 
NOS3 rs1800779 G A 0.96 0.230 0.92 0.039 0.97 0.104 0.96 0.466 0.98 0.683 same 
PPARG rs1801282 G C 1.06 0.201 1.11 0.041 1.05 0.342 1.05 0.497 0.98 0.696 same 
PRKGA2 rs7805747 G A 1.01 0.764 0.94 0.362 1.05 0.334 0.99 0.872 0.99 0.872  
PVT1 rs11993333 T C 0.98 0.506 0.98 0.542 0.98 0.560 1.01 0.888 0.97 0.408  
PVT1 rs2648875 G A 1.03 0.353 1.02 0.567 1.03 0.523 1.03 0.623 0.99 0.792  
RGMA – MCTP2 rs12437854 T G 0.85 0.066 0.85 0.111 1.04 0.732 0.77 0.092 1.03 0.801  
RPS12 rs7769051 C A 0.99 0.892 0.94 0.279 0.98 0.736 0.99 0.226 1.00 0.965  
SASH1  rs6930576 G A 0.97 0.314 0.95 0.165 0.93 0.089 0.96 0.472 0.98 0.582  
SOX11 rs16864170 T C 0.98 0.844 0.97 0.791 0.93 0.523 1.03 0.865 0.95 0.703  
UMOD rs12917707 T G 0.98 0.558 0.94 0.213 1.00 0.937 1.01 0.873 0.99 0.780  
UNC13B rs13293564 T G 1.02 0.437 1.04 0.333 1.07 0.097 1.02 0.694 1.00 0.975  
VEGFA rs833061 T C 1.01 0.690 0.98 0.597 1.02 0.595 1.03 0.650 0.96 0.404  
ZMIZ1 rs1749824 C A 1.02 0.569 0.99 0.843 1.02 0.608 1.03 0.597 0.99 0.887  
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Discussion  
I. Estimating chip-based heritability of various DN phenotypes  
A key challenge in performing GWAS for DKD that based on albuminuria and 
eGFR levels, there are many ways in which the phenotype can be defined (micro-
albuminuria, macro-albuminuria, ESRD, CKD, and CKD with and without 
Albuminuria).  At the onset, some prior information about the heritability sub-
phenotypes might help in the prioritization of the DKD phenotypes.  Accordingly, 
we calculated chip-based heritability of various DKD sub-phenotypes and aimed to 
understand if there are differences in the chip heritability of various sub-phenotypes 
of DKD.   
Genome complex trait analysis (GCTA) 
154
 
121
 has been used to estimate chip-based 
heritability for several common complex disorders, including diabetes, hypertension 
and hyperlipidaemia.  The primary motivation for developing GCTA was to identify 
the “hidden heritability” for complex phenotypes which the GWAS studies failed to 
explain.  GWAS studies usually report estimates from single SNP association 
analysis and may not have adequate power and effect sizes to detect SNPs with 
modest effects, given the rigorous threshold of p-values and replications.  Hence, the 
method  measures the additive genetic variance explained by all the SNPs combined 
in the GWAS study on the background of genetic relation matrix estimated from 
GWAS SNPs
121
.  This could be useful approach as it  can provide a priori 
information about heritability of a trait before running a GWAS which in turn can 
help in prioritizing phenotypes.  Another function of GCTA is the novel bivariate 
analysis.  This approach has advantages over the approach described above as it can 
be used to identify shared genetic determinants between two correlated states or 
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phenotypes estimated by genetic correlation rg.  An rg=1 will imply that there is a 
complete overlap in genetic variants shared between two states or phenotypes while 
an rg<1 will mean that at-least some genetic variants are underlying the two traits are 
different.  This is important to understand if there are shared genetic determinants of 
co-related phenotypes such as blood pressure and eGFR or Hba1C and eGFR.  
One of the major drawbacks of GCTA is the fact that it ignores heritability due to 
factors such as gene-gene interactions, copy number variations etc.  Thus, the 
estimates represent the lower bounds of the actual heritability- estimated from the 
genome-wide representative SNPs giving rise to the term “chip based heritability”.  
This is evident from the results of GCTA, for example, human height is about 80% 
heritable; however, the estimates from GCTA for several studies are around 40%
121
.   
In the present study, we categorized the cases into different subgroups based mainly 
on albuminuria excretion and presence and absence of CKD.  The phenotypes 
interrogated for their chip-based heritability were eGFR as a continuous trait, eGFR 
as a categorical variable (eGFR<60) a combination of albuminuria and eGFR (CKD-
DN) (eGFR<45 and macro-albuminuria vs eGFR>60 and no albuminuria), macro-
albuminuria, micro-albuminuria and any albuminuria.  Our study shows some 
evidence that CKD, CKD-DN, macro-albuminuria, and ESRD are more heritable as 
compared to micro-albuminuria and any-albuminuria phenotype.  This is consistent 
with the observation that micro-albuminuria is a more variable trait and is more 
likely to be influenced by environmental factors such as fever and transient 
hyperglycaemia
155
.  This can decrease the power to detect variations in micro-
albuminuria due to genetic determinants.  However, the confidence intervals 
associated with the chip-based heritability estimates were very high precluding us 
from making any meaningful conclusions. 
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We conducted a bivariate analysis of blood pressure and eGFR.  Our study showed 
limited overlap of genetic determinants underlying eGFR and blood pressure 
suggesting that there is a possibility of identifying variants affecting eGFR, which do 
not act through their effect on blood pressure.  Again, the confidence intervals 
associated with the estimates genetic-correlation between the two phenotypes were 
very high precluding us from making any meaningful conclusions. 
We calculated the chip-based heritability with both imputed and directly genotyped 
data.  Interestingly, the difference between the heritability estimates calculated from 
imputed and directly genotyped data was not significant.  The use of imputed data 
did not show a significant increase in heritability, even with a substantial increase in 
the number of interrogated variants, suggesting that the directly genotyped data alone 
sufficiently captured the chip-based heritability present in SNP level data. 
A key limitation of this study is the relatively small sample size studied.  It would be 
interesting to combine individual level GWAS data across all the SUMMIT cohorts 
and see its effect on heritability estimates for various albuminuria phenotypes.  
However, combining genotype data across different cohorts and platforms is a 
challenging task because of a) governance challenges in acquiring individual level 
data and b) differences in genotyping  due to use of different genotyping platforms. 
In summary we showed some suggestive evidence that macroalbuminuria, ESRD 
and chronic kidney disease (eGFR<60) are be more heritable than other DKD 
phenotypes; however, because of small sample sizes and limited power we could not 
prioritise the GWAS phenotypes based on their chip-based heritability. 
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II. GWAS for upstream risk factors of DKD (BP  and HbA1c) OR doing 
Genetic risk scores with known loci and testing their association with DN 
phenotypes 
In this study, we provide first replication of Blood Pressure and HbA1C associated 
SNPs in patients with Type 2 diabetes (n=~7000) and study the cumulative effect of 
known BP and HbA1C associated SNPs on diabetic kidney disease. 
There is an increasing interest in investigating the role of abdominal obesity, 
dyslipidaemia, hypertension, fasting hyperglycaemia and HbA1c in the development 
of kidney disease in patients with diabetes
156
.  Several studies have shown 
association of higher HbA1c and high blood pressure with onset of kidney disease in 
patients with Type 2 Diabetes.  Multiple large-scale clinical trials, including the 
Diabetes Complications and Control Trial (DCCT) in Type 1 diabetes
157
 and the 
United Kingdom Prospective Diabetes Study (UKPDS)
158
 in Type 2 diabetes, have 
shown that the risk for DKD begins to increase at an HbA1c level of 6.5%.  
Hypertension on the other hand has long been recognized as both, a consequence of 
renal impairment and an important factor in the progression of DKD
156
.  Shulman et 
al showed that  the incidence of a decline in renal function over 5 years is greater 
among older patients with hypertension
159
 and Retnakaran et al showed that 
hypertension is an independent risk factor for development of albuminuria or renal 
impairment among patients with type II diabetes
160
.  Since hypertension is both a 
consequence and a risk factor of DKD,  a conclusive role of hypertension as an 
upstream risk factor for DKD a can be established by Mendelian randomization 
study looking at the association for genetic  determinants for high blood pressure and 
DKD.  Similarly, an association between the genetic risk score for high HbA1C and 
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DKD will clearly establish HbA1C as a risk factor for DKD.  Mendelian 
randomization is a method of using measured variation in genes of known function 
to examine the causal effect of a modifiable exposure on disease in non-experimental 
studies
161
.  Gray and Wheatley (1991)
161
 first described this method for obtaining 
unbiased estimates of the effects of a putative causal variable without conducting a 
traditional randomised trial. 
There have been several genome-wide association studies for hypertension.  The 
HYPERGENES Project was a two-staged case controlled study by Salvi et al 
showed that significant association exists between HTN and rs3918226 located on 
eNOS gene in its promoter region
162
.  Newton et al conducted a GWAS and 
identified eight loci associated with HTN
163
.  The loci identified were CYP17A1, 
CYP1A2, FGF5, SH2B3, MTHFR, c10orf107, ZNF652 and PLCD3.  Padmanabhan 
et al conducted a GWAS nearly 1600 HTN patients and 1700 controls and showed 
that a locus on chromosome 16, rs13333226, in the uromodulin gene region was 
identified to have significant association with HTN
164
.  In a joint meta-analysis of 
30,000 individuals in CHARGE Consortium (Cohorts for Heart and Aging Research 
in Genome Epidemiology) with Global BP gen consortium (n=35,000 patients) and 
10 novel SNPs associated with BP were identified
165
.  GWAS significance was 
attained in four (ATP2B1, CYP17A1, PLEKHA7, SH2B3) SNPs for SBP, 6 SNPs 
(ATP2B1, CACNB2, CSK/ULK3, SH2B3, TBX3/TBX5, ULK4), for DBP. 
Percent HbA1c (glycated haemoglobin) is an informative trait for diabetes diagnosis 
and management and is used in quantifying chronic glycaemic exposure of 
erythrocytes for the preceding 2 to 3 month.  There is strong correlation between 
HbA1c levels and occurrence of diabetes complications.  There are several GWAS 
studies looking at genetic determinants of HbA1c levels.  In 2010, MAGIC (Meta-
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analyses of Glucose and Insulin related traits Consortium) identified ten genetic loci 
associated with HbA1c
166
.  The ten loci associated included three loci in or near 
genes likely involved in glycaemic control pathways: G6PC2, GCK, and MTNR1B 
and seven loci in or near genes likely to be involved in erythrocyte biology, 
including  SPTA1, HFE, ANK1, HK1, APT11A, FN3K, and TMPRSS6.  A large study 
by Paré et al performed in 14,618 non-diabetic individuals identified HK1 (encodes 
for enzyme hexokinase) as associated with HbA1c levels
167
.  Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 
Research Group (DCCT-EDIC) have reported SORCS1 as major locus for HbA1c 
levels in patients with Type 1 Diabetes
168
. 
The studies identifying SNPs for both hypertension and HbA1c have been performed 
in general population with a small proportion of patients with Type 2 diabetes. In 
fact, the biggest study identifying genetic determinants of HbA1c (MAGIC) was 
performed in non-diabetic participants.  Type 2 Diabetes and concomitant presence 
of DKD can either attenuate or exaggerate the effects of these SNPs on hypertension 
and HbA1c hence it is important to test the effect of known HbA1c loci in patients 
with diabetes.  Hence, we decided to perform a replication analysis of the top GWAS 
SNPs associated with blood pressure and HbA1c in patients with Type 2 diabetes.  
We identified SNPs convincingly associated by blood pressures and HbA1c from the 
Catalogue of Published Genome-Wide Association Studies
169
 and selected 60 SNPs 
associated with blood pressures and 14 SNPs associated with HbA1c.  Of the 60 
SNPs for hypertension, 20 were significantly associated with blood pressure after 
correction of multiple testing; while from 14 SNPs associated with HbA1c eight 
SNPs from six genes were associated with Hba1c in the Type 2 diabetes cohort.  
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This suggests that the genetic determinants of blood pressure and HbA1c in Type 2 
diabetes are shared with those in general populations. 
Next, we looked at the effect of the variants associated with HbA1c and blood 
pressure on albuminuria in patients with Type 2 diabetes.  Since these variants 
explain a small proportion of (usually less than 1%) heritability of hypertension and 
HbA1c
166
, we decided to study the cumulative effect of these variants on DKD and 
calculated beta-weighted genetic risk scores for each study participant.  The age and 
sex adjusted genetic risk scores for hypertension and HbA1c were significantly 
associated with macro-albuminuria and ESRD phenotypes in the Go-DARTS 
datasets.  This Mendelian randomization approach conclusively establishes the 
causal effect of hypertension and HbA1c on DKD.  We show that  genetic risk score 
for blood pressure is associated with DKD leading us to presume that BP is upstream 
risk factor of DKD.  However, it is possible that some of these loci have an effect on 
the physiology, biochemistry of kidneys  which in turn regulate the blood pressure.  
Thus, the effect of these SNPs can be on kidneys rather than the blood pressure 
itself.  However, as most of the SNPs have been associated with blood pressure in 
non-diabetic non- kidney disease population , it can be assumed that majority these 
SNPS act of the kidneys by their action on blood pressure and not vice versa. 
In summary, we replicated the association of several known loci for Hypertension 
and HbA1c in patients with Type 2 diabetes and show that these variants have a 
cumulative effect on albuminuria in patients with Type 2 diabetes. 
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III. VI. Replication of CKDgen Consortium eGFR loci Hits  
We replicate the association of UMOD GCKR, and SHROOM3 with eGFR in 
patients with Type 2 diabetes.  Our study confirms the findings of previous studies 
showing the association of UMOD with eGFR and diabetic nephropathy
170-173
 and 
association of GCKR, and SHROOM3 with eGFR
174-176
.  A study by Gudbjartsson et 
al showed and interaction of UMOD with age
173
; while another study
170
 could not 
replicate this interaction. In the present study we do not see an interaction of UMOD 
with age in a patients with Type 2 Diabetes (P=0.84). 
None of the other variants were associated with eGFR after correction for multiple 
testing; however, the direction of effect for most of the SNPs was consistent with the 
previous studies.  Our study had limited power to estimate the effect of these variants 
on eGFR.  Taken together all these variants explain 1.4-14% heritability of eGFR
177
 
(with each SNP contributing typically less than 0.5% heritability of eGFR). Our 
study had 97% power to detect an association with a SNP explaining 0.5% 
variability in eGFR due to individual SNP and anything below 0.5% can remain 
undetected.  It is also possible that some of these SNPs are not the causal SNPs and 
because of varying linkage disequilibrium, (LD) structure in our population could 
not be detected.  It is also possible that effects of some of these SNPs were 
attenuated by diabetes or diabetic kidney disease and hence were not associated with 
eGFR in this study. 
We examined the association of these loci with decline in renal function using a 
Cox-proportional hazard model and estimated effect of these loci on time to stage 3B 
CKD (eGFR<45mls/min/1.73m2).  Given the high mortality associated with diabetic 
nephropathy, cross-sectional studies are prone to survival bias, as patients with 
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severe forms of nephropathy are less likely to be included in the study.  Hence, it is 
important to investigate the eGFR loci in a time dependent manner.  Of the 15 SNPs, 
only rs12917707 in UMOD was associated with time to stage 3B-CKD with the 
minor allele ‘T’ showing a protective effect.  UMOD has a stronger effect on 
baseline eGFR as compared to other 14 markers suggesting that SNPs with a strong 
effect on baseline eGFR influences decline in renal function over a period. 
We did a stratified analysis to examine the effect of albuminuria on the known 
genetic associations with eGFR.  In T2D, nephropathy albuminuria may be more 
closely associated with decline in renal function and the impact of genetic 
determinants of eGFR may differ depending on the presence or absence of 
nephropathy.  Hence, we examined the effects on eGFR stratified by albuminuria.  
There is clear difference in the effect sizes in those with sustained normalbuminuria 
and those with albuminuria.  For example, the UMOD has twice the effect in patients 
with sustained normalbuminuria as compared to those with albuminuria (P-
interaction=0.002) while SHROOM3 (P-interaction=0.003) and GCKR (P-
interaction=0.08) had larger effect sizes in those with albuminuria.  It is known that 
kidney diseases characterized by albuminuria, such as diabetic nephropathy can have 
ultrafiltration and high eGFR in the early stage of disease while those characterised 
by reduced renal function like hypertensive kidney disease may manifest with 
normo-albuminuria because of the reduced renal efficiency
71,72
.  Hence, studying the 
genetic determinants of eGFR without adjusting for albuminuria status or studying 
genetic determinants of albuminuria without accounting for eGFR can reduce the 
power of these studies to identify true genetic effects.  Cumulatively, eGFR 
associated loci explain only a small fraction of the total heritable contribution eGFR 
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and stratifying by albuminuria status in our existing GWAS datasets
177-179
 can help 
us to uncover the missing heritability.  The heterogeneity in the effect sizes suggests 
different mechanisms by which these genes impact upon the kidney function; it is 
possible that UMOD is a basal kidney function gene and the diabetic albuminuria 
attenuates its effect on renal function.  It is possible that the heterogeneity seen at the 
UMOD, SHROOM3 and GCKR arises due to difference in the baseline 
characteristics between the two cohorts (i.e with (n=2097) and without albuminuria 
(n=613)).  However, the regression analysis adjusted for baseline characteristics such 
as age, sex, BMI, BP and duration of diabetes thereby minimizing the effects of 
baseline differences 
In summary, our results show that some of the genetic determinants of eGFR in 
general population are common to patient with Type 2 diabetes.  However, in 
patients with Type 2 diabetes it is essential to adjust for albuminuria status while 
investigating the genetic determinants of renal function. 
 
IV. GWAS for biomarker for DN (sRAGE) 
We report the first genome-wide association study to identify genetic determinants 
of circulating sRAGE levels and confirm the association of rs2070600 (G28S), a 
non-synonymous SNP located in exon 3 of RAGE, with circulating sRAGE and 
esRAGE levels.  Moreover, we identified novel polymorphisms rs10940285 in 
ITGA1-ITGA2 gene region and rs9272346 in AGER-HLA-DQA1 associated with 
sRAGE levels. 
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Association of known variant in AGER   gene with sRAGE levels 
The ‘T’ allele in rs2070600 (G28S) encodes for serine and is shown to be associated 
with lower sRAGE levels in European
180,181
 and Asian populations
181
 and our study 
confirms this findings.  Mechanisms whereby SNP rs2070600 (G28S) affects the 
sRAGE plasma concentrations remain unknown.  It has been proposed that the 
alteration of the N-glycosylation state of the protein, caused by the rs2070600 
(G28S) polymorphism, induces structural changes in the protein that makes RAGE 
more vulnerable for the action of proteinases, such as a disintegrin and 
metalloproteinases 10
182
 and matrix metalloproteinase-9
183.  The minor allele ‘T’ of 
rs2070600 (associated with lower sRAGE levels) has been associated with increased 
risk of Alzheimer’s disease184, Type 1 diabetes185 and asthma186.  All three diseases 
have been associated with lower sRAGE levels
184
.  Two other SNPs of AGER, 
previously associated with HLA-DR/DQ haplotype independent diabetes risk 
(rs9469089, and rs17493811)
187
, were not associated with sRAGE levels in this 
study. 
 
Association of HLA-DQA1 gene (HLA Class II region) with sRAGE levels 
We identified a novel marker rs9272346 in the HLA-DQA1 gene associated with the 
sRAGE levels.  A genome-wide conditional analysis using summary statistics from 
the CARDS- Go-DARTS meta-analysis (with the algorithm implemented in GCTA) 
suggests that the association of rs9272346 with the sRAGE levels is independent of 
the known marker rs2070600 (G28S) in the AGER gene.  The ‘G’ of rs9272346 
allele was associated with higher sRAGE levels.  Carriers of “G” allele of rs9272347 
have lower risk for T1D and Asthma 
188,189
 and interestingly, sRAGE is deficient in 
both T1D and in neutrophilic asthma and chronic obstructive pulmonary disease 
 
 
165 
 
(COPD)
190,191
.  Although this variant is independent of the known rs2070600 (G28S) 
in the AGER gene, it is possible that this variant could be in long range LD with 
another SNP in AGER gene. 
 
Association of ITGA1 gene with sRAGE levels 
We identified a novel marker rs10940285 in 3 prime UTR of ITGA1 gene associated 
with sRAGE levels.  This gene encodes the alpha 1 subunit of integrin receptors.  
This protein heterodimerizes with the beta 1 subunit to form a cell-surface receptor 
for collagen and laminin.  The heterodimeric receptor is involved in cell-cell 
adhesion and may play a role in inflammation and fibrosis.  The alpha 1 subunit 
contains an inserted (I) von Willebrand factor type I domain which is thought to be 
involved in collagen binding.  ITGA1 has demonstrated genetic pleiotrophy as 
variants in the ITGA1 have been associated with bone  mineral density, Type 2 
diabetes, fasting insulin,  β-cell function by homeostasis model assessment, and 2-h 
post–oral glucose tolerance test glucose and insulin levels,  liver fibrosis, insulin 
secretion, and bone healing
192-195
.  While it is unclear how ITGA1 affects sRAGE 
levels, we hypothesize that through its action on fasting glucose and insulin, ITGA1 
might affect the formation of advanced glycation end-products which in turn can 
regulate the sRAGE levels.  It is interesting to note that the effect of this 
polymorphism on sRAGE levels is more significant in patients with Type 2 diabetes.  
We did not find association between rs10940285 in ITGA1 and fasting glucose and 
insulin in the CARDS study, however, this analysis might be limited by the smaller 
sample size as compared to original reports.  Interestingly, the RAGE ligands include 
matrix proteins such as Collagen I and IV
196
.  ITGA1 forms cell-surface receptors for 
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collagen n and through ligand, sharing by ITGA1 might influence the levels of 
circulating sRAGE. 
 
Association of promoter variants in AGER gene with sRAGE levels 
Two promoter variants in the AGER gene rs1800624 (374 T>A) and rs1800625 (429 
T>C) have been frequently investigated for their association with diabetes, 
cardiovascular disease and other metabolic traits.  For example, rs1800624 
(374T>A) is shown to be associated cerebrovascular disease in both Type 1 and 
Type 2 diabetes as well as in those without diabetes
197-200
, while rs1800625 has been 
associated with pre-diabetic state, with higher HbA1c and insulin resistance
201,202
.  
Neither rs1800624 (P-value=0.59) nor rs1800625 (P-value=0.22) were associated 
with sRAGE level the CARDS-Go-DARTS meta-analysis.  
 
 
Chip-based heritability for sRAGE levels 
We provide first evidence for the heritability of sRAGE levels using GCTA.  One 
drawback of GCTA is the fact that it ignores heritability due to factors such as, copy 
number variations, runs of homozygosity and other sources of heritability
148
.  Thus, 
the estimates represent the lower bounds of the real heritability, giving rise to the 
term “chip-based heritability”.  Nonetheless, we show that the point-estimate for 
chip-based heritability of sRAGE is 37% and the three genome-wide significant 
SNPs in the study explain 10% of this heritability in European populations. 
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GWAS for sRAGE/esRAGE ratio 
We performed a GWAS for splice variant endogenous secretory RAGE (esRAGE) 
levels and esRAGE/sRAGE ratio using the GWAS data in the CARDS dataset.  We 
did not find any variant differentially associated with esRAGE as compared to 
sRAGE levels and no marker reached the accepted threshold of significance in the 
GWAS for esRAGE/sRAGE ratio (data not shown).  It has been shown that esRAGE 
constitutes only a small proportion of the total sRAGE pool and is highly correlated 
with the sRAGE levels
203
.  Since the esRAGE and sRAGE are highly correlated, the 
identification of genetic variants specifically associated with esRAGE and not with 
sRAGE will need study with very large sample size.  There is very limited 
epidemiological data about esRAGE/sRAGE ratio, with some reports indicating that 
the ratio can change in diseases states like pre-eclampsia
204
.  Further epidemiological 
characterization of the esRAGE/sRAGE ratio will be useful to identify the genetic 
determinants of the esRAGE/sRAGE ratio. 
 
 
Study Limitations 
Our study had several limitations.  With a discovery, sample-size of 1,377 it had 
60% power to detect a SNP, which explains 2% variation in sRAGE levels, and only 
9% power to detect a SNP, which explains 1% variation in sRAGE levels.  Hence, 
variants with small effects on sRAGE level could have been missed in this GWAS 
analysis.  Additionally, since the GWAS chips and imputations capture only the 
common tagging variants in the genome, the novel variant rs9272346 could be 
tagging a causal underlying variant and a dense fine-mapping and sequencing of this 
region might help to identify this variant.   
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In summary, we identified in novel variants in the in ITGA1-ITGA2 and HLA-DQA1 
region associated with sRAGE levels, confirmed the association of rs2070600 
(G28S) with sRAGE and show that sRAGE levels have a heritable component.  
Further studies are needed to investigate the mechanisms by which ITGA1-ITGA2 
and HLA-DQA1 influence sRAGE levels.  Adequately powered GWAS studies can 
identify the additional variants associated with sRAGE.  The identified variants can 
be utilized in Mendelian randomization studies to establish the causality between 
sRAGE and diabetic complications and vascular diseases, and further functional 
studies of the variants can identify pathways involved in the AGE-RAGE axis and 
vascular diseases.  
 
V. Meta-analysis of GWAS data with other DKD datasets 
We performed a genome-wide association study to investigate genetic susceptibility 
to Diabetic Kidney Disease in Type 1 and Type 2 diabetes.  Previous genome-wide 
association studies
97,112,114,115,118,119
 for diabetes-associated kidney disease in 
Japanese, Pima Indians, and Caucasian Americans have identified several potential 
DKD loci such as ELMO1, PVT1, FRMD3, and CARS.  As discussed earlier, these 
GWAS’s had several limitations such as a small sample size, varying definitions of 
DKD and inadequate duration of diabetes for the controls.  The proven heritability of 
DKD using both conventional family based methods and chip-based methods, 
suggests that  GWAS studies should be performed to identify novel genetic 
determinants of DKD.  Hence, we performed GWAS for diabetic kidney disease 
using for both Type 1 and Type 2 diabetic kidney disease using ~3,000 individuals 
from the Go-DARTS cohort for Type 2 diabetes and 1,000 individuals for the 
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EURODIAB cohort for Type 1 Diabetes and meta-analysed these dataset in an 
international consortium (SUMMIT). 
In the results presented below, I performed the GWAS analysis of two Go-darts 
datasets and EURODIAB dataset for all the DKD phenotypes.  I then assisted a 
team of analysts in the SUMMIT consortium to perform the GWAS meta-
analysis for all the phenotypes. 
Novel Findings for DKD in Type 1 and Type 2 Diabetes 
We report two genome-wide significant SNPs for the CKD and Micro-albuminuria 
phenotype in Type 2 diabetes.  For CKD we identified a locus in PLCB4, which 
encodes phospholipase C beta 4.  This enzyme catalyses the formation of inositol 
1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate.  
This reaction plays an important role in the intracellular transduction of many 
extracellular signals in the retina and PLCB4 might be involved in maintenance of 
the circadian rhythm.  Neutrophils are the most abundant subtype of white blood 
cells (WBCs), comprising 50–70% of all WBCs. Yukinori Okada Hum et.al205  did a 
GWAS in 5771 individuals with Japanese ancestry.  They identified locus in 20p12 
associated with neutrophil count (rs2072910 in PLCB4 at 20p12, P = 3.1 × 10−10).  
This locus is not in LD with the SNP associated with DKD in SUMMIT GWAS 
analysis.  No study has yet shown association of neutrophil count with DKD 
however, high neutrophil count is known to be associated with lower serum albumin, 
elevated creatinine, and increased mortality risk in haemodialysis patients
206
.  Hence, 
if this locus were to replicate we can study the association of neutrophil count with 
DKD in Go-DARTS dataset.  (Neutrophil percentage is available in GO-Darts 
dataset). 
 
 
170 
 
 For micro-albuminuria, a GWAS significant locus was seen at a SNP between 
GABRR1 and GABRR2.  GABA is the major inhibitory neurotransmitter in the 
mammalian brain where it acts at GABA receptors, which are ligand-gated chloride 
channels.  GABRR1 is a member of the rho subunit family. Several transcript 
variants encoding different isoforms have been found for this gene. GABRR1 is a 
known locus for bipolar schizoaffective disorder
207
 and alcohol dependence
208
.  
There is no known association of this locus with diabetes or any other autoimmune 
disorder.  GABRR1/2 is shown to be putatively associated with diabetic cataract in a 
study performed in Taiwanese population
209
. This study was performed in 109 T2D 
patients with cataract and 649 patients with no cataract. However, the association of 
GABRR1/2 with cataract was not genome-wide statistically significant and hence 
larger studies will be required to confirm this association. The initiating mechanism 
in diabetic cataract seems is the generation of polyols from glucose by aldose 
reductase and these can also play role in pathogenesis of DKD .  If this locus is 
successfully replicated for DKD it would be interesting to further study its 
association with diabetic cataract
210
.  
We identified three loci were associated with micro-albuminuria at p <10
-7
, 
including rs1143914 in the intron of COL4A1.  This gene encodes collagen type IV, 
one of the major components of the glomerular basement membrane
211
, making it a 
strong candidate for involvement in DKD.  Another interesting locus for Type 2 DN 
phenotype was chr4:55939605: I (p=2.1x10
-6
) situated near KDR gene.  KDR 
encodes the VEGF-receptor 2 that is expressed on endothelial cells, podocytes and 
tubular cells, and is known to be essential for normal glomerular function
212
.  Both 
KDR and VEGF are up-regulated in diabetes
213
 and overexpression of VEGF in 
animal models results in proteinuria
214
.  For ESRD in Type 2 diabetes a less 
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significant but biologically relevant signal was detected near KLF10.  KLF10 is a 
transcriptional repressor that acts as an effector of transforming growth factor beta 
(TGF-beta) signalling
215
 which is known  to be a pivotal player in the development 
of DKD. 
For The T1D- CKD-DN phenotype, we observed a genome-wide significant locus at 
AFF3 gene.  AFF3 (AF4/FMR2 family, member 3) has been earlier associated with 
T1D-ESRD in a meta-analysis including both FinnDiane and SDR
97
.  Variants near 
this gene have been associated with T1D and rheumatoid arthritis
216
.  Since, 
FinnDiane and SDR cohorts have contributed data to this meta-analysis this locus 
cannot be regarded as a novel locus.  For the T1D-ESRD phenotype a strong 
association was also seen for rs76729345 in INSR (Insulin Receptor gene) 
(P=4.40x10
-6
).  Binding of insulin to the insulin receptor stimulates glucose uptake 
into cells.  INSR is expressed in kidneys, and the gene expression is higher in 
patients with T1D-DKD compared with healthy kidney donors
217
.  Variants in this 
gene have been suggestively associated   with diabetic retinopathy in patients with 
T1D.  Nearly all T1D patients with ESRD have at least some level of diabetic 
retinopathy, and this locus may be a common associated SNP for the two major 
microvascular complications of T1D.  For the macro-albuminuria ESRD phenotype 
in T1D, we observed a suggestive GWAS significance at INSIG2.  INSIG2 encodes 
an endoplasmic reticulum protein that regulates lipid synthesis by blocking the 
proteolytic activation of sterol regulatory element binding proteins (SREBPs) and 
their transportation to the Golgi.  Given its role in lipid metabolism, this is an 
interesting candidate for DKD. 
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Replication of Previous Results 
We studied previous GWAS loci reported in diabetic nephropathy, either T1D or 
T2D.  We also included a number of candidate gene loci that were significantly 
associated with DN in a literature-based meta-analysis.  Further, we included three 
SNPs significantly associated with CKD in non-diabetic CKD.  None of the SNPs 
were significantly associated with disease after correction for multiple testing.  
Nominal significance (P<0.05) with an effect in the same direction as the original 
finding was seen for SNPs in ADIPOQ ELMO1 NOS3 PPARG.  The non-replication 
of previously reported loci in the GWAS suggests either 1) publication bias in the 
candidate gene studies whereby only positive findings are reported, or 2) difference 
in the linkage disequilibrium (LD) pattern between our GWAS cohorts and earlier 
studies.  Although this is not very likely given most of the GWAS and candidate 
gene studies are reported in European populations, it would mean that the underlying 
tagging variant could not be captured in our study.  3) Alternatively, it could mean 
that the underlying variant has a modest effect and our data did not have adequate 
power to capture it. 
Limitations 
We will now discuss some of the limitations of the Genome-wide DKD Meta-
analysis in the SUMMIT consortium 
Heterogeneity of DKD phenotype 
 Despite of our large sample size, we did not achieve genome-wide statistical 
significance for our main DN phenotype (any albuminuria vs No Albuminuria with 
15-year duration of diabetes) for both Type 1 and Type 2 Diabetes suggesting that 
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this phenotype may have been too heterogeneous to detect significant associations 
with a sample of this size.  Using the most severe forms of DN to define cases (e.g. 
ESRD or eGFR<45+macroalbumiuria) reduces some potential misclassification but 
definitely does not overcome the critical imprecision of case definition not based on 
histology (many other kidney diseases can cause macro-albuminuria and ESRD).   
Cross-sectional study design 
The problems associated with cross-sectional study design to identify the genes for 
diabetes complications and risk factors for diabetes complications have been well 
documented.  For example, lifelong glycaemic control - a known risk factor for DKD 
- is not well captured in most existing cohorts and could not be used.  Similarly, the 
use of antihypertensive over the duration of follow-up is not captured in all cohorts.  
Ideally, a time dependent analysis using time to event models should be used to 
investigate the genetic loci associated with DKD with adjustments for drugs and 
other relevant covariates.  Further, the diabetic patient is exposed to many 
nonspecific kidney-damaging events in the course of disease (e.g. contrast agent 
imaging) which can cause transient renal dysfunction giving risk to albuminuria or 
reduced eGFR.  Overall, the misclassification involved in using exclusively clinical 
DKD definitions in cross-sectional studies reduces statistical power to detect 
underlying genetic variants.  
Additional Confounding factors 
 
DKD is a complex disorder produced by the interplay of large number factors and 
additional confounding because of these can reduce the power of GWAS to detect 
novel associations.  Long-term glycaemic control (measure of HbA1c) is the most 
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important factor, which can affect the onset of DKD.  Given the cross-sectional 
nature of our study, we could not adjust for variations/fluctuations in HbA1c during 
the follow-up period.  Similarly, we did not adjust for relevant covariates like insulin 
dose, diet, and exercise.  Although the individual GWAS analysis across the 
SUMMIT cohorts was performed in homogenous population and were adjusted for 
eigenvectors from PCA, we cannot rule out confounding by population stratification.   
Generalizability and Effect sizes 
 
We performed the GWAS meta-analysis in European Caucasian populations and 
these results cannot be generalized to Asian, African and other admixed 
populations(African Americans, Hispanics) etc.  Hence, these SNPs if replicated in 
Caucasians will have to be investigated in different ethnicities before they can be 
established as causal variants in all the diabetes population in the world.  Although 
we have not estimated the effect sizes of these SNPs (as they are yet to be 
replicated), indications are that they will explain small proportion of variability of 
DKD in these populations.  For, example the top SNP in UMOD explains less than 
1% variation in eGFR in patients with diabetes.  Despite of this very large GWAS 
effort to detect the genetic determinants of DKD, it is likely that we will be able to 
explain a small proportion of heritability of DKD. 
Functional analysis 
With this meta-analysis of DN in T1D patients and T2D DN patients, we have taken 
an important step towards defining the genetic architecture of DN.  Strengths of the 
study include its large sample size, consideration of alternative DN phenotypes based 
albuminuria and eGFR staging.  Now the challenge will be further investigations and 
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interpretations of these results in the context of pathophysiology of DKD.  Since we 
have not replicated the GWAS hits for DKD, we have still not undertaken a 
functional analysis of the identified SNPs.  How these SNPs interact in vivo to 
contribute to the pathogenesis of DKD can be studied using mouse models, tissue 
specific expressions once the SNPs are replicated in independent cohorts. 
Future Directions 
Genome-wide meta-analysis for Type 1 and Type 2 Diabetes in the SUMMIT 
consortium have revealed several potential loci associated with DKD.  A logical next 
step would be to replicate these loci in independent cohorts.  Given the huge amount 
of data accumulated due to meta-analysis of multiple phenotypes for DKD it is a 
challenge to select a right number of SNPs for replication.  Top SNPs for replication 
can be selected in several ways.  A straightforward way to do this would be to select 
the top independent SNPs for all phenotypes at a suggestive GWAS significance 
threshold (P<10-6) and carry them forward for replication.  Other way would be to 
look at these top associations and selected SNPs that lie in biologically relevant 
pathways for DKD.  Both these approaches have limitations.  If only the top SNPs 
i.e. with a GWAS significance threshold (P<10-6) were selected, we would miss a 
number of important SNPs which are significant in multiple phenotypes at a 
significance of P<10-5.  These could be relevant for DKD given that they are 
consistently significant across various stages or albuminuria.  On the other-hand if 
we were to select SNPs based on their representation in biologically relevant 
candidates for DKD we will lose, a large number of loci –given that all the pathways 
for DKD have not been elucidated.   
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One way to deal with the multiple correlated phenotypes would be to use a new 
multivariate method that TATES (Trait-based Association Test that uses Extended 
Simes procedure), inspired by the GATES procedure proposed by Li et al (2011)
218
.  
For each component of a multivariate trait,  TATES combines p-values obtained in 
standard univariate GWAS to acquire one trait-based p-value, while correcting for 
correlations between components.  Extensive simulations, probing a wide variety of 
genotype–phenotype models, show that TATES's false positive rate is correct, and 
that TATES's statistical power to detect causal variants explaining 0.5% of the 
variance can be 2.5–9 times higher than the power of univariate tests based on 
composite scores and 1.5–2 times higher than the power of the standard MANOVA.  
Unlike other multivariate methods, TATES detects both genetic variants that are 
common to multiple phenotypes and genetic variants that are specific to a single 
phenotype, i.e. TATES provides a more complete view of the genetic architecture of 
complex traits.  As the actual causal genotype–phenotype model is usually unknown 
and probably phenotypically and genetically complex, TATES, available as an open 
source program, constitutes a powerful new multivariate strategy that allows 
researchers to identify novel causal variants. 
We would also need to perform a genome-wide conditional analysis on the summary 
level data accumulated through these GWAS analysis.  It is likely that some SNP 
with big effect can mask SNPs with smaller effect sizes.  For example, a GWAS for 
DKD stratified by effect of MHY9 gene uncovered the association of FRMD3 with 
DKD
114
. 
Perhaps the greatest challenge in the ‘post-GWAS’ era is to understand the 
functional consequences of the associated loci.  Biological insights from functional 
analysis can then be translated to clinical benefits, screening, and disease prevention.  
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Our understanding of the way in which a risk variant initiates disease pathogenesis 
progresses from statistical association between genetic variation and trait or disease 
variation to functionality and causality.  The functional consequences of variants in 
protein-coding regions causing most monogenic disorders are easy to interpret, as we 
know the genetic code.  For non-Mendelian or multifactorial traits, most of the 
common DNA variants have so far mapped to non-protein–coding regions, where 
our understanding of functional consequences and causality is extremely limited. 
One way, that the trait-associated alleles exert their effects is by being a transcription 
activator (such as transcript levels and splicing) through multiple mechanisms.  A 
transcriptional activator is a protein that increases gene transcription of a gene or set 
of gene.  After confirmation of the associated loci, (following replication studies) we 
can use appropriate assays and models to test the functional effects of both SNPs and 
genes associated with DKD. 
In summary, the future work will involve confirmation of the loci through 
replications in independent populations, studying the effect of the replicated loci in 
different ethnicities and ascertaining the mechanism through which these loci affect 
the pathogenesis of DKD. 
In conclusion this thesis has shown that a) estimation of chip based heritability of 
various DKD sub-phenotypes using GCTA has limited utility and requires GWAS 
studies with extremely large sample sizes b) the genetic determinants of renal 
function (eGFR) can interact with albuminuria in patients with T2D c) there are yet 
unidentified genetic markers associated with DKD  and have identified  potentially 
novel genetic markers associated with sRAGE (an important biomarker for DKD) 
and  DKD itself which can be investigated in future studies for their reproducibility 
and functional consequences. 
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Appendix I 
Script for running IMPUTE 2 and GTOOL 
lineval=`awk 'match($1,/^[0-9]/){  
interval=5000;  
count++; 
    if (count==1)  { 
        start=$1; 
    } 
    if (count%(interval)==0 && count >1) { 
        end=$1;  
        system("qsub -cwd -q 64bit.q -b y -l ram=8000M ./impute2 -m 
/homes/hcolhoun/Eurodiab/shapeit/genetic_map_chr11_combined_b37.txt  -known_haps_g 
/homes/hcolhoun/Eurodiab/shapeit/chr11.haps   -h 
/homes/hcolhoun/Eurodiab/shapeit/ALL_1000G_phase1integrated_v3_chr11_impute.hap.gz   -l 
/homes/hcolhoun/Eurodiab/shapeit/ALL_1000G_phase1integrated_v3_chr11_impute.legend.gz  -Ne 
20000 -int " start "  " end " -o /homes/hcolhoun/Eurodiab/shapeit/chr11/OUTPUT_FILE_chunk_" 
start "  -allow_large_regions  -seed 367946"); 
        print $cmdline; 
    } 
    if ((count-1)%(interval)==0) { 
        start=$1; 
    } 
}' $1` 
 
echo $lineval; 
Script for running QC on SNPTEST results in R 
data<-
read.table('hld.adjustedbaseline_test',header=T,stringsAsFactors=FALSE,sep=
" ") 
data1<-
subset(data,select=c("X10","rsid","pos","allele_A","allele_B","average_maxi
mum_posterior_call","all_AA","all_AB","all_BB","all_maf","cohort_1_hwe","De
ltaLn_frequentist_add_xage_xsex_LogB_score_pvalue","DeltaLn_frequentist_add
_xage_xsex_LogB_score_info","DeltaLn_frequentist_add_xage_xsex_LogB_score_b
eta_1","DeltaLn_frequentist_add_xage_xsex_LogB_score_se_1")) 
data2<-
data1[data1$all_maf>0.01&data1$DeltaLn_frequentist_add_xage_xsex_LogB_score
_info>0.60,] 
data2$cohort_1_hwe<-as.numeric(as.character(data2$cohort_1_hwe)) 
data3<-
data2[!(data2$all_maf<0.05&data2$cohort_1_hwe<0.0001)&!(data2$all_maf>0.05&
data2$cohort_1_hwe<0.00000057),] 
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names(data3)<-
c("CHR","MARKER","POS","NEA","EA","CALL_RATE","N0","N1","N2","MAF","HWE_P",
"PVAL","INFO","BETA","SE") 
data3$BETA<-as.numeric(data3$BETA) 
data3$SE<-as.numeric(data3$SE) 
data3$INFO<-as.numeric(data3$INFO) 
data3$N0<-as.numeric(data3$N0) 
data3$N1<-as.numeric(data3$N1) 
data3$N2<-as.numeric(data3$N2) 
EAF=(2*data3$N2+data3$N1)/(2*data3$N0+2*data3$N1+2*data3$N2) 
N=data3$N0+data3$N1+data3$N2 
data4<-
subset(data3,select=c("id","MARKER","POS","NEA","EA","HWE_P","PVAL","INFO",
"BETA","SE","CALL_RATE")) 
data5<-cbind(data4,EAF,N) 
data8<-data5[!(data5$PVAL<0) & !(data5$INFO<0),] 
data9<-
subset(data8,select=c("id","MARKER","POS","NEA","EA","EAF","N","HWE_P","PVA
L","INFO","BETA","SE","CALL_RATE")) 
write.table(data9,file='hld.adjustedbaseline_out_qc',sep=" 
",row.names=FALSE,quote=FALSE) 
data8$PVAL<-as.numeric(data8$PVAL) 
Nsummary<-summary(data8$N) 
Psummary<-summary(data8$PVAL) 
infosummary<-summary(data8$INFO) 
BETAsummary<-summary(data8$BETA) 
totalsummary<-rbind(Nsummary,Psummary,infosummary,BETAsummary) 
write.table(totalsummary,file="hld.adjustedbaseline.summary",sep=" 
",row.names=FALSE,quote=FALSE) 
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Abstract
Aims To replicate the association of genetic variants with estimated glomerular filtration rate (GFR) and albuminuria,
which has been found in recent genome-wide studies in patients with Type 2 diabetes.
Methods We evaluated 16 candidate single nucleotide polymorphisms for estimated GFR in 3028 patients with Type 2
diabetes sampled from clinics across Tayside, Scotland, UK, who were included in the Genetics of Diabetes Audit and
Research Tayside (GoDARTs) study. These single nucleotide polymorphisms were tested for their association with
estimated GFR at entry to the study, with albuminuria, and with time to stage 3B chronic kidney disease (estimated
GFR<45 ml/min/1.73 m2). We also stratified the effects on estimated GFR in patients with (n = 2096) and without
albuminuria (n = 613).
Results rs1260326 in GCKR (b=1.30, P = 3.23E-03), rs17319721 in SHROOM3 (b = 1.28, P-value = 3.18E-03)
and rs12917707 in UMOD (b = 2.0, P-value = 8.84E-04) were significantly associated with baseline estimated GFR.
Analysis of effects on estimated GFR, stratified by albuminuria status, showed that in those without albuminuria
(normoalbuminura; n = 613), UMOD had a significantly stronger effect on estimated GFR (bnormo = 4.03  1.23 vs
balbuminuria = 1.72  0.76, P = 0.002) compared with those with albuminuria, while GCKR (bnormo = 0.45  0.89 vs
balbuminuria = 1.12  0.55, P = 0.08) and SHROOM3 (bnormo = 0.07  0.89 vs balbuminuria = 1.43  0.53,
P = 0.003) had a stronger effect on estimated GFR in those with albuminuria. UMOD was also associated with a
lower rate of transition to stage 3B chronic kidney disease (hazard ratio = 0.83[0.70, 0.99], P = 0.03).
Conclusion The genetic variants that regulate estimated GFR in the general population tend to have similar effects in
patients with Type 2 diabetes and in this latter population, it is important to adjust for albuminuria status while
investigating the genetic determinants of renal function.
Diabet. Med. 30, 1230–1235 (2013)
Introduction
Recent genome-wide association studies have identified
several genetic variants associated with estimated (e)GFR
and chronic kidney disease (CKD). Previous investigations of
these eGFR polymorphisms were typically carried out in
populations where < 10% of patients were diagnosed with
Type 2 diabetes [1]. It remains to be established if these
variants are associated with eGFR in patients with Type 2
diabetes for whom there are different reasons for loss of renal
function, in particular diabetic nephropathy, when compared
with patients without diabetes. Most of these studies are cross-
sectional [2–5], and so clinically relevant dynamic phenotypes
cannot be studied. Longitudinal datasets capturing renal
function can be used to investigate if the genetic variants
identified are associated with a rapid decline in renal function
(end-stage renal disease or stage 3 CKD) in patients with Type
2 diabetes. About 20% of patients with Type 2 diabetes with
CKD defined according to the ADA guidelines may have
normoalbuminuria (albumin/creatinine ratio [ACR] <2.5 mg/
mmol in males and ACR<3.5 mg/mmol in females) [6]. The
genetic and pathological mechanisms that determine the
relationship between reduced eGFR and albuminuria status
in patients with Type 2 diabetes remain unknown [7].
Although the genetic variants associated with eGFR do not
seem to be associated with albuminuria [8], it remains to be
seen if these genetic variants have the same effect on eGFR in
Correspondence to:HarshalA.Deshmukh. E-mail: h.deshmukh@dundee.ac.uk
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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those with and without albuminuria. In the present study,
using a longitudinal cohort of patients with Type 2 diabetes,
we investigated the association of 16 recently identified eGFR-
associated loci (LASS2, GCKR, NAT8, TFDP2, SHROOM3,
DAB2, SLC34A1, VEGFA, PRKAG2, ADAM28, PIP5K1B,
ATXN2, DACH1, UBE2Q2, UMOD, SLC7A9) with base-
line eGFR albuminuria, and time to stage 3B CKD
(eGFR<45 ml/min/1.73 m2), in patients with Type 2 diabetes.
Methods
The study population comprised 3028 patients with Type 2
diabetes identified from an on-going study, the Genetics of
Diabetes Audit and Research Tayside (GoDARTs) study, and
recruited in Tayside, Scotland, UK, between 1 October 1997
and 1 March 2010. The baseline clinical characteristics of the
GoDARTs subset included in the present analyses were very
similar to the baseline clinical characteristics of the remain-
ing GoDARTS cohort, except that those not included were
slightly older and had a lower eGFR (Table 1); therefore, the
subset of patients used for the present analysis was very
representative of the entire GoDARTs cohort. Calculations
for eGFR were made using the Modification of Diet in Renal
Disease formula [9] which requires age, sex, race and
creatinine data. We assessed the association of the 16 single
nucleotide polymorphisms (SNPs) with eGFR at baseline by
linear regression analysis using the gPLINK program [10],
adjusting for age, sex, BMI, population structure, HbA1c,
duration of diabetes and systolic blood pressure. To inves-
tigate whether the association of these loci with eGFR
differed according to albuminuria status, we carried out a
stratified analysis in patients with sustained normoalbumin-
uria (ACR <2.5 mg/mmol in males and <3.5 mg/mmol in
females and with a duration of diabetes >15 years at end of
follow-up) and in those with any albuminuria (ACR
 2.5 mg/mmol in males and  3.5 mg/mmol in females,
either at baseline or at the end of follow-up).
To investigate if any of these SNPs were associated with a
rapid decline in renal function over the follow-up period, we
performed an analysis of time to stage 3B CKD
(eGFR<45 ml/min/1.73 m2). Individuals with stage 3B
CKD at baseline were excluded. By using this threshold,
4% of our patients were excluded from the analysis. If we
had chosen to study progression to stage 3A CKD
(eGFR<60 ml/min/1.73 m2), 20% of patients would have
been excluded from the analysis. Stage 3B CKD was defined
as three consecutive eGFR measurements of eGFR <45 ml/
min/1.73 m2 at least 1 month apart. Those who did not
progress to stage 3B CKD were censored at the end of the
follow-up period or at date of death. We used a Cox
proportional hazards model (the Proc PHREG tool in the SAS
statistical package), with date of birth as ‘time in’ and ‘last
date’ as the first date of eGFR <45 ml/min/1.73 m2 or the
end of follow-up period/date of death, and with genotype,
age, sex, BMI and baseline eGFR as covariates. The
interaction of individual SNPs with albuminuria was tested
using PLINK option ‘interaction’ with age, sex, BMI,
albuminuria and genotypes as covariates in the linear
regression model. We adopted a conservative threshold for
significance (0.05/number of loci tested) and a P value <
0.003 was considered to indicate statistical significance. A
weighted genetic risk score analysis was performed to test the
joint effect of the 16 loci on baseline eGFR and time to stage
3B CKD. We calculated weighted genetic risk score (number
of risk alleles*b) for each individual using all 16 SNPs, and
tested the association of this genetic risk score with baseline
eGFR and time to stage 3B CKD, adjusting for age, sex, BMI,
HbA1c, duration of diabetes, and systolic blood pressure. All
analyses were performed in PLINK version 1.07 [10] and SAS
What’s new?
• This is the first study comparing common genetic
variants associated with estimated GFR between the
general population and patients with Type 2 diabetes.
• This is the first report of the interaction of genetic
effects of estimated GFR-associated loci (UMOD
GCKR and SHROOM3) with albuminuria in patients
with Type 2 diabetes.
• The study stresses the need to adjust for albuminuria
while investigating the genetic determinants of renal
function.
Table 1 Demographic characteristics of the GoDARTs cohort
Characteristic, mean (SD) GoDARTs cohort in the present study GoDARTs cohort not included in the present study
Age at baseline, years 59.1 (11.0) 66.2 (11.6)
Sex,% female 46.4 42.3
Baseline BMI 30.6 (5.3) 31.5 (6.1)
Baseline eGFR, ml/min/1.73m2 73.9 (18.7) 70.9 (15.8)
Baseline systolic blood pressure, mmHg 142.8 (18.4) 141.7 (18.8)
Baseline HbA1C, mmol/mol 7.54 (1.3) (58 mmol/mol)* 7.3 (1.4) (56 mmol/mol)*
Baseline cholesterol, mmol/L 4.40 (0.97) 4.34 (0.91)
Duration of diabetes at baseline, years 8.71 (7.44) 7.75 (6.61)
*These are HbA1c values in IFCC units.
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9.2. Power calculations for quantitative traits were per-
formed using R 2.15.
Samples were genotyped at Affymetrix’s service laboratory
on the Genome-Wide Human SNP Array 6.0. Complete
genotype data have been described previously [11]. The study
complied with the Declaration of Helsinki guidelines. Since
October 1997, all individuals with diabetes in the GoDARTs
database have been invited to give consent for DNA
collection as part of the Wellcome Trust United Kingdom
Type 2 Diabetes case–control collection. As of June 2009,
8000 cases and 7000 control subjects of European ancestry
have participated in this GoDARTS study. Informed consent
was obtained from all the study participants.
Results
Table 1 shows the baseline characteristics of the GoDARTs
cohort included in the present study as well as the
GoDARTs cohort not genotyped at the conception of this
study. Genotype data were available for 3028 patients
(46.4% females) with Type 2 diabetes. Their mean (SD)
baseline BMI was 30.6 (5.3) kg/m2, mean (SD) age was 59.1
(11) years, mean (SD) HbA1c was 58 mmol/mol (7.54 (1.3).
The mean (SD) follow-up period for the entire study was
10.6 (9.1) years with a median of three eGFR readings/year/
person (interquartile range 2–4) and a mean (SD) baseline
eGFR of 73.9 (18.7) ml/min/1.73 m2.
Table 2 shows the association found for the 16 eGFR-
associated loci with baseline eGFR and albuminuria; the
study population was stratified by albuminuria status and the
association of these SNPs with time to stage 3B CKD. The
minor alleles ‘T’ of GCKR (b = 1.30, P-value = 3.23E-03),
and ‘T’ of UMOD (b = 2.0 P-value = 8.84E-04) were
associated with a higher eGFR at baseline and the minor
‘A’ of SHROOM3 (b = 1.28, P-value = 3.18E-03) was
associated with a lower eGFR at the predefined threshold
(P  0.003). None of the other SNPs was associated with
baseline eGFR. None of the 16 SNPs included in the study
were associated with albuminuria after correction for multi-
ple testing (data not shown). In patients with sustained
normoalbuminuria (n = 613), minor allele ‘T’ of UMOD
was associated with eGFR (b = 4.03, P-value = 1.10E-03),
while in patients with albuminuria (n = 2096) minor allele
‘T’ of GCKR (b = 1.12, P-value = 4.27E-02) and ‘A’ of
SHROOM3 (b = 1.43, P-value = 7.28E-03) were associ-
ated with eGFR. Of the 16 SNPs, UMOD (hazard
ratio = 0.83(0.70, 0.99), P-value = 0.03), PIP5K1B (hazard
ratio = 0.85(0.75, 0.96), P-value = 0.01) and SLC7A9 (haz-
ard ratio = 0.86(0.76, 0.98) P-value = 0.02) was associated
with time to stage 3B CKD (eGFR<45 mls/min/1.73 m2) at
the 0.05 threshold for significance. Although the PIP5K1B
locus was significant at P < 0.05, the direction of effect was
not consistent with a previous report by K€ottgen et al. [4]
and hence this cannot be regarded as a positive replication of
this SNP for its association with eGFR and time to CKD
stage 3B.
Since the variants tested in this study are associated with
age-related decline in eGFR in general population (and not
with any disease-specific decline) we used time-to-event
analysis with date of birth as the starting point; however, we
performed a sensitivity analysis in which we used the baseline
of GoDARTs study as the starting point. Although this
analysis decreases power because of a reduction in the
person-years follow-up, we see a similar effect size of
association with progression to stage 3B CKD. For example,
the hazard ratio of UMOD with time to stage 3B CKD with
the starting point as the GoDARTs study baseline (hazard
ratio = 0.87(0.74, 1.03) P-value = 0.1) is very similar to the
hazard ratio with date of birth as a starting point. The
weighted genetic risk score for the 16 SNPS explained the
1% variation in baseline eGFR and was significantly asso-
ciated with baseline eGFR after adjustments for age, sex,
BMI, HbA1c, duration of diabetes and systolic blood pressure
(P = 0.0026, b = 0.84(0.28). The weighted genetic risk
score was not associated with time to stage 3B CKD
(P = 0.52).
Discussion
In the present study, we replicated the association of
UMOD, GCKR and SHROOM3 with eGFR in patients
with Type 2 diabetes. The study confirms the findings of
previous studies showing the association of UMOD with
eGFR and diabetic nephropathy [12–15] and the association
of GCKR and SHROOM3 with eGFR [1,16,17]. A study
by Gudbjartsson et al. [12] demonstrated the interaction of
UMOD with age [15]; while another study could not
replicate this interaction. In the present study, we did not
observe an interaction of UMOD with age in patients with
Type 2 diabetes (P-value = 0.84).
None of the other variants were associated with eGFR
after correction for multiple testing; however, the direction
of effect was consistent with the previous studies for all the
statistically significant loci (GCKR, SHROOM3, UMOD)
and for the loci that did not pass the threshold of significance
(except TFDP2 and PIP5K1B). Our study had limited power
to estimate the effect of these variants on eGFR. Taken
together, all these variants explain the 1.4–14% heritability
of eGFR [5] (with each SNP contributing typically < 0.5%
heritability of eGFR). Our study had 97% power to detect an
association with a SNP explaining 0.5% variability in eGFR
and anything below 0.5% can remain undetected. It is also
possible that some of these SNPs are not the causal SNPs and
because of varying linkage disequilibrium, structure in our
population could not be detected. It is also possible that the
effects of some of these SNPs were attenuated by diabetes or
diabetic kidney disease and therefore were not associated
with eGFR in this study.
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We examined the association of the 16 loci with a decline
in renal function using a Cox proportional hazard model and
estimated the effect of these loci on time to stage 3B CKD
(eGFR<45ml/min/1.73 m2). Given the high mortality asso-
ciated with diabetic nephropathy, cross-sectional studies are
prone to survival bias, as patients with severe forms of
nephropathy are less likely to be included. Hence, it is
important to investigate the eGFR loci in a time-dependent
manner. Of the 16 SNPs, none were associated with time to
stage 3B CKD at the predefined threshold of 0.003, however,
UMOD and SLC7A9 were associated with time to stage 3B
CKD at the threshold of 0.05 (with the direction of effects
consistent with that reported previously). UMOD and
SLC7A9 have a stronger effect on baseline eGFR as
compared with other markers suggesting that SNPs with a
strong effect on baseline eGFR influence the decline in renal
function over time.
We performed a stratified analysis to examine the effect of
albuminuria on the known genetic associations with eGFR.
In Type 2 diabetic, nephropathy, albuminuria may be more
closely associated with decline in renal function and the
impact of genetic determinants of eGFR may differ depend-
ing on the presence or absence of nephropathy; therefore, we
examined the effects on eGFR stratified by albuminuria.
There is a clear difference in the effect sizes in those with
sustained normalbuminuria and those with albuminuria. For
example, the UMOD has twice the effect in patients with
sustained normalbuminuria as compared with those with
albuminuria (P-interaction = 0.002) while SHROOM3 (P-
interaction = 0.003) and GCKR (P-interaction = 0.08) had
larger effect sizes in those with albuminuria. It is known that
kidney diseases characterized by albuminuria, such as
diabetic nephropathy can have ultrafiltration and high eGFR
in the early stage of disease, while those characterized by
reduced renal function such as hypertensive kidney disease,
may be manifested with normoalbumiuria because of the
reduced renal efficiency [18,19]. Hence, studying the genetic
determinants of eGFR without adjusting for albuminuria
status or studying genetic determinants of albuminuria
without accounting for eGFR can reduce the power of these
studies to identify the true genetic effects. Cumulatively,
eGFR-associated loci explain only a small fraction of the
total heritable contribution eGFR and stratifying by albu-
minuria status in our existing genome-wide association study
datasets [3–5] can help us to uncover the missing heritability.
It is important to point out, however, that the interaction of
albuminuria with the genetic variants associated with eGFR
in patients with Type 2 diabetes seen in the present study is
the first report of this interaction in patients with Type 2
diabetes and needs to be confirmed in an independent
sample.
In summary, our results show that some of the genetic
determinants of eGFR in the general population are common
to patients with Type 2 diabetes; however, in patients with
Type 2 diabetes it is essential to adjust for albuminuria status
while investigating the genetic determinants of renal
function.
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association with the  LPA SNP was replicated in the PRO-
spective Study of Pravastatin in the Elderly at Risk (PROS-
PER) trial ( P = 0.009). Using CARDS data, we further 
showed that atorvastatin therapy did not alter lipoprotein(a) 
[Lp(a)] and that Lp(a) levels accounted for all of the asso-
ciations of SNPs in the LPA gene and the apparent LDL-c 
response levels. However, statin therapy had a similar effect 
in reducing cardiovascular disease (CVD) in patients in the 
top quartile for serum Lp(a) levels (HR = 0.60) compared 
with those in the lower three quartiles (HR = 0.66;  P = 0.8 
for interaction). The data emphasize that high Lp(a) levels 
affect the measurement of LDL-c and the clinical estimation 
of LDL-c response.  Therefore, an apparently lower LDL-c 
response to statin therapy may indicate a need for measure-
ment of Lp(a). However, statin therapy seems benefi cial 
even in those with high Lp(a). —Deshmukh, H. A., H. M. 
Colhoun, T. Johnson, P. M. McKeigue, D. J. Betteridge, P. N. 
 Abstract  We carried out a genome -wide association study 
(GWAS) of LDL-c response to statin using data from partici-
pants in the Collaborative Atorvastatin Diabetes Study 
(CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Out-
comes Trial (ASCOT; n = 895), and the observational phase 
of ASCOT (n = 651), all of whom were prescribed atorvasta-
tin 10 mg. Following genome-wide imputation, we combined 
data from the three studies in a meta-analysis. We found as-
sociations of LDL-c response to atorvastatin that reached 
genome-wide signifi cance at rs10455872 ( P = 6.13 × 10   9 ) 
within the  LPA gene and at two single nucleotide polymor-
phisms (SNP) within the  APOE region (rs445925;  P = 2.22 × 
10   16 and rs4420638;  P = 1.01 × 10   11 ) that are proxies for 
the   2 and   4 variants, respectively, in APOE. The novel 
 The CARDS trial was cofunded by Pfi zer Ltd., Diabetes UK, and National Health 
Service R&D. Genotyping was funded by Pfi zer Ltd. The Anglo-Scandinavian 
Cardiac Outcomes Trial and establishment of the associated genetic repository 
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pean Commission’s Seventh Framework Program (FP7/2007–2013) under 
Grant HEALTH-F2-2009-223004 PHASE. CARDS registration number: 
NCT00327418. ASCOT registration number: EUDRACT2008-007494-20. 
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daily and followed for a median of 3.7 years. Allocation was dou-
ble blinded. Mean serum LDL-c concentration during baseline 
visits prior to randomization had to be   4.14 mmol/l (160 mg/
dl) and serum triglycerides   6.78 mmol/l (600 mg/dl). After 
randomization, total cholesterol (TC), HDL-C, and triglycerides 
were measured at one, two, and three months, and then every six 
months. Patients attended after an overnight fast. LDL-c was cal-
culated with the Friedewald formula ( 7 ), or if serum triglycerides 
exceeded 4.0 mmol/l, by removing VLDL by ultracentrifugation 
and then measuring the change in infranatant cholesterol con-
tent when LDL was removed by precipitation of apolipoprotein 
B-containing lipoproteins. For this genome-wide study, the analy-
ses were restricted to those randomized to atorvastatin, and the 
mean of two pretreatment LDL-c measurements was used as the 
baseline LDL-c and a weighted average of fi ve post-randomiza-
tion values within the fi rst year post-randomization was the out-
come measure or “on treatment LDL-c,” with weights (0.6 for 
month 1 and then 0.1 for measurements at 2, 3, 6, and 12 
months). Lipoprotein(a) concentrations were determined by an 
immunoturbidimetric assay with Immuno LEIA® reagents from 
Technoclone Ltd., Dorking, UK (now www.PathwayDiagnostics.
com), which is calibrated against the IFCC standard preparation 
PRM02. 
 ASCOT 
 Of 19,342 hypertensive patients (40–79 years of age with at 
least three other cardiovascular risk factors) who were random-
ized to one of two antihypertensive regimens in ASCOT, 10,305 
with nonfasting TC concentrations of 6.5 mmol/l or less (mea-
sured at the nonfasting screening visit) had been randomly as-
signed additional atorvastatin 10 mg or placebo. These patients 
formed the lipid-lowering arm of the study. For this genome-wide 
study, two subpopulations from ASCOT were included. The fi rst 
subpopulation included individuals randomized to 10 mg ator-
vastatin in whom pretreatment LDL-c was measured at the (fast-
ing) randomization visit and on-treatment LDL-c was calculated 
as the simple average of measures at the (fasting) visits 6 months 
and 12 months post-randomization. LDL-c was estimated using 
the Friedewald equation as in CARDS. Following the end of the 
randomization phase, there was an observational period. The 
second subpopulation included all individuals not originally ran-
domized to 10 mg atorvastatin (i.e., those randomized to placebo 
and those not eligible for the LLA) who were subsequently pre-
scribed atorvastatin 10 mg. For these individuals, pretreatment 
LDL-c was defi ned as the measurement on the last visit before or 
equal to date of starting atorvastatin, and on-treatment LDL-c was 
defi ned as the measurement taken from the fi rst visit after date of 
starting atorvastatin. 
 PROSPER (replication cohort) 
 All data were from the PROspective Study of Pravastatin in the 
Elderly at Risk (PROSPER) ( 8 ). PROSPER was a prospective mul-
ticenter randomized placebo-controlled trial to assess whether 
treatment with pravastatin diminishes the risk of major vascular 
events in elderly. Between December 1997 and May 1999, we 
screened and enrolled subjects in Scotland (Glasgow), Ireland 
(Cork), and the Netherlands (Leiden). Men and women 70–82 
years of age were recruited if they had preexisting vascular dis-
ease or increased risk of such disease because of smoking, hyper-
tension, or diabetes. A total number of 5,804 subjects were 
randomly assigned to pravastatin or placebo, of which 2,550 sub-
jects assigned to the Pravastatin arm of the trial were included in 
the present study. TC, HDL-C, and triglycerides were assessed af-
ter an overnight fast, at baseline, and at 3, 6, 12, 24, and 36 months 
post-randomization. LDL-C was calculated by the Friedewald 
formula. The pretreatment measurement was at baseline before 
Durrington, J. H. Fuller, S. Livingstone, V. Charlton-Menys, 
A. Neil, N. Poulter, P. Sever, D. C. Shields, A. V. Stanton, A. 
Chatterjee, C. Hyde, R. A. Calle, D. A. DeMicco, S. Trompet, 
I. Postmus, I. Ford, J. W. Jukema, M. Caulfi eld, and G. A. 
Hitman on behalf of the CARDS, ASCOT, and PROSPER 
investigators.  Genome-wide association study of genetic de-
terminants of LDL-c response to atorvastatin therapy: im-
portance of Lp(a).  J. Lipid Res. 2012.  53: 1000–1011. 
 Supplementary key words genetics • low density lipoprotein • LDL/
metabolism • lipoprotein(a)• statins 
 Statin therapy is now widely accepted for the primary 
and secondary prevention of cardiovascular disease (CVD) 
in certain patient groups. However, there is considerable 
variation in response to statin therapy that remains poorly 
understood. For example, in the Collaborative Atorvastatin 
Diabetes Study (CARDS) trial ( 1 ), among self-reported 
and pill count-validated compliant recipients of atorvasta-
tin 10 mg daily, the absolute change in LDL-c at one month 
post-randomization varied from   2 to   0.6 mmol/l, (5 th 
and 95 th centiles of the range), and the percentage lower-
ing from baseline varied from 67% to 22%. Understanding 
the pathways and determinants involved in this variation in 
response to therapy could lead to improved treatments. 
Even without understanding the pathways, identifying pre-
dictors of poorer response could identify those most in 
need of additional or alternative therapeutic strategies. 
 Two genome-wide association studies (GWAS) of statin 
response and several candidate gene association studies 
have been reported ( 2–5 ). From these, the only consistent 
fi nding is that variants in the  APOE gene region are associ-
ated with variation in LDL response. Here, we report a 
genome-wide analysis of LDL-c response from two ran-
domized clinical trials of atorvastatin, CARDS and the 
Anglo-Scandinavian Outcomes Trial (ASCOT) ( 6 ), to in-
vestigate genetic effects on LDL-c response to atorvastatin. 
We chose to model genetic determinants of LDL-c re-
sponse to atorvastatin among those assigned to atorvastatin 
in these trials. An alternative approach would be to model 
the interaction of genotype on the effect of atorvastatin on 
LDL-c using data from both placebo and active treatment 
groups. However, we did not consider this latter approach 
as optimal as testing for interactions is much less powerful 
than direct tests of association and as, in any case, we did 
not consider genetic effects on change LDL-c in the pla-
cebo groups to be plausible. 
 MATERIALS AND METHODS 
 Study populations and phenotype defi nition 
 Both trials were conducted with Ethics Committee/IRB ap-
proval, under good clinical practice guidelines and in accordance 
with the Declaration of Helsinki principles. Patients gave consent 
for genetic studies. 
 CARDS 
 Methods in CARDS have been described previously. In brief, 
2,838 patients with type 2 diabetes and no previous CVD were 
randomized to receive either placebo or atorvastatin 10 mg once 
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mated relatedness with PLINK, and those individuals with Pi_
HAT > 0.25(excluding fi rst- and second-degree relatives) were 
removed (n = 0). Only LDL-c values from time points at which 
the person was compliant with atorvastatin (based on pill count > 
80% ) were used. 
 ASCOT genotyping.  Genotyping was carried out on Hu-
manCNV370 (Illumina) array on 3,868 individuals at Centre 
National de Génotypage (CNG) in two batches. Samples were 
excluded if they had   5% missing data (two samples). SNPs 
were excluded based on the following criteria:  i ) they had been 
mapped to different chromosomes or positions in the different 
releases (two SNPs), or  ii ) they were polymorphic A/T or C/G in 
either release or in the combined dataset, or  iii ) they had call 
rate   97% in either release or in the combined dataset (47,744 
SNPs), or  iv )  they had HWE  P -value   10   7 in either release or in 
the combined dataset (8,502 SNPs). After applying the above ex-
clusions, samples were excluded if they had estimated related-
ness > 0.1875 (halfway cut point between second- and third-degree 
relatives), estimated using a using a subset of 101,954 SNPs ob-
tained by linkage disequalibrium (LD) -based pruning (87 dupli-
cates, 15 fi rst-degree relatives and 4 presumed second-degree 
relatives removed. Then SNPs were excluded if they showed sig-
nifi cant differences in allele frequency between the different 
batches at  P < 10   7 (20 SNPs), if they were monomorphic in the 
combined dataset (3,838 SNPs), if they were not in HapMap r22 
(12,817 SNPs) or had different alleles to HapMap r22 (6 SNPs), 
or if they showed signifi cant differences ( P < 10   7 using Fisher’s 
exact test) in allele frequency between the combined dataset and 
HapMap r22 (308 SNPs). After applying all the above exclusions, 
ancestry outliers were excluded (n = 143) by using ancestry prin-
cipal component analysis ( 11 ) on a subset of 100,905 SNPs se-
lected by LD-based pruning, and ancestry principal components 
(PCs) were calculated for the remaining 3,804 individuals. 
 PROSPER genotyping.  A whole genome-wide screening was 
performed in the sequential PHASE project. DNA was available 
for genotyping 5,763 subjects. Genotyping was performed with 
the Illumina 660K beadchip. After QC (call rate < 95%), 5,244 
subjects and 557,192 SNPs were left for analysis ( 12 ). 
 Statistical analysis 
 Imputation of genotypes.  The CARDS genotype data were 
combined with phased haplotypes from HapMap phase II CEU 
r22 to compute posterior probability distribution of genotype at 
all HapMap loci using the IMPUTE program ( 13 ). For ASCOT 
and PROSPER, genotypes at unmeasured SNPs were imputed us-
ing MACH ( 14 ) and phased haplotypes from HapMap CEU r22. 
For ASCOT, a randomly chosen subset of 400 individuals was 
used to estimate transition and emission probabilities (i.e., to es-
timate recombination rates between SNPs and per-SNP genotyp-
ing error rates) using MACH options “-greedy -r 100” for each 
(entire) chromosome in turn. Using these estimated rates (the .
rec and .erate fi les), genotypes were imputed for the whole sam-
ple of 3,804 individuals using MACH options “-greedy-mle-mlde-
tails” for each (entire) chromosome in turn. 
 CARDS data analysis.  The EIGENSTRAT program ( 15 ) was 
used to adjust for population structure. Using PLINK ( 16 ), we 
generated a pruned subset of 152,587 SNPs that are in approxi-
mate linkage equilibrium with each other in the CARDS dataset. 
Principal components analysis was undertaken using this subset 
of SNPs. Thirty-seven individuals identifi ed as outliers in the initial 
principal components analysis were excluded from the subse-
quent computation of principal components, leaving 1174 per-
sons evaluable for statin response. The fi rst three principal 
randomization, and the posttreatment was the mean of the lipid 
measurements after randomization. 
 Phenotype transformation 
 To maximize power to detect associations and to improve test 
statistic behavior under the null for low minor allele frequency 
(MAF ) single nucleotide polymorphisms (SNP), we transformed 
measured LDL-c levels to conform to the distributional assump-
tions made by our association analysis model using the same 
transformation for off- and on-treatment measures to preserve 
the relationship between the two. We maximized the fi t of the 
residuals in a regression of on-treatment on the pretreatment 
value to a Gaussian distribution. We used a 2-parameter Box-Cox 
transform of the form   αβ α/x  applied to baseline and on-
treatment LDL-c values. The parameter values   and   were 
chosen by maximizing the likelihood of a model with linear re-
gressions of the transformed pretreatment and response (trans-
formed pretreatment minus transformed pretreatment) values 
on the covariates (age and sex), with the joint distribution of 
the residuals from the two regression models being bivariate 
Gaussian. 
 The parameter values obtained were   = 0.156,   =   0.505 
mmol/l in CARDS. In ASCOT, the parameters were   = 0.6807, 
  = 0.8850 mmol/l in the randomized dataset, and   = 0.4805, 
  = 0.5813 mmol/l in the observational dataset. This transforma-
tion has the same motivation as the inverse normal transform 
used in some GWAS applications ( 9, 10 ), but the use of a para-
metric transform preserves the relationship between pre and on-
treatment measures, thereby allowing the difference between the 
two, adjusted for pretreatment value, to be used as a response 
variable as was done in ASCOT or as simply the on-treatment 
adjusted for pretreatment value as in CARDS (these are equiva-
lent). The effect sizes in discovery cohorts (CARDS and ASCOT) 
and the replication cohort (PROSPER) were scaled so that the 
residuals had unit variance, thereby allowing studies using differ-
ent transforms to be combined. 
 DNA extraction and genotyping 
 CARDS.  DNA was extracted from whole-blood EDTA sam-
ples. DNA was isolated from 10 ml of frozen blood using the Gen-
tra Puregene DNA Isolation Kit from Qiagen (Cat. no. 158389). 
Briefl y, RBC was lysed with an anionic detergent in the presence 
of a DNA stabilizer that limits the activity of intracellular DNases. 
White blood cells were collected by centrifugation at 2,000  g for 
2 min. RNA was removed by treatment with RNase A. Protein was 
removed by salt precipitation (centrifugation at 2000  g for 5 
min). Genomic DNA was recovered by precipitation with isopro-
panol and centrifugation at 2,000  g for 5 min, the DNA pellet was 
washed in 70% ethanol, air dried, and dissolved in hydration so-
lution (1 mM EDTA, 10 mM Tris·CI , pH 7.5). Purifi ed DNA was 
stored at   20°C. DNA aliquots were genotyped at Perlegen Sci-
ences using a proprietary SNP set comprising 599,164 SNPs. Of 
these, 243 SNPs that had discrepant map positions between Hap-
Map and Perlegen were dropped. We set a minimum SNP call 
rate threshold of 80% for including SNPs in the analysis, and we 
required that the  P -value for a test of deviation from Hardy-Wein-
berg equilibrium (HWE) was not < 10   5 . This gave 517,746 SNPs 
for analysis. The average call rate was 98%, with 86.25% SNPs 
with a call rate of greater than 90%. SNP annotation was based on 
build 36 of the Human Genome Sequence. All SNPs were used in 
the analysis regardless of allele frequency, but the allele fre-
quency was considered when evaluating putative associations. Al-
lele frequency was below 1% at 6% of SNPs. We selected samples 
from those people who had been allocated atorvastatin 10 mg 
daily, had given consent for genotyping, and had a sample SNP 
call rate > 80%. After applying the exclusions of HWE, we esti-
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studies) is obtained as a summary measure of the effi ciency of 
genotype imputation. For concise presentation, we focus here on 
showing the results of the meta-analysis rather than each study 
separately and provide study-specifi c estimates of effect only at 
the most extreme signifi cance levels. In the data presentation, 
those loci at which the overall proportion of information ex-
tracted was less than 30% across the studies have been excluded. 
We have used the  P -value threshold of <5 × 10   8 as the threshold 
for declaring a genome-wide signifi cant association. 
 Distinguishing indirect and direct effects of genotype on on-
treatment LDL.  Effects of genetic variation on treatment re-
sponse as measured by on-treatment LDL-c could be mediated 
through effects on the pretreatment LDL-c. To evaluate whether 
genetic on-treatment LDL-c likely refl ects residual effect on pre-
treatment LDL-c, it is necessary to adjust for the pretreatment 
LDL-c levels and to correct the maximum likelihood estimate of 
the adjusted effect of genotype on on-treatment value for the 
noise in pretreatment values (the noise is both random measure-
ment error and intra-individual variation in usual LDL-c). From 
the rules of path analysis, we calculated the direct effect   of geno-
type on an on-treatment trait value as        (1    	 ) /  	 , where   is 
the coeffi cient of regression for on-treatment trait value on geno-
type adjusted for measured pretreatment value,  	 is the intraclass 
correlation between replicate measurements of pretreatment val-
ues, and   is the coeffi cient of regression for on-treatment value 
on observed pretreatment value. For these calculations, we used 
 	 = 0.8 as a plausible value for the intraclass correlation based on 
the within-person correlation in LDL-c values taken over two pre-
treatment visits in CARDS. 
 RESULTS 
 Table 1  compares baseline characteristics of participants 
in the three studies.  Fig. 1  shows a quantile-quantile plot 
of the   log 10  P -values for association of each SNP with 
LDL-c response to treatment, obtained by meta-analyzing 
effect size estimates across the CARDS and ASCOT data-
sets. This plot shows that the cumulative distribution of 
test statistics approximates the null distribution over most 
of its range but that there is a tail of extreme results.  Fig. 2 
 shows a Manhattan plot of the   log 10  P -values by map posi-
tion.  Table 2  shows all loci at which the summary test for 
association yielded a nominal  P -value < 10   6 . The estimates 
of effect (  ) are for the transformed response variable 
(see Materials and Methods). In CARDS, the response 
variable was transformed on-treatment LDL-c with trans-
formed pretreatment LDL-c entered as a covariate in the 
model. This is mathematically equivalent to modeling 
change in LDL-c with pretreatment LDL-c as a covariate 
(i.e., the difference in transformed on-treatment and ad-
justment for pretreatment LDL) as was done in ASCOT. A 
negative   for an allele means that the modeled allele is 
associated with a bigger reduction in posttreatment LDL-c 
and a better response to statins. 
 The strongest associations were with rs10455872 in the 
 LPA gene on chromosome 6, and with SNPs in the 
 BCAM / PVRL2 / APOE / APOC1 gene region on chromosome 
19, where genome-wide signifi cant associations were 
found. The SNPs in the  LPA and  APOE region explained 
4% of the variance in LDL-c response in CARDS. The next 
components were retained and included as covariates in all tests 
of association. 
 On-treatment values for LDL-c for each individual at 1, 2, 3, 6, 
and 12 months post-randomization were available. We initially 
used the fi rst available post-randomization LDL-c and established 
that the previously reported APOE genotype at rs445925 was the 
strongest association in a genome-wide analysis of response at  P = 
1.1 × 10   13 . To maximize the power to detect any further new as-
sociations, we trained the weighting of post-randomization LDL-c 
time points to maximize the strength of the association of LDL 
response with  APOE genotype at rs445925. Based on this, the 
nonmissing values for each individual were combined in a 
weighted average, with the one-month value allocated a weight of 
0.6 and the four subsequent values, weights of 0.1 each ( P -value 
for rs445925 with these weights = 2.2 × 10   16 ). SNPTEST ( 13 ) was 
used to test for association of LDL response with genotype in a 
linear regression with the weighted average post-randomization 
LDL value as dependent variable and with covariates, including 
transformed pretreatment LDL-c, age, sex, and scores on the fi rst 
three principal components of population stratifi cation. The 
missing-data likelihood option was used to allow for uncertainty 
of genotypes at each imputed locus. In practice, the use of several 
weighted post-randomization LDL-c values rather than a single 
fi rst value made very little difference to the results (see supple-
mentary table II). 
 We used the conditional analysis test in PLINK ( 16 ) to test for 
independence of SNP associations over short regions within the 
same gene; a null model based on equating the effects of haplo-
types that differed only at the SNP under test was compared with 
a more general model in which the effects of these haplotypes 
were unconstrained. The null hypothesis is that the SNP under 
test accounts for all associations of haplotypes with response. 
Other analyses included those carried out to explore initial asso-
ciations, including a test of whether LPA genotype modifi es the 
effect of atorvastatin on CVD. This was carried out by estimating 
the hazard ratio associated with allocation to atorvastatin in a 
Cox regression model of time to fi rst CVD event and using a like-
lihood ratio test comparing a model with this main treatment ef-
fect and one including a term for interaction of genotype × 
treatment effect. 
 ASCOT data analysis.  We regressed the response variable 
(transformed on-treatment minus transformed pretreatment 
LDL-c) onto imputed expected genotype dosage as implemented 
in ProbABEL ( 14, 17 ). This is asymptotically equivalent to score 
test for taking into account uncertainty in imputed genotypes (as 
in SNPTEST) but with improved fi nite sample size operating 
characteristics ( 18 ). Age, sex, age*sex, and transformed pretreat-
ment LDL were used as covariates, plus 10 ancestry principal 
components. 
 PROSPER data analysis.  The response variable was re-
gressed (natural log of transformed on-treatment minus natural 
log of pretreatment LDL-c) onto imputed expected genotype 
dosage as implemented in SNPTEST. Age, sex, transformed pre-
treatment LDL, and top three principal components were used 
as covariates. 
 Meta-analysis.  The score and observed information for the 
effect parameter were summed over studies to obtain a summary 
score test. This is algebraically equivalent (based on the quadratic 
approximation of the log-likelihood) to obtaining a weighted av-
erage of the maximum likelihood estimates with weights inversely 
proportional to the squared standard errors, with the useful fea-
ture that the ratio of observed to complete information (calcu-
lated by summing numerators and denominators over the three 
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change in LDL-c with statin therapy at one month was ap-
proximately   43% in those with at least one “G” allele at 
rs10455872 (MAF = 8%) compared with   46.5% in ho-
mozygotes for the “A” allele. There was no signifi cant ef-
fect of this SNP on change in LDL-c post-randomization in 
those in the placebo group ( P = 0.28). 
 To investigate the association with  LPA genotype fur-
ther, we fi rst confi rmed that  LPA genotypes predicted 
serum lipoprotein(a) [Lp(a)] levels, which had been mea-
sured in CARDS but not in ASCOT.  Fig. 4  shows the re-
sults of the GWAS for serum Lp(a) levels; all signifi cantly 
associated loci were in the  LPA region, consistent with 
other reports ( 19 ). In a linear regression model that included 
age, sex, and population structure covariates, 12 SNPs in 
the  LPA region had independent effects on serum Lp(a) 
(rs10455872, rs5014650, rs783147, rs6919346, rs3103349, 
most signifi cant  P -value was that for the  ALG10 region on 
chromosome 12, but this did not reach genome-wide sig-
nifi cance. There was no evidence of gene-gender interac-
tion for all the top SNPs reported in the study. The effect 
sizes for all top SNPs were similar in CARDS, where all the 
participants had type 2 diabetes, and in ASCOT, where 
21% of the participants had type 2 diabetes ( Table 2 ), sug-
gesting that diabetes per se was not a strong determinant 
of the genetic effect of the top SNPs. 
 LPA 
 In the  LPA gene SNP, rs10455872 showed a genome-
wide signifi cant association with LDL-c response ( Fig. 3 ). 
 The effect at rs10455872 was modest; the   shown in  Table 
2 is not easily directly interpretable given the transforma-
tion used, but in CARDS, for example, the percentage 
 Fig.  1. Quantile-quantile plot of meta-analysis  P- values for statin response. A plot of the quantiles of ob-
served and expected distribution of  P- values against each other. 
 TABLE 1. Characteristics of patients and studies included in the meta-analysis 
CARDS ASCOT-R ASCOT-Obs
 n = 1194  n = 895  n = 691 
Age (mean years ± SD) 61.6 ± 8.2 64.1 ± 8.0 64.2 ± 8.6
Ethnicity Caucasian 
(UK and Ireland)
Caucasian 
(UK and Ireland)
Caucasian 
 (UK and Ireland)
Women (%) 47 11.0 13.1
Diabetes (%) 100 21 21
Follow-up years 
(median IQR)
3.9 years (3.0–4.7) First year was used First year was used
Hypertension (%) 87 100 100
LDL-c level at baseline 
(mean mmol/l ± SD)
3.04 ± 0.71 3.47 ± 0.70 3.75 ± 0.85 a 
Lipid entry criterion Fasting LDL-c   4.14 
mmol/l
Non-fasting TC   6.5 
mmol/l
None
Fasting status for lipids b Overnight fast Fasting Fasting
Statin dose Atorvastatin 10 mg daily Atorvastatin 10 mg daily Atorvastatin 10 mg daily
Platform Perlegen 6 Illumina HumanCNV370 Illumina HumanCNV370
pHWE c exclusion 10   5 10   7 10   7 
Imputation software IMPUTE 2 MACH MACH
NCBI build for imputation HapMap CEU r22 HapMap CEU r22 HapMap CEU r22
ASCOT-Obs, observational arm of ASCOT; ASCOT-R, randomized arm of ASCOT.
 a In N = 656 with nonmissing LDL-c at baseline; the missingness is nonrandom because these are individuals 
with baseline triglycerides too high for Friedewald formula.
 b Fasting status for LDL-c at baseline (see previous row) and for response to statin measure.
 c P -value threshold for exclusion of SNPs not in HWE.
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(30%) with median levels being 7.6 mg/dl [interquartile 
range (IQR) 4.1–14 mg/dl], 50.5 mg/dl (IQR 37–68 mg/dl) 
and 55.2 mg/dl (IQR 51–113 mg/dl) in those with AA, 
AG, and GG genotype, respectively. We then adjusted the 
rs2063347, rs6415084, rs10455782, rs394487, rs6926458, 
rs316174, rs3127569). Together, these SNPs explained 
40% variation in the serum Lp(a) levels in CARDS; how-
ever, most of this was attributable to the rs10455872 SNP 
 TABLE 2. Combined analysis (CARDS, ASCOT randomized, and ASCOT observational) 
CHR POS (cM) SNP
Modeled 
Allele
Minor Allele 
(Frequency)
CARDS Ascot-R Ascot-Obs Meta-analysis
 P Gene c   SE   SE   SE Rsq a   b SE
6 195.419 rs10455872 A G (0.07)   0.35 0.08   0.36 0.11   0.1 0.18 0.54   0.35 0.06 6.13E-09 LPA
12 55.598 rs1627770 G T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.17 0.03 1.81E-07 LOC390301-ALG10
12 55.598 rs863626 C T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.18 0.03 1.39E-07 LOC390301-ALG10
12 55.598 rs11053045 A T (0.2) 0.18 0.05 0.13 0.05 0.17 0.06 1 0.18 0.03 1.34E-07 LOC390301-ALG10
12 55.598 rs1619785 A A (0.2)   0.18 0.05   0.13 0.05   0.17 0.06 1   0.18 0.03 1.28E-07 LOC390301-ALG10
12 55.599 rs10844779 A A (0.2)   0.18 0.05   0.14 0.05   0.17 0.06 1   0.18 0.03 1.44E-07 ALG10-LOC260338
12 55.599 rs11053068 C C (0.2)   0.18 0.05   0.14 0.05   0.17 0.06 1   0.18 0.03 1.44E-07 ALG10-LOC260338
12 55.599 rs5004272 A G (0.21) 0.18 0.05 0.12 0.05 0.17 0.06 1 0.17 0.03 2.81E-07 ALG10-LOC260338
12 55.599 rs10844823 C C (0.21)   0.18 0.05   0.12 0.05   0.17 0.06 0.99   0.17 0.03 2.86E-07 ALG10-LOC260338
16 27.656 rs721843 C G (0.46) 0.13 0.04 0.12 0.05 0.14 0.05 0.97 0.14 0.03 6.05E-07 LOC653737-GRIN2A
19 80.713 rs4803760 C T (0.2) 0.24 0.06 0.08 0.05 0.19 0.07 0.97 0.18 0.04 4.23E-07 BCAM-PVRL2
19 80.766 rs1985096 A A (0.16)   0.33 0.07   0.16 0.06   0.28 0.08 0.8   0.27 0.04 9.49E-11 BCAM-PVRL2
19 80.877 rs395908 A A (0.16)   0.21 0.06   0.1 0.06   0.23 0.07 0.92   0.19 0.04 3.46E-07 PVRL2-BCAM-TOMM40
19 80.954 rs6857 C T (0.14)   0.32 0.07   0.06 0.07   0.23 0.08 0.93   0.23 0.04 7.43E-08 PVRL2-BCAM-TOMM40
19 81.023 rs405509 G T (0.48)   0.17 0.05   0.1 0.04   0.21 0.05 0.99   0.17 0.03 3.46E-09 APOE-TOMM40-APOE
19 81.051 rs445925 A A (0.11)   0.44 0.08   0.36 0.07   0.34 0.09 0.77   0.42 0.05 1.59E-17 LOC100129500-APOE 
 APOC1
19 81.081 rs4420638 A G (0.16)   0.44 0.08   0.15 0.07   0.32 0.09 0.56   0.33 0.05 1.12E-11 APOC1 APOC1 APOC4
SNPs associated with LDL-c response to statins with meta-analysis values of  P < 10   6 and Rsq > 0.30.
Ascot-Obs, ASCOT observational; Ascot-R, ASCOT randomized; CHR, chromosome; POS, position.
 a Estimate of squared correlation between imputed and true genotypes.
 b A positive   value means that the modeled allele is associated with a bigger posttreatment LDL-c and, therefore, a lower response to statins. A 
negative   value means that the modeled allele is associated with lower posttreatment LDL-c and, therefore, a better response to statins.
 c For SNPs that lie in the intergenic regions, the location of the nearby genes is shown.
 Fig.  2. Manhattan plot of  P -values from meta-analysis of all SNPs that passed stringent quality control. The Manhattan plots [also known 
as   log 10 ( P ) association plots[ show the chromosomal position of SNPs exceeding the genome-wide signifi cance threshold ( P < 5 × 10 
  8 ) 
as indicated by the solid red line. 
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effect of statin on Lp(a) levels;   was   0.23 mg/dl, (95% 
CI:   2.25 to 1.80) for difference in Lp(a) levels with ator-
vastatin versus placebo at one year post-randomization, 
adjusted for baseline Lp(a), age, and sex. 
 To assess whether serum Lp(a) levels might alter effi -
cacy of statin therapy on CVD itself, we examined whether 
there was any evidence of interaction (deviation from a 
multiplicative model of joint effects on a hazard scale) be-
tween high serum Lp(a) levels and atorvastatin on CVD 
end points in CARDS. The hazard ratio for CVD events 
associated with statin use was 0.60 (95% CI: 0.32–1.13) 
among those in the top quartile for serum Lp(a) (>22 mg/dl) 
compared with 0.66 (95% CI: 0.46–0.93) among those 
association of genotype at SNPs in the  LPA gene with 
LDL-c response to statin for measured serum Lp(a) levels 
in the CARDS data to test whether the genetic effects seen 
are likely to be mediated through the effect of  LPA on 
serum Lp(a) levels ( Table 3 ).  The estimate of the stan-
dardized regression coeffi cient at the associated SNP 
(rs10455872) in  LPA in CARDS was reduced from   0.35 
(±0.08) to   0.09 (±0.08), consistent with the effect of gen-
otype on apparent response to statin being mediated 
through Lp(a) levels. We noted that Lp(a) levels had an 
independent association with apparent LDL-c response to 
statin beyond genotype in these analyses ( P = 0.001). Fur-
ther analysis in CARDS also confi rmed that there was no 
 Fig.  3. Regional association plot of LPA locus with statin response. Correlations between the target SNP 
(the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb region. The  r 2 values 
were based on the HapMap CEU population. 
 Fig.  4. Regional association plot of LPA locus with Lp(a) levels in the CARDS dataset. Correlations be-
tween the target SNP (the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb 
region. The  r 2 values were based on the HapMap CEU population. 
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16 events among the 294 trial participants with at least one 
copy of the G allele. 
 Replication of the LPA SNP 
 We tested the effect of  LPA SNP (rs10455872) in 2,550 
participants in the PROSPER trial randomized to 40 mg/
day of pravastatin. In this study, “A” allele of rs10455872 
was also associated with lower response to statins with a 
scaled   of –0.18 ± 0.04,  P = 0.009. The combined  P -value 
for the three studies was 1.2E-09 (  =   0.28 ± 0.04). 
with serum Lp(a) below this level (likelihood ratio test for 
interaction  P = 0.8). 
 Nor was there any evidence of interaction between 
rs10455872 genotype at  LPA and atorvastatin for effects on 
CVD end points ( P = 0.27 for the interaction of genotype 
at rs10455872 locus). Here the HR associated with atorvas-
tatin in those homozygous for the A allele was 0.58 (95% 
CI: 0.41–0.83) and the HR in those with at least one G al-
lele was 1.03 (95% CI: 0.38–2.78). However, the power to 
detect such an interaction was limited as there were only 
 TABLE 3. Effect of adjustment for serum Lp(a) levels in CARDS 
CHR POS (cM) SNP
Modeled 
Allele
Minor Allele 
(Frequency)
Before Lp(a) Adjustment After Lp(a) Adjustment
  SE  P   SE  P Gene a 
6 195.419 rs10455872 A G (0.07)   0.35 0.08 1.12E-05   0.09 0.08 2.96E-01 LPA
12 55.598 rs1627770 G T (0.2) 0.18 0.05 5.08E-04 0.19 0.05 3.21E-04 LOC390301-ALG10
12 55.598 rs863626 C T (0.2) 0.18 0.05 3.83E-04 0.19 0.05 2.48E-04 LOC390301-ALG10
12 55.598 rs11053045 A T (0.2) 0.18 0.05 3.73E-04 0.2 0.05 2.40E-04 LOC390301-ALG10
12 55.598 rs1619785 A A (0.2)   0.18 0.05 3.60E-04   0.2 0.05 2.28E-04 LOC390301-ALG10
12 55.599 rs10844779 A A (0.2)   0.18 0.05 4.22E-04   0.19 0.05 2.79E-04 ALG10-LOC260338
12 55.599 rs11053068 C C (0.2)   0.18 0.05 4.27E-04   0.19 0.05 2.82E-04 ALG10-LOC260338
12 55.599 rs5004272 A G (0.21) 0.18 0.05 5.82E-04 0.19 0.05 4.14E-04 ALG10-LOC260338
12 55.599 rs10844823 C C (0.21)   0.18 0.05 5.88E-04   0.19 0.05 4.19E-04 ALG10-LOC260338
16 27.656 rs721843 C G (0.46) 0.13 0.05 4.67E-01 0.13 0.04 3.69E-01 LOC653737-GRIN2A
19 80.713 rs4803760 C T (0.2) 0.24 0.06 3.43E-05 0.23 0.06 7.73E-05 BCAM-PVRL2
19 80.766 rs1985096 A A (0.16)   0.33 0.07 8.31E-07   0.33 0.07 1.39E-06 BCAM-PVRL2
19 80.877 rs395908 A A (0.16)   0.21 0.06 2.10E-04   0.21 0.06 3.65E-04 PVRL2-BCAM-
 TOMM40
19 80.954 rs6857 C T (0.14)   0.32 0.07 1.85E-06   0.3 0.07 1.75E-05 PVRL2-BCAM-
 TOMM40
19 81.023 rs405509 G T (0.48)   0.17 0.05 3.36E-04   0.14 0.05 4.31E-03 APOE-TOMM40-
 APOE
19 81.051 rs445925 A A (0.11)   0.44 0.08 1.13E-08   0.42 0.08 1.39E-07 LOC100129500-
 APOE APOC1
19 81.081 rs4420638 A G (0.16)   0.44 0.08 1.65E-08   0.43 0.08 1.39E-07 APOC1 APOC1 
 APOC4
Effect of adjustment for serum Lp(a) levels in CARDS for SNPs associated with an LDL-c response to statins with a meta-analysis of  P <10   6 .
CHR, chromosome; POS, position.
 a For SNPS that lie in the intergenic regions, the location of the nearby genes is shown.
 Fig.  5. Regional association plot of APOE locus with statin response. Correlations between the target SNP 
(the SNP with the lowest  P value, depicted in purple) and nearby SNPs within a 500 kb region. The  r 2 values 
were based on the HapMap CEU population. 
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Thus we tested for residual effects of SNP haplotypes con-
ditioning either on rs445925 (as a proxy for rs7412) or on 
rs4420638 (as a proxy for rs429358). When conditioned 
on rs4420638, the  
 4 proxy, the additional percentage 
variance explained by residual haplotype effects is 0.7% (F 
statistic with 8 and 854, df = 3.21,  P = 0.001). When condi-
tioned on rs445925, the proxy for  
 2, the additional per-
centage variance explained by residual haplotype effects is 
only 0.2% (F statistic with 8 and 854, df = 1.76,  P = 0.08), 
suggesting that  
 2 accounts for most of the variance in re-
sponse at this locus. 
 ALG10 
 Beyond these associations of LDL-c response with  APOE 
and  LPA, no other genome-wide signifi cant associations 
were found. The next most signifi cant SNPS were those in 
the ALG10 gene region ( Fig. 6 )  on chromosome 12 where 
several SNPs had  P < 10   6 . ALG10 codes for asparagine-
linked glycosylation protein 10 homolog A. Of these SNPs, 
most map to intergenic regions either side of the ALG10 
gene itself with one imputed SNP within ALG10 having a 
 P -value for association with statin response of 6.79 × 10   6 . 
 Effect of pretreatment LDL-C 
 To demonstrate that these fi ndings are unlikely to be 
confounded by baseline LDL-c,  Table 4  shows unadjusted, 
adjusted, and corrected estimates of the direct effect of 
genotype on posttreatment LDL at the strongest SNPs for 
the  APOE region  LPA and  ALG10 in the CARDS dataset. At 
the  APOE  
 2 proxy SNP (rs445925), without adjusting for 
baseline LDL-c, the apparent LDL-c response to statins 
would be more than double that observed in our baseline-
adjusted model (  =   1.01 vs.   0.44 per copy of “A” al-
lele), emphasizing the effect of adjusting for baseline 
LDL-c. However, adjusting our effect size estimate further 
by modeling measurement noise at baseline reduced the 
apparent effect just slightly to   =   0.30, suggesting there 
 APOE 
 Several SNPs in the  BCAM/PVRL2 / APOE / APOC1 / APOE 
gene region reached genome-wide signifi cance for statin 
response ( Fig. 5 ).  The effect on LDL-c response to statin 
therapy associated with these SNPs at in this region was 
modest; in CARDS for example the % change in LDL-c 
with statin therapy at one month was approximately -51% 
in those with at least one “A” allele at rs445925 compared 
with -45% in common GG homozygotes and was approxi-
mately -37% in those with at least one “G” allele at 
rs4420638 compared with -47% in common “AA” homozy-
gotes. These effects were independent of the effect of gen-
otype at rs10455872 in  LPA and of Lp(a) levels. In the 
CARDS dataset we confi rmed that there was no signifi cant 
effect of these SNPs on change in LDL-c post randomiza-
tion in those in the placebo group ( P = 0.47). 
 We examined whether the effects in this region could 
be accounted for by the known  
 2/ 
 3/ 
 4 protein poly-
morphism of apolipoprotein E, which corresponds to 
 APOE SNP haplotypes T-T, T-C, and C-C, respectively, at 
rs429358 and rs7412. The presence of the “T” allele at 
rs7412 contrasts the  
 2 protein variant with other protein 
variants, whereas presence of the “C” allele at rs429358 
contrasts the  
 4 protein variant with other protein vari-
ants. These two SNPS were not directly typed and could 
not be imputed as they are not in the HapMap II. 
 The “A” allele at rs445925, which we found to be associ-
ated with a higher statin response (  =   0.44) is in LD 
with the “T” allele at rs7412 with a reported  r 2 of 0.76; thus, 
it is a proxy for the  
 2 protein variant ( 20 ). The “G” allele 
at rs4420638, which was associated with lower response to 
statin, is in LD with the “C” allele at rs429358 with reported 
 r 2 of 0.62 but with a low  r 2 of 0.01 for rs7412 ( 21 ); thus, it is 
a proxy for the  
 4 protein variant. 
 These two proxy SNPs are in the HapMap and could be 
imputed in this analysis with percentage information con-
tent (i.e., imputation quality) of 77% and 56%, respectively. 
 Fig.  6. Regional association plot of ALG10 locus with statin response before Lp(a) adjustments. Correla-
tions between the target SNP (the SNP with the lowest  P value, depicted in purple) and nearby SNPs within 
a 500 kb region. The  r 2 values were based on the HapMap CEU population. 
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highly skewed distribution; for example, in CARDS, the 
median serum Lp(a) was 8.9 mg/dl (IQR 4.5–21.3 mg/dl) 
and with values as high as 238 mg/dl. Approximately 30% 
of variance in Lp(a) levels has been reported as deter-
mined by the kringle IV type 2 (KIV-2) copy number vari-
ant in  LPA , which is known to encode variability in the size 
of apo(a). Some variance in measured Lp(a) attributable 
to genes is also due to apo(a) size heterogeneity affecting 
the results of the immunochemical methods used to quan-
tify Lp(a), as is the case with the assay we used ( 22 ). That 
is, genotype can induce some measurement error in Lp(a), 
although recent data from the Framingham study suggest 
the measurement error is likely to be of little practical im-
portance ( 23 ). The Lp(a)-raising genotype associated with 
the kringle repeat and high Lp(a) levels themselves have 
also been reported to be associated with increased car-
diovascular risk in several studies ( 24–28 ). As such, re-
cent guidelines emphasize the importance of detecting 
high Lp(a) phenotype and possible intervention with nia-
cin ( 26 ). 
 The rs10455872 SNP that we found associated with 
LDL-c response is in strong LD with the KIV-2 copy num-
ber variant in Lp(a) ( 29 ). Consistent with this, variation at 
rs10455872 accounted for 30% of variance in Lp(a) in the 
CARDS data. However, the explanation for the apparently 
lower LDL-c response in those with genotypes associated 
with high Lp(a) lies in understanding what LDL-c estima-
tion actually captures. The standard Friedewald formula 
calculates LDL-c levels from TC, HDL-cholesterol, and 
plasma triglyceride and actually includes the cholesterol 
that resides in Lp(a). For most patients, this is of little im-
portance as usually only about 5% of what is measured as 
LDL-cholesterol is estimated to reside in Lp(a). However, 
it is estimated that about 8% of apparent LDL-c resides in 
Lp(a) if Lp(a) levels are in the range 30–60 mg/dl and as 
much as 20% if Lp(a) is > 60 mg/dl ( 30 ). As we show de-
fi nitively here in the CARDS trial, statin therapy did not 
lower Lp(a) levels. Thus, individuals who had an appre-
ciable fraction of their total plasma cholesterol carried on 
Lp(a) particles had some cholesterol in statin-responsive 
LDL particles and some in statin-unresponsive Lp(a) par-
ticles. For such patients, true LDL-c response will be un-
derestimated because apparent on-treatment LDL-c will 
comprise truly falling LDL-c but static Lp(a) levels. This 
phenomenon has previously been noted in the context of 
nephrotic syndrome ( 31 ) and has been emphasized by 
Scanu et al. ( 32 ). Our estimate that those with at least one 
copy of the Lp(a)-raising G allele at rs10455872 have about 
a 5 percentage points lower apparent statin response (45% 
in “GG” and “AG” genotype vs. 40% in “AA” genotype) 
and that this association disappears when adjusted for 
Lp(a) levels is consistent with these observations . 
 Although the effect of the G allele on statin response is 
modest, this allele only accounts for about 30% of variance 
in Lp(a) levels. The data highlight a more general clinical 
point that individuals with raised Lp(a) levels for any rea-
son have a somewhat lower apparent response to statin 
therapy and, therefore, that an apparently lower LDL-c 
response to statin may be an indication for checking Lp(a) 
is little residual effect of baseline due to measurement 
noise. At the  APOE  
 4 proxy SNP and at the  LPA SNP, the 
estimated effect of baseline LDL-c adjustment is much 
less, and thus, the adjustment for measurement noise al-
ters the association only slightly. 
 Other genes of interest 
 Previously reported variants associated with statin re-
sponse in the  PCSK9 (rs11591147),  HMGCR (rs1047443, 
rs17671591, rs6453131),  KIF-6 (rs20455),  ABCB1 (1236/
2677/3435 TTT haplotype),  CLMN (rs80141914, associ-
ated with TC response to statin), and  GCKR (rs1260326 
associated with triglyceride level response to statin) genes 
were not signifi cantly associated at with LDL-c response to 
statin in this study at an accepted genome-wide association 
threshold ( P   10   8 ) or even at thresholds typically ex-
pected to declare replication (say,  P   10   2 ) . However, 
 PCSK9 (rs11591147) and  GCKR (rs1260326) were signifi -
cant at a threshold of 0.05 (see supplementary Table I). 
We have refrained from comparing the directionality and 
magnitude of these effects in the present study because of 
the different phenotype characterization and transforma-
tions across the studies and, in some studies, lack of infor-
mation about the modeled alleles. 
 DISCUSSION 
 In this genome-wide association study of LDL-c response 
to atorvastatin therapy, we report that those with geno-
types in the  LPA gene that lead to higher Lp(a) levels have 
an apparently lower LDL-c response to statin, and we rep-
licate the previously reported association of a higher re-
sponse to statin in those with the A allele at the  APOE  
 2 
locus. The top three SNPs in the study, rs10455872 in  LPA 
and the  APOE  
 2 and  APOE  
 4 variants, explained only 4% 
variance in the LDL-c response to statin treatment; however, 
it is possible that that larger studies might detect more SNPs 
with smaller effect sizes or that there are larger effects at rarer 
variants not captured by our imputed genotypes. 
 LPA 
 Lipoprotein(a) is a plasma lipoprotein consisting of a cho-
lesterol-rich LDL particle with one molecule of apolipopro-
tein B100 and an additional protein, apolipoprotein(a), 
attached via a disulfi de bond. Serum levels of Lp(a) have a 
 TABLE 4. Effect of genotype on posttreatment LDL-c (CARDS only) 
SNP 
  unadjusted for 
baseline LDL
  adjusted for 
observed baseline 
LDL but uncorrected 
for measurement 
noise
  adjusted for 
baseline LDL and 
corrected for 
measurement 
noise
rs445925   1.01   0.44   0.38
rs4420638   0.54   0.44   0.42
rs10455872 
( LPA )
  0.49   0.35   0.32
rs10844779 
( ALG10 )
  0.18   0.18   0.18
With and without correction for measurement noise in baseline 
LDL.
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superset of 5,745 individuals studied for candidate gene 
associations only, three SNPs in  APOE and one SNP in 
 PCSK9 reached genome-wide signifi cance ( 2 ). In a meta-
analysis of three trials that included 3,932 treated subjects 
( 3 ) a SNP in the  CLMN gene was signifi cant at  P < 10   7 for 
association with TC response, and there was a weak asso-
ciation with SNP in  APOE. In the same study, polymor-
phism in the  GCKR gene was shown to be associated with 
statin-induced change in triglycerides. Candidate gene 
analyses have shown that a common  LDLR 3-UTR haplo-
type is associated with attenuated lipid-lowering response 
to simvastatin treatment ( 34 ). In the same study,  HMGCR 
gene polymorphisms were also associated with reduced 
plasma LDL-c and with reduced LDL-c response to simvas-
tatin. The association of  HMGCR gene with statin response 
was also reported in a population-based cohort of patients 
with diabetes ( 35 ). These effects were more evident in Af-
rican-Americans than in European-Americans. In a sepa-
rate study, carried out in acute coronary syndrome patients, 
carriers of a polymorphism in  kinesin-like protein 6 (KIF-6) 
have been reported to have greater benefi t from pravasta-
tin versus placebo with respect to CVD outcome but not 
with respect to lipid or C-reactive peptide response ( 36 ). 
Additionally, association of the  ABCB1 gene with statin re-
sponse has been reported ( 4, 37 ). Apart from the  APOE 
association, none of these other associations were repli-
cated here. 
 Finally, we note that the effects identifi ed in this study 
are of modest size: the importance of further studying the 
genetics of response to statin therapy may be not in pre-
dicting who will benefi t from statins but in identifying 
other therapeutic targets.  
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T
he 3-hydroxymethyl-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, also known as statins, are
widely prescribed and are highly effective in the manage-
ment and prevention of cardiovascular disease. Statin therapy
results in a lowering of low-density lipoprotein cholesterol (LDL-
C) levels by up to 55%1 and a 20–30% reduction of cardiovascular
events2. Despite the clinical efﬁcacy of statins in a wide range of
patients2, interindividual variability exists with regard to LDL-C-
lowering response as well as efﬁcacy in reducing major
cardiovascular events3. The suggestion that some of this
variability may be due, in part, to common pharmacogenetic
variation is supported by previous studies that have identiﬁed
genetic variants associated with differential LDL-C response to
statin therapy4–6.
A small number of genome-wide association studies (GWAS)
have previously identiﬁed loci associated with statin response on
a genome-wide level. A GWAS in the JUPITER trial identiﬁed
three genetic loci, ABCG2 (rs2199936), LPA (rs10455872) and
APOE (rs7412), that were associated with percentage LDL-C
reduction following rosuvastatin therapy7. In the CARDS and
ASCOT studies, single nucleotide polymorphisms (SNPs) at LPA
(rs10455872) and APOE (rs445925 and rs4420638) were
associated with LDL-C response to atorvastatin treatment8. A
combined GWAS in three statin trials identiﬁed a SNP within
CLMN (rs8014194) that is associated with the magnitude of
statin-induced reduction in plasma cholesterol9. However, two
other GWAS identiﬁed no genetic determinants of LDL-C
response to statin therapy at a genome-wide signiﬁcant level6,10.
On the basis of these studies, as well as previous candidate gene
studies4,6, the only genetic variants that have been consistently
identiﬁed to be associated with variation in LDL-C response to
statin therapy, irrespective of statin formulation, are located at or
nearby APOE and LPA. To determine whether additional loci
may inﬂuence LDL-C response to statins, we formed the
Genomic Investigation of Statin Therapy (GIST) consortium
and conducted a pharmacogenetic meta-analysis using GWAS
data sets from randomized controlled trials (RCTs) and
observational studies. We identify two loci not previously
identiﬁed in GWAS, SORT1/CELSR2/PSRC1 and SLCO1B1. In
addition, we conﬁrm the associations within the APOE and LPA
genes. These ﬁndings will extend the knowledge of the
pharmacogenetic architecture of statin response.
Results
First-stage meta-analysis. The GIST consortium includes 6 RCTs
(n¼ 8,421 statin recipients) and 10 observational studies
(n¼ 10,175 statin recipients) that participated in the ﬁrst stage
(see Methods; Supplementary Tables 1 and 2; Supplementary
Notes 1 and 2). To search for genetic variants associated with
differential LDL-C response to statin therapy, each study inde-
pendently performed a GWAS among statin users, using the
difference between the natural log-transformed LDL-C levels on-
and off-treatment as the response variable (see Methods).
The ﬁrst-stage meta-analysis identiﬁed three loci, including 13
SNPs, that attained genome-wide signiﬁcance (Po5 10 8) for
association with LDL-C response to statin treatment (Fig. 1;
Table 1). The most signiﬁcant association was for a SNP on
chromosome 19, at APOE (rs445925, minor allele frequency
(MAF)¼ 0.098, b¼  0.043, s.e.¼ 0.005, P¼ 1.58 10 18;
Fig. 2a), indicating that carriers of the rs445925 SNP respond to
statins with an additional 4.3% increase per allele in LDL-C
lowering effect compared with non-carriers. The second strongest
association was with a SNP at LPA on chromosome 6 (rs10455872,
MAF¼ 0.069, b¼ 0.041, s.e.¼ 0.006, P¼ 1.95 10 11; Fig. 2b),
indicating a 5.9% smaller LDL-C lowering per minor allele for
carriers of the SNP compared with non-carriers. Associations at
both loci have previously been described7,8. A third genome-wide
signiﬁcant association was found with a SNP at RICTOR
on chromosome 5 (rs13166647, MAF¼ 0.230, b¼  0.253,
s.e.¼ 0.046, P¼ 4.50 10 8), although genotypes for this SNP
were only available in two studies within the ﬁrst stage (n¼ 2,144).
Second-stage meta-analysis. We selected 246 SNPs with P
o5 10 4 from 158 loci for further investigation in three addi-
tional studies comprising up to 22,318 statin-treated subjects (see
Methods; Supplementary Tables 1 and 5; Supplementary Note 3).
This second stage conﬁrmed the genome-wide signiﬁcant asso-
ciations between variations within the APOE and LPA loci and
LDL-C response, as observed in the ﬁrst stage (Table 1;
Supplementary Fig. 2; Supplementary Table 5). In addition,
SNPs at two new loci with P values between 6.70 10 7 and
2.26 10 6 in the ﬁrst phase were shown to be signiﬁcantly
associated with statin-induced LDL-C lowering after statin
treatment in the total combined meta-analysis at a genome-wide
level: SORT1/CELSR2/PSRC1 (rs646776, b¼  0.013, s.e.¼ 0.002,
P¼ 1.05 10 9 and rs12740374, b¼  0.013, s.e.¼ 0.002,
P¼ 1.05 10 9; Fig 2c) and SLCO1B1 (rs2900478, b¼ 0.016,
s.e.¼ 0.003, P¼ 1.22 10 9; Fig 2d), indicating an additional
1.5% increase per allele in LDL-C lowering effect for carriers of the
SORT1/CELSR2/PSRC1 SNP and a 1.6% smaller LDL-C lowering
per minor allele for carriers of the SLCO1B1 SNP.
The six next-ranked SNPs with P values just below 5 10 8 in
the combined meta-analysis, including the two SNPs at RICTOR
(rs13166647 and rs13172966), were selected for additional
genotyping in the Scandinavian ASCOT participants (see Meth-
ods). None of these six SNPs reached genome-wide signiﬁcance
after this additional genotyping (Supplementary Table 6). There-
fore, our overall genome-wide signiﬁcant ﬁndings were the SNPs at
APOE, LPA, SORT1/CELSR2/PSRC1 and SLCO1B1.
Subfraction analyses. To extend our results for the novel GWAS
ﬁnding SORT1/CELSR2/PSRC1, we performed additional asso-
ciation analyses, using measurements of cholesterol levels in four
LDL subfractions (large, medium, small and very small) from two
of the trials in GIST, CAP and PRINCE (Table 2; see Methods).
The minor allele of SORT1 rs646776 was associated with greater
statin-induced reductions in levels of all LDL subfractions, and
there was a nonsigniﬁcant trend for larger effect sizes and greater
statistical signiﬁcance for lowering of small and very small LDL
(Table 2). In contrast, the APOE SNP associated with greater
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Figure 1 | Results of the GWAS meta-analysis. Manhattan plot presenting
the  log10 P values from the combined meta-analysis (n¼40,914) on
LDL-C response after statin treatment. P values were generated using linear
regression analysis.
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LDL-C response to statins (rs445925) showed a small and non-
signiﬁcant association with change in very small LDL (Table 2).
For the minor allele of rs2900478 (SLCO1B1), the borderline
signiﬁcant association with smaller magnitude of LDL-C reduc-
tion showed a trend for preferential association with larger versus
smaller LDL subfractions. The lack of association of rs10455872
(LPA) with changes in LDL subfractions is consistent with evi-
dence discussed below that this locus affects levels of lipopro-
tein(a) (Lp(a)) and not LDL particles. Using generalized
estimating equations, we tested the association of log change in
each of the LDL subfractions with interactions of the four SNPs.
For very small LDL, the association with the rs646776 minor
allele was signiﬁcantly different from that of the other minor
alleles (P¼ 0.03 after adjustment for multiple testing).
Effects of off-treatment LDL-C. To demonstrate that our ﬁnd-
ings for LDL-C response to statin treatment are unlikely to be
explained through associations with baseline LDL-C levels, we
performed a number of additional analyses (see Methods). First,
Supplementary Table 7 shows regression coefﬁcients for baseline-
adjusted and measurement noise-corrected estimates of the direct
effect of genotype on on-treatment LDL-C at the strongest SNPs
in the GIST meta-analysis (Po1 10 8), which were available
in the CARDS data set. Correcting our effect size estimate further
and modelling measurement noise at baseline reduced the
apparent effect only slightly for all the markers, suggesting that
there is little effect of measurement noise. Next, within the
JUPITER trial, additional analyses were performed to determine
whether there was an interaction between LDL-C change and
statin or placebo allocation. Supplementary Table 8 shows sig-
niﬁcant P values for interaction (all o5 10 2) for SNPs at the
four genome-wide signiﬁcant loci in the GIST meta-analysis, also
suggesting that genetic effects on baseline LDL-C as manifested in
the placebo group contribute at most only in part to genetic
effects on LDL-C response in the statin group.
Genome-Wide Conditional Analysis. To investigate whether
there were multiple SNPs within any gene and multiple loci
associated with differential LDL-C lowering to statin therapy, we
performed a conditional analysis across the genome using the
summary statistics of the combined meta-analysis. The results of
the Genome-Wide Conditional Analysis (GWCA; see Methods;
Supplementary Table 9) showed 14 SNPs independently asso-
ciated with statin response and these explained B5% of the
variation in LDL-C response to statin treatment. Of the 14
independent SNPs, 6 were genome-wide signiﬁcant in the com-
bined GWAS meta-analysis (Supplementary Table 5).
Previous ﬁndings. In Supplementary Table 10, we performed a
look-up in our GWAS meta-analysis for SNPs previously
described in the literature (NHGRI Catalogue11 of Published
GWAS and Candidate gene studies) to be associated with statin
response, besides the loci associated at a genome-wide level in the
current study. None of these SNPs was associated with statin
response in our GWAS after correcting for multiple testing.
Functional analyses. Functional characterization of the 246 SNPs
selected for the second stage was performed using a range of
bioinformatics tools (see Methods). A total of 420 expression
quantitative trait loci (eQTL) associations were identiﬁed across a
wide range of tissues (Supplementary Data 1), which comprised 67
independent gene eQTL associations. Eleven genes, including
APOE, SORT1, CELSR2 and PSRC1, showed eQTLs in liver, which
considering its primary role in mediating statin-induced LDL
reduction may be particularly relevant to statin response. Putative
gene eQTLs were combined with genes annotated to variants in
linkage disequilibrium (LD) with LDL-C response-associated
variants, resulting in a list of 185 candidate gene loci, deﬁned by
2,681 SNPs (Supplementary Data 2 and 3). To identify statin
responsive genes among the candidate loci, gene expression data
measured in response to statin treatment in a range of cell lines
was retrieved from the Connectivity Map resource12 (see
Methods). Five genes (APOE, BRCA1, GRPEL1, ADRB2 and
ETV1) showed convincing evidence of statin responsiveness on
the basis of greater than twofold differential expression in
response to statin treatment. Eight genes showed suggestive
evidence (1.5- to 2-fold change; TOMM40, SREBP1, PSRC1, BCL3,
BCAM, ANK3, SIVA1 and RANBP9; Supplementary Data 3).
Finally, involvement in statin response was investigated at a
pathway level using GeneGo Metacore (Thomson Reuters13).
Brieﬂy, 87 literature-reported genes linked to statin response were
combined with the 185 candidate gene loci reported here
Table 1 | Genome-wide signiﬁcant associations in stage 1, stage 2 and combined meta-analysis.
Chr Position Lead SNP Gene Coding
allele
Noncoding
allele
Phase N Frequency-
coding
allele
Beta* s.e. % Extra
reductionw
P value
1 109620053 rs646776 SORT1/
CELSR2/
PSRC1
C T Stage 1 16,697 0.230 0.015 0.003 1.5 6.70 10 7
Stage 2 21,902 0.216 0.010 0.003 1.0 2.43 104
Combined 38,599 0.013 0.002 1.3 1.05 109
6 160930108 rs10455872 LPA G A Stage 1 12,981 0.069 0.041 0.006 4.1 1.95 10 11
Stage 2 18,075 0.087 0.059 0.005  5.9 7.14 10 35
Combined 31,056 0.052 0.004  5.2 7.41 1044
12 21260064 rs2900478 SLCO1B1 A T Stage 1 16,749 0.165 0.016 0.003  1.6 2.26 10 6
Stage 2 7,504 0.164 0.017 0.006  1.7 3.54 10 3
Combined 24,253 0.016 0.003  1.6 1.22 109
19 50107480 rs445925 APOE A G Stage 1 13,909 0.098 0.043 0.005 4.3 1.58 10 18
Stage 2 3,613 0.157 0.088 0.011 8.8 1.41 10 15
Combined 17,522 0.051 0.005 5.1 8.52 10 29
Chr, chromosome; SNP, single nucleotide polymorphism.
*Beta for difference between the natural log-transformed on- and off-treatment low-density lipoprotein cholesterol (LDL-C) levels adjusted for natural log-transformed off-treatment LDL-C-, age-,
sex- and study-speciﬁc covariates. The beta reﬂects the fraction of differential LDL-C lowering in carriers versus non-carriers of the SNP; a negative beta indicates a better statin response (stronger LDL-C
reduction), a positive beta a worse statin response. Betas and P values were generated using linear regression analysis.
wThis percentage reﬂects the % extra LDL-C lowering in carriers versus non-carriers of the SNP.
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(Supplementary Data 3). A conservative network of direct
interactions was constructed between query genes (Supplementary
Data 4). The network included 24 genes located in the LDL-C-
associated loci (Supplementary Fig. 4). Collectively, our functional
and pathway analysis conﬁrms a strong biological and functional
role in statin response for several strongly associated gene loci,
including APOE/TOMM40/PVRL2 and SORT1/CELSR2/PSRC2.
Discussion
We have performed a meta-analysis of GWAS including more
than 40,000 subjects, investigating genetic variants associated
with variation in LDL-C lowering on statin treatment indepen-
dent from associations with baseline LDL-C. We identiﬁed four
loci at genome-wide signiﬁcance, including the previously
identiﬁed APOE and LPA, and the novel GWAS loci SORT1/
CELSR2/PSRC1 and SLCO1B1.
Nine SNPs in the APOE gene region reached genome-wide
signiﬁcance for LDL-C response. The minor allele of the lead
SNP rs445925, which is a proxy for the apoE e2 protein
variant deﬁning SNP rs7412 (ref. 14), was associated with a larger
LDL-C-lowering response to statins compared with carriers of the
major allele. The magnitude and direction of the effect size was
similar to previously reported ﬁndings for the rs445925 variant in
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Figure 2 | Regional association plots of the genome-wide signiﬁcant associations with LDL-C response after statin treatment. The plots show the
genome-wide signiﬁcant associated loci in the combined meta-analysis (n¼40,914), the APOE locus (a), the LPA locus (b), the SORT1/CELSR2/PSRC1 locus
(c) and the SLCO1B1 locus (d) (generated using LocusZoom (http://genome.sph.umich.edu/wiki/LocusZoom)). The colour of the SNPs is based on the LD
with the lead SNP (shown in purple). The RefSeq genes in the region are shown in the lower panel. P values were generated using linear regression analysis.
Table 2 | Associations of the minor alleles of rs646776, rs445925, rs2900478 and rs10455872 with changes in LDL-C and LDL
subfractions in response to statin in the combined CAP and PRINCE studies.
Change* SORT1/CELSR2/PSRC1
rs646776 (MAF 0.2)
APOE
rs445925 (MAF 0.086)
SLCO1B1
rs2900478 (MAF 0.16)
LPA
rs10455872 (MAF 0.056)
Beta s.e. P value Beta s.e. P value Beta s.e. P value Beta s.e. P value
LDL-C total 0.023 0.008 0.003 0.046 0.018 0.008 0.010 0.005 0.04 0.032 0.019 0.09
Large LDL-C 0.028 0.014 0.042 0.075 0.029 0.009 0.02 0.008 0.01 0.036 0.031 0.23
Medium LDL-C 0.027 0.015 0.075 0.079 0.032 0.012 0.016 0.009 0.07 0.010 0.034 0.77
Small LDL-C 0.047 0.018 0.009 0.071 0.037 0.050 0.002 0.010 0.83 0.024 0.039 0.54
Very small LDL-C 0.034 0.009 0.00006 0.022 0.017 0.202 0.001 0.005 0.90 0.008 0.019 0.67
LDL-C, low-density lipoprotein cholesterol; MAF, minor allele frequency.
*Change: ln (on treatment) ln (baseline) models adjusted for log (baseline variable), age, sex, body mass index, smoking(y/n) and study (CAP versus PRINCE). Betas and P values were assessed using
a generalized estimating equation method.
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the GWAS study performed in CARDS and ASCOT8 and of the
SNP rs7412 in JUPITER7. Since the apoE E2 protein results in
increased hepatic cholesterol synthesis, it may also predispose to
stronger inhibition of cholesterol synthesis by statin treatment8,10.
Three independent SNPs at LPA were signiﬁcantly associated
with LDL-C response to statins. The minor G allele of the lead
SNP rs10455872 was associated with smaller LDL-C reduction
than the major allele. This result was similar to the previous
GWAS ﬁndings for this SNP in the JUPITER trial and the
combined ASCOT and CARDS study7,8. The rs10455872 SNP
was strongly associated with the KIV-2 copy number variant in
Lp(a), which encodes variability in apo(a) size and is responsible
for B30% of variance in Lp(a) levels8,15. Furthermore,
rs10455872 was shown to be strongly associated with plasma
Lp(a) levels16. Standard assays of LDL-C, as well as the
Friedewald formula, include cholesterol that resides in Lp(a)6,8.
Carriers of this LPA variant are characterized by higher Lp(a)
levels and a larger proportion of their measured LDL-C resides in
Lp(a) particles8,10. Since statin therapy does not reduce the
number of Lp(a) particles17, their presence attenuates the
measured LDL-C response to statins.
Two SNPs at SORT1/CELSR2/PSRC1 (rs646776 and
rs12740374) on chromosome 1p were associated with an
enhanced statin LDL-C response. A similar association was
previously observed in a large candidate gene study in HPS6;
however, we demonstrate this ﬁnding now ﬁrst at a genome-wide
signiﬁcance level. The minor allele of rs12740374 has been shown
to generate a binding site for the transcription factor C/EBPa18.
Transcription results in upregulation of hepatic expression of
three genes at this locus, SORT1, CELSR2 and PSRC1 (ref. 18),
which we also showed in our eQTL analysis (Supplementary
Data 1). Of these, SORT1 is most notable, in that it encodes the
multifunctional intracellular trafﬁcking protein sortilin, which
has been shown to bind tightly to apoB19. Sortilin-induced
lowering of plasma LDL-C results from two mechanisms: reduced
secretion of apoB-containing precursors, and, perhaps of greater
importance, increased hepatic LDL uptake via binding to sortilin
at the cell surface, with subsequent internalization and lysosomal
degradation19. Notably, the minor allele of rs646776 is
preferentially associated with lower levels of small and very
small LDL (Table 2), suggesting that sortilin is of particular
importance for regulating levels of these particles18. Smaller LDL
subfractions have been shown to be relatively enriched in
particles with reduced LDL receptor binding afﬁnity and
cellular uptake20, a property that may contribute to their
associations with increased risk for cardiovascular disease21.
This property may also underlie the diminished efﬁcacy of statins
for reduction of these particles (Supplementary Fig. 3)22, since
statins act to reduce LDL-C levels to a large extent by increasing
LDL receptor expression as a result of upregulation of the
transcription factor SREBP2, whereas SORT1 is not regulated by
this mechanism. Hence, the greater statin-mediated reduction of
LDL-C among carriers of the rs646776 minor allele could be
attributed to relative depletion of LDL particles dependent on
sortilin for clearance and hence a residually greater proportion of
those LDL particles whose uptake is more dependent on the LDL
receptor than on sortilin.
Notably, the strong association of rs646776 with statin-induced
reductions in small and very small LDL particles contrasts to the
weaker associations of changes in these particles with rs445925,
likely the result of differing mechanisms underlying the effects of
these SNPs on statin response. As noted above, rs445925 is a
proxy for the SNP deﬁning the apoE E2 protein variant that is
thought to predispose to heightened statin response as a result of
greater statin inhibition of cholesterol synthesis and hence
upregulation of SREBP and LDL receptor activity.
The SLCO1B1 rs2900478 minor allele was associated with a
smaller LDL-C reduction in response to statin treatment.
SLCO1B1 encodes the organic anion-transporting polypeptide
OATP1B1 and facilitates the hepatic uptake of statins23. SNP
rs2900478 is in strong LD (r2¼ 0.89) with rs4149056, which
represents the Val174Ala substitution resulting in complete loss
of function. In the HPS trial, which used simvastatin, this
candidate gene SNP was associated with a 1% lower LDL-C
reduction per allele6. Single-dose studies have shown that the
observed area under the curve of plasma level of active
simvastatin after a dose of 40mg was 221% higher in
rs4149056 CC homozygotes compared with rs4149056 TT
homozygotes, as compared with atorvastatin 20mg (144%
higher for CC versus TT) and rosuvastatin 40mg (117% higher
for CC versus TT)24. This ﬁnding results from the slower hepatic
uptake of statins caused by the genetic variant, which would also
be expected to result in a reduction in the cholesterol-lowering
effect25. In a GWAS of the genetic risk factors for simvastatin-
induced myopathy, SLCO1B1 showed the strongest association25.
Homozygous carriers of the SLCO1B1 variant had a 16.9 times
higher risk for myopathy compared with non-carriers. This might
have led to a decrease in study medication adherence, and
consequently a decreased effect on LDL-C in carriers of this SNP.
In addition, previous analysis in the GoDARTS study showed that
the effect of the SLCO1B1 gene on statin efﬁcacy was abolished
after removal of individuals who showed signs of intolerance26.
GWCA identiﬁed three independent loci in the APOE gene
region and two loci in the LPA gene region (Supplementary
Table 9). GWCA also showed several other loci with
P o5 10 8 that were not GWAS signiﬁcant on single-SNP
analysis (HGD, RNF175, ISCA1L-HTR1A, GLIS3-SLC1A1,
LOC100128657, NKX2-3-SLC25A28 and PELI2). These ﬁndings
will require replication in independent, larger data sets. The
signiﬁcant SNPs in the GWCA analysis explained B5% of the
variation in LDL-C response to statin treatment. Whether this 5%
is clinically relevant should be investigated by other studies. For
example, it would be of interest to investigate whether this
differential LDL-C lowering is also associated with differential
event reduction by statin treatment.
In the current study, we combined the results of 6 randomized
clinical trials and 10 observational studies in the ﬁrst stage. This
approach resulted also in combining several types of statins, since
different statins were studied in the trials and within the
observational studies (Supplementary Table 2). This, and the
variation in statin dosage during follow-up for an individual, is a
limitation of the current study, since, for example, the impact of
the SLCO1B1 variant on statin pharmacogenetics is known to be
highly dependent on statin type and dose24,27. To overcome this
limitation, the individual study analyses were adjusted for statin
dose. Dividing the actual statin dose given by the statin-speciﬁc
dose equivalent (Supplementary Table 3) gives the statin-adjusted
equivalent based on the daily dosages required to achieve a mean
30% LDL-C reduction. Using this table, we made the different
statin dosages and types comparable within the studies. To
correct for between-study variance, we used a ﬁxed effect meta-
analysis with inverse variance weighting. Since we observed that
the SLCO1B1 gene was genome-wide signiﬁcantly associated with
LDL lowering, this highlights the thoroughness of our analytical
approach, in which the analyses were correctly adjusted for the
type and dose of statins used (Supplementary Table 3). Moreover,
a comparison of the estimates of the SNPs between the RCTs
(where there are no intra-individual differences in dosages) with
the estimates of the SNPs in the observational studies showed
large homogeneity between the estimates in the various study
designs (Supplementary Fig. 2), indicating that our adjustment
for dosage seems to be sufﬁcient within this study.
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Another possible limitation of the current study is the inﬂuence
of the identiﬁed genetic variants on baseline LDL-C levels. In
pharmacogenetic studies investigating the LDL-C-lowering
response to statins, it is important to eliminate the effect of
association between the genetic variant and baseline LDL-C
levels, since those ﬁndings may confound the response to
treatment associations. Previous large GWAS studies have shown
strong associations between baseline LDL-C levels and genetic
variants in SORT1/CELSR2/PSRC1, APOE and LPA28. To
eliminate those possible confounding effects, our response to
treatment analyses were adjusted for baseline LDL-C levels. In
addition, additional analysis in CARDS and JUPITER suggests no
or little inﬂuence of genetic associations with baseline LDL-C on
the genetic effects on LDL-C-lowering response.
In conclusion, this study is the largest meta-analysis of GWAS
for LDL-C response to statin therapy conducted to date. Our
results demonstrate that apart from the previously identiﬁed
APOE and LPA loci, two new loci, SORT1/CELSR2/PSRC1 and
SLCO1B1, also have a modest but genome-wide signiﬁcant effect
on LDL-C response. The minor alleles of the APOE rs445925 and
SORT1/CELSR2/PSRC1 rs646776 SNPs were associated with a
larger statin response, whereas the minor alleles of the LPA
rs10455872 and SLCO1B1 rs2900478 SNPs were associated with a
smaller statin response. Our ﬁndings advance the understanding
of the pharmacogenetic architecture of statin response.
Methods
Study populations. The meta-analysis was conducted in the GIST consortium,
which includes data from 8 randomized controlled statin trials (RCTs) and 11
prospective, population-based studies. The initial analysis (ﬁrst stage) was per-
formed in 8,421 statin-treated subjects from 6 RCTs (ASCOT, CARDS, CAP,
PRINCE, PROSPER and TNT) and 10,175 statin-treated subjects from 10 obser-
vational studies (AGES, ARIC, BioVU, CHS, FHS, GoDARTS I, GoDARTS II,
Health ABC, HVH and MESA). Further investigation (second stage) was per-
formed in 21,975 statin-treated subjects from two randomized trials (HPS and
JUPITER) and one observational study (Rotterdam Study). Six SNPs were addi-
tionally genotyped in the Scandinavian participants of the ASCOT study. The
details of the ﬁrst- and second-stage studies can be found in the Supplementary
Tables 1 and 2 and Supplementary Notes 1 and 2.
Subjects. Response to statin treatment was studied in statin-treated subjects only
and not in those treated with placebo. Subjects included in the observational stu-
dies’ analysis should be treated with statins and have LDL-C measurements before
and after start of statin treatment. Subjects of reported or suspected non-European
ancestry were excluded. All participants gave written informed consent and the
study was approved by all institutional ethics committees.
Outcome measurements. The response to statin treatment was deﬁned as the
difference between the natural log-transformed on- and off-treatment LDL-C
levels. The beta of the corresponding regression thus reﬂects the fraction of dif-
ferential LDL lowering in carriers versus non-carriers of the SNP. For observational
studies, the on-treatment LDL-C levels were taken into account for all kinds of
prescribed statins, at any dosage, for any indication and for at least 4 weeks before
measurement. Characteristics of on- and off-treatment LDL-C levels and statins
used in each study are shown in Supplementary Table 2. For each individual, at
least one off-treatment LDL-C measurement and at least one on-treatment LDL-C
measurement were required. When multiple on- or off-treatment measurements
were available, the mean of the cholesterol measurements was used. Subjects with
missing on- or off-treatment measurements were excluded, with the exception of
the GoDARTS cohorts for which missing off-treatment LDL-C levels were esti-
mated using imputation methods (Supplementary Note 2). In the HPS, propor-
tional LDL-C response was deﬁned by the changes in natural log lipid levels from
the screening visit before starting statin therapy to the randomization visit6.
Genotyping and imputation. Genotyping, quality control, data cleaning and
imputation were performed independently in each study using different genetic
platforms and software as outlined in Supplementary Table 4. In all studies, gen-
otyping was performed using Illumina, Affymetrix or Perlegen genotyping arrays,
and MACH, Impute or BIMBAM software was used for imputation.
GWAS analysis. Each study independently performed the GWAS on the differ-
ence between natural log-transformed on- and off-treatment LDL-C levels. To
control for possible associations with off-treatment LDL-C levels, analyses were
adjusted for the natural log-transformed off-treatment LDL-C level. An additive
genetic model was assumed and tested using a linear regression model. For
imputed SNPs, regression analysis was performed onto expected allele dosage.
Analyses were additionally adjusted for age-, sex- and study-speciﬁc covariates (for
example, ancestry principal components or country). Analyses in the observational
studies were, if available, additionally adjusted for the statin dose by the natural
logarithm of the dose equivalent as deﬁned in Supplementary Table 3. This table
shows the dose equivalent per statin type; dividing the statin dosage of an indi-
vidual by the dose equivalent shown in Supplementary Table 3 will give the
adjusted statin dosage.
Quality control and meta-analysis. Centrally, within each study, SNPs with MAF
o1% or imputation qualityo0.3 were excluded from the analysis. QQ-plots were
assessed for each study to identify between-study differences (Supplementary
Fig. 1). The software package METAL was used for performing the meta-analysis
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html). A ﬁxed effects, inverse
variance weighted approach was used. Using an inverse variance weighted meta-
analysis will give smaller weights to studies with large s.e.. To correct for possible
population stratiﬁcation, genomic control was performed by adjusting the within-
study ﬁndings and the meta-analysis results for the genomic inﬂation factor.
Second stage. SNPs with P values o5 10 4 in the ﬁrst-stage meta-analysis
were selected for further investigation in a second stage. A maximum of two SNPs
per locus were selected, based on statistical signiﬁcance, except for the APOE locus,
for which all genome-wide signiﬁcant associated SNPs were selected for validation.
A total of 246 SNPs, within 158 independent loci, were selected for the second
stage, which was performed in the JUPITER trial, HPS study and the Rotterdam
Study, which all had GWAS data and response to statin treatment available. For 2
of the 246 SNPs, a proxy was used in the JUPITER trial, and 31 SNPs were not
available, nor was a proxy SNP. HPS provided data on 151 directly genotyped SNPs
from GWAS and IPLEX experiments, including 48 of the requested SNPs and 103
proxy SNPs (r240.8). Analysis in HPS was not adjusted for ln baseline LDL-C
levels. In addition, the number of subjects with data varied from SNP-to-SNP and
ranges fromB4,000 for variants with GWAS data toB18,000 for some candidate
genes. Results of the ﬁrst and second stage were combined using ﬁxed effects,
inverse variance weighted meta-analysis and analysed by METAL. As a third stage,
six SNPs with P values 5 10 8oPo5 10 7 in the combined meta-analysis
were selected for additional genotyping in the Scandinavian participants of the
ASCOT study. Kaspar assays were designed for four of the SNPs using the
KBioscience Primerpicker software, and oligos were provided by Intergrated DNA
technologies (http://eu.idtdna.com/site). Full Kaspar methodology is available from
LGC SNP genotyping (http://www.lgcgenomics.com/genotyping/kasp-genotyping-
reagents/). Two SNPs (rs981844 and rs13166647) were genotyped using Taqman
assays supplied by Life Technologies (http://www.lifetechnologies.com/uk/en/
home.html) using the standard Taqman protocol. Results of the additional geno-
typing were combined with results from the ﬁrst and second stages using a ﬁxed
effects, inverse variance weighted meta-analysis and analysed by METAL.
Determination of changes in LDL subfractions. LDL subclasses were analysed as
described previously29 using non-denaturing gradient gel electrophoresis of fasting
plasma samples taken at baseline and after 6 weeks of simvastatin 40mg per day (CAP
study, n¼ 579) or 12 weeks of pravastatin 40mg per day (PRINCE study, n¼ 1,284).
Aliquots of 3.0ml of whole plasma were mixed 1:1 with a sampling buffer of 20%
sucrose and 0.25% bromophenol blue. Electrophoresis of samples and size calibration
standards was performed using 2–14% polyacrylamide gradients at 150V for 3h
following a 15-min pre-run at 75V. Gels were stained with 0.07% Sudan black for 1h
and stored in a 0.81% acetic acid, 4% methanol solution until they were scanned by
computer-assisted densitometry for determination of areas of LDL IVb (22.0–23.2nm),
LDL IVa (23.3–24.1nm), LDL IIIb (24.2–24.6 nm), LDL IIIa (24.7–25.5nm), LDL IIb
(25.6–26.4 nm), LDL IIa (26.5–27.1nm) and LDL I (27.2–28.5 nm). The cholesterol
concentrations of the subfractions (mgdl 1 plasma) were determined by multiplying
percent of the total stained LDL area for each subfraction by the LDL-C for that sample.
For genetic association analyses, subfractions were grouped into large LDL (LDL Iþ IIa),
medium LDL (LDL IIb), small LDL (LDL IIIa) and very small LDL (LDL
IIIbþ IVaþ IVb) as described previously18. A generalized estimating equation method
was used to test the association of log change with the interaction of the four SNPs by
LDL subfraction.
Effect of off-treatment LDL-C. Effects of genetic variation on treatment response
as measured by on-treatment LDL-C could be mediated through effects on the off-
treatment LDL-C. To evaluate whether genetic on-treatment LDL-C likely reﬂects
residual effect on off-treatment LDL-C, it is necessary to adjust for the off-treat-
ment LDL-C levels and to correct the maximum likelihood estimate of the adjusted
effect of genotype on on-treatment value for the noise in off-treatment values (the
noise is both random measurement error and intra-individual variation in usual
LDL-C). This analysis was only carried out in CARDS in which multiple baseline
measurements were available. From the rules of path analysis, we calculated the
direct effect g of genotype on an on-treatment trait value as b ad (1 r)/r, where
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b is the coefﬁcient of regression for on-treatment trait value on genotype adjusted
for measured off-treatment value, a is the coefﬁcient of regression of baseline LDL
on genotype, r is the intraclass correlation between replicate measurements of off-
treatment values and d is the coefﬁcient of regression for on-treatment value on
observed off-treatment value8. For these calculations, we used r¼ 0.8 as a plausible
value for the intraclass correlation based on the within-person correlation in LDL-
C values taken over two off-treatment visits in CARDS. The interaction of
candidate SNPs with statin versus placebo allocation was assessed in the JUPITER
trial, since this study was not involved in the ﬁrst-stage meta-analysis. Regression
models were applied to the combined population of statin- and placebo-treated
subjects by including extra terms encoding placebo allocation and the product of
placebo allocation with SNP minor allele dose7.
GWCA using Genome-Complex Trait Analysis. There may be multiple causal
variants in a gene and the total variation that could be explained at a locus may be
underestimated if only the most signiﬁcant SNP in the region is selected. To
identify independent SNPs, we ideally can perform a conditional analysis, starting
with the top associated SNP, across the whole genome followed by a stepwise
procedure of selecting additional SNPs, one by one, according to their conditional
P values. Such a strategy would allow the discovery of more than two associated
SNPs at a locus. To identify independent SNPs across the genome-wide data, we
used an approximate conditional and joint analysis approach implemented in
Genome-Complex Trait Analysis (GCTA) software (http://www.complex-
traitgenomics.com/software/gcta/). We used summary-level statistics from the ﬁrst-
and second-stage-combined meta-analysis and LD corrections between SNPs
estimated from CARDS GWAS data. SNPs on different chromosomes or more
than 10Mb distant are assumed to be in linkage equilibrium. The model selection
process in GCTA starts with the most signiﬁcant SNP in the single-SNP meta-
analysis across the whole genome with P value o5 10 7. In the next step, it
calculates the P values of all the remaining SNPs conditional on the top SNP that
have already been selected in the model. To avoid problems due to colinearity, if
the squared multiple correlations between a SNP to be tested and the selected
SNP(s) is larger than a cut-off value, such as 0.9, the conditional P value for that
SNP will be set to 1. Select the SNPs with minimum conditional P value that is
lower than the cut-off P value. Fit all the selected SNPs jointly in a model and drop
the SNPs with the P value that is greater than the cut-off P value. This process is
repeated until no SNPs can be added or removed from the model.
Pathway analysis and construction of a statin response network. Genes
showing evidence of association (based on direct association or LD (HapMap CEU
r240.8)) were reviewed for evidence of involvement in statin response at a pathway
level using GeneGo Metacore (Thomson Reuters (portal.genego.com)). A statin
response network was constructed in two stages. First, all genes with a literature-
reported involvement in statin response (based on Medical Subject Headings
(MeSH)) were identiﬁed using GeneGo MetaCore (Supplementary Data 3). Second,
these genes were combined with all genes in associated loci (including genes in LD)
and a network was constructed based on direct interactions only. By including direct
interactions only, we created a conservative network of direct gene interactions that
have been consistently linked to statin response in the literature.
eQTL analysis. LDL-C-associated index SNPs (246 SNPs) were used to identify
1,443 LD proxy SNPs displaying complete LD (r2¼ 1) across four HapMap builds
in European ancestry samples (CEU) using the SNAP tool (http://www.broadin-
stitute.org/mpg/snap/). The primary index SNPs and LD proxies were searched
against a collected database of expression SNP (eSNP) results, including the fol-
lowing tissues: fresh lymphocytes30, fresh leukocytes31, leukocyte samples in
individuals with Celiac disease32, whole-blood samples33–36, lymphoblastoid cell
lines (LCL) derived from asthmatic children37,38, HapMap LCL from three
populations39, a separate study on HapMap CEU LCL40, additional LCL
population samples41–43 (Mangravite et al., unpublished), CD19þ B cells44,
primary phytohaemagglutinin-stimulated T cells41, CD4þ T cells45, peripheral
blood monocytes44,46,47, CD11þ dendritic cells before and after Mycobacterium
tuberculosis infection48, omental and subcutaneous adipose33,43,49, stomach49,
endometrial carcinomas50, ERþ and ER breast cancer tumour cells51, brain
cortex46,52,53, prefrontal cortex54,55, frontal cortex56, temporal cortex53,56, pons56,
cerebellum53,56, three additional large studies of brain regions including prefrontal
cortex, visual cortex and cerebellum, respectively57, liver49,58,59, osteoblasts60,
ileum49,61, lung62, skin43,63 and primary ﬁbroblasts41. Micro-RNA QTLs were also
queried for LCL64 and gluteal and abdominal adipose65. The collected eSNP results
met the criteria for association with gene expression levels as deﬁned in the original
papers. In each case where a LDL-C-associated SNP or proxy was associated with a
transcript, we further examined the strongest eSNP for that transcript within that
data set (best eSNP), and the LD between the best eSNP and GIST-selected eSNPs
to estimate the concordance of the LDL-C and expression signals.
Statin response connectivity map analysis. The Connectivity Map (Cmap) data
set is available at the Broad Institute (www.broadinstitute.org/cmap) and contains
more than 7,000 expression proﬁles representing 1,309 compounds used on ﬁve
different cultured human cancer cell lines (MCF7, ssMCF7, HL60, PC3 and
SKMEL5). We selected (prostate tumour-derived) PC3 cells as they showed the
most responsiveness to statins at a genome-wide level. Four statins were included
in our analysis, including pravastatin, atorvastatin, simvastatin and rosuvastatin.
PC3 Instance reference ﬁles for each statin treatment were extracted (as deﬁned by
Lamb et al.12), that is, a treatment associated to its control pair. Transcripts were
considered to show evidence of differential expression with a fold change 42.
A fold change41.5 was considered to be suggestive of differential expression only.
Exploration of functional impact among directly and indirectly associated
variants. Genes and variants across all LDL-C-associated loci were investigated for
evidence of functional perturbation using a range of bioinformatics tools and
databases. Variants showing LD (CEU r240.8) with associated variants were
explored for impact on coding gene function using Annovar66 and regulatory
function using a combination of HaploReg67 and Regulomedb68, which both draw
on comprehensive data from the Encyclopedia of DNA Elements (ENCODE)69
and the NIH Roadmap Epigenomics consortium70. Building on the functional
annotation, we also identiﬁed variants that were shown to mediate eQTLs. Genes in
associated loci were also used to query the NIH connectivity map for evidence of
differential expression in PC3 cell lines treated with pravastatin, simvastatin and
rosuvastatin. By combining a wide range of functional data and pathway support,
we were able to build up a view of genes with the highest level of support in statin
response.
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